	Page 1
1	GRAVES CIRCUIT COURT DIVISION 1
2	COMMONWEALTH OF KENTUCKY JUDGE TIMOTHY C. STARK
3	X
4	CAROLYN WARD WIMAN and LATTA W. WIMAN,
5	Plaintiffs,
6	vs. DEPOSITION UNDER ORAL EXAMINATION OF
7 8	JACQUELINE MOLINE, M.D.
9	TRIANGLE ENTERPRISES, et al.,
	Defendants.
10	Case No: 18-CI-00181
11 12 13	X
14 15	Transcript of the deposition of the witness, called for Oral Examination in the above-captioned
16	matter, said deposition being taken pursuant to Federal Rules of Civil Procedure by and before BRENDA
17	FITZGERALD, a Notary Public and Shorthand Reporter, at the Northwell Health, 175 Community Drive, Great
18	Neck, New York on Monday, November 25, 2019, commencing at 10:10 in the forenoon.
19 20	commencing at 10°10°111 the following
21	
22	PRIORITY-ONE COURT REPORTING SERVICES, INC. 290 West Mt. Pleasant Avenue
23	Livingston, New Jersey 07039 (718) 983-1234
24	Job No. 3782925
25	

	T
Page 2	Page 4
2 WITNESS EXAMINATION BY PAGE	1 JACQUELINE MOLINE, having been first
3 Jacqueline Moline, M.D. Mr. Ewald 4 4 Mr. Gault 117	2 duly sworn by a Notary Public of the State of New
5 EVHIDETS	3 York, was examined and testified as follows:
EXHIBITS 6	4 EXAMINATION BY
MOLINE DESCRIPTION FOR IDENT 7	5 MR. EWALD:
1 Deposition notice 20	6 Q. Good morning, Dr. Moline.
8 2 Dr. Moline's Reference & Reliance List 20	7 A. Good morning.
9 3 Dr. Moline's Curriculum Vitae 22	8 Q. How many hours have you spent preparing
10	9 for your deposition today?
4 Dr. Moline's Deposition/Trial List 25	10 A. Can you define what you mean by that?
5 Dr. Moline's handwritten notes 26	11 Q. Sure. Let's make it broader. How much
6 Dr. Moline's Materials Reviewed/Relied 27	12 time have you spent on your work in this case
7 Accepted copy of manuscript entitled	13 specifically?
Mesothelioma Associated with the Use of Cosmetic Talc 27	14 A. I would say approximately ten hours.
15	15 Q. Can you please detail how you spent
8 AMA Analytical Services, Inc. Certificate 16 of Analysis 94	16 those ten hours.
17 9 Johnson & Johnson press release 97 18 10 Accepted copy of Exponent manuscript 101	17 A. Reading through the medical records,
19 11 Copy of article entitled Health Effects	18 going through taking notes on the medical records.
of Censored Elongated Mineral Particles 107	19 Reading through the materials that were sent to me
12 Copy of PowerPoint slide 110	20 was the majority of the time, and then I had a brief
21 13 Copy of PowerPoint slide 111	21 meeting with Ms. Long on Friday.
22 14 Copy of PowerPoint slide 113	Q. How long was that meeting?
23	A. Where we discussed the case, probably
*15 List of contents of documents in three 24 binders 117	24 about 30 minutes, if that long.
25 * To be provided - oOo -	25 Q. Have you prepared an invoice for your
Page 3	Page 5
1 APPEARANCES:	1 work in this case?
2 LEVY KONIGSBERG, LLP	2 A. No, not yet.
Attorneys for Plaintiff 3 800 Third Avenue	3 Q. What are the case-specific opinions
New York, New York 10022	4 you're offering here?
4 BY: AMBER LONG, ESQ.	5 MS. LONG: Objection to form.
5 6 ORRICK, HERRINGTON & SUTCLIFFE, LLP	6 A. That Carolyn Wiman is suffering from
Attorneys for the Defendant(s)	7 peritoneal mesothelioma as a result of her exposures
7 Johnson & Johnson	8 to asbestos.
51 West 52nd Street	9 Q. What asbestos exposures have you
8 New York, New York 10019-6142 BY: JOHN L. EWALD, ESQ.	10 identified that Ms. Wiman encountered?
9 ANNA E. STUART, ESQ.	11 A. She had exposure from her husband who
10	12 worked at General Tire, her first husband. Her
11 NAPIER, GAULT, SCHUPBACH & STEVENS, PLC Attorneys for the Defendant(s)	13 second husband also worked at General Tire, but he
12 Continental Tire	14 was retired by the time they married, and her
730 West Main Street	15 exposures to Johnson & Johnson products.
	13 CAPOSULES TO JOHNSON & JOHNSON PROGUCTS.
13 Louisville, Kentucky 40202	
BY: PATRICK W. GAULT, ESQ.	There is a question with no information
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15	There is a question with no information 17 whether her father might have had exposure when he
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - oOo -	There is a question with no information whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - oOo - 17	There is a question with no information Whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion plant in Kentucky, but there's no it's a possible
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - oOo -	There is a question with no information whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion plant in Kentucky, but there's no it's a possible exposure because there is no information related to
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - oOo - 17 18 19 20	There is a question with no information whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion plant in Kentucky, but there's no it's a possible exposure because there is no information related to what he actually did there, and also she assisted her
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - oOo - 17 18 19 20 21	There is a question with no information whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion plant in Kentucky, but there's no it's a possible exposure because there is no information related to what he actually did there, and also she assisted her mother with the laundry, but really helped hang it
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - oOo - 17 18 19 20	There is a question with no information whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion plant in Kentucky, but there's no it's a possible cerposure because there is no information related to what he actually did there, and also she assisted her mother with the laundry, but really helped hang it rather than shake it out and do the laundering, she
BY: PATRICK W. GAULT, ESQ. 14 (TELEPHONICALLY) 15 16 - 0O0 - 17 18 19 20 21 22	There is a question with no information whether her father might have had exposure when he worked as a carpenter helper at the gaseous diffusion plant in Kentucky, but there's no it's a possible exposure because there is no information related to what he actually did there, and also she assisted her mother with the laundry, but really helped hang it

Page 6 Page 8 1 were the ones I mentioned. 1 was very large, that fell down on a regular basis and Q. Let's take the last one first. The 2 they either fell on top of them or fell to the floor 3 father's potential exposure, what kind of work would 3 that were then run over by the forklifts with

16

19

23

24

- 4 he have to have been doing for it to be an actual
- 5 exposure to asbestos in your view?
- MS. LONG: Objection to form.
- 7 A. Well, it isn't necessarily the work he
- 8 was doing, it's the environment he was in and whether
- 9 they were using asbestos in the areas where he was
- 10 working in the building of this plant. His work as a
- 11 carpenter might or might not have included direct use
- 12 of asbestos-containing materials, but he could have
- 13 been around others who were using asbestos-containing
- 14 materials.
- 15 Q. So you're offering the opinion that that
- 16 was a potential exposure to asbestos?
- 17 A. I feel in the interest of completeness I
- 18 have to include it as a potential exposure, but I
- 19 have no information beyond that he worked there. I
- 20 think it would be erroneous to not mention that that
- 21 is a potential exposure for approximately four years,
- 22 but beyond that I cannot testify specifically that he
- 23 had an exposure that led to Ms. Wiman's having an
- 24 exposure.
- 25 Q. What information did you review

- Q. Sure. Let's start --They were married in 1950 and he started
- 25 working there after they were married, so he started

4 re-entrainment from the fallen asbestos. That was

7 tornado and there was a significant amount of dust

8 that was generated during the period when there were

9 multiple -- when everything was shaken up, and then

12 there was a potential where he had asbestos exposure

13 during the manufacturing of the tires, similarly from 14 the insulated steam pipes or from other insulation

15 that might have occurred in the tire production area.

17 of time by years that Mr. Ward would have been

20 stopped in 1997, he retired in 1997 and he worked

21 there -- I mean does it matter? It only matters when

18 exposed to asbestos in his job?

Q. Do you have an opinion as to the length

A. Well, Mr. Ward worked there, I think he

11 a tire builder and in the calendering area where

10 there was also some discussion of Mr. Ward working as

There was also an issue when there was a

5 from the depositions of the co-workers.

Page 7

- 1 regarding the father's work as a carpenter?
- Whatever was provided in these binders.
- 3 It was Ms. Wiman and then her sister's deposition
- 4 were the ones that had any information at all.
- Did you attempt to conduct any
- 6 additional investigation beyond the materials that
- 7 were provided to you by counsel?
- 8 MS. LONG: Objection to form.
- At this point I did not. Also, there
- 10 was -- I don't know if Mr. Ellenbecker was just asked
- 11 about these questions, so it would have been from
- 12 reading his industrial hygiene -- he's an industrial
- 13 hygienist, from reading his deposition. I did not
- 14 personally go to the plant. I don't even know if the
- 15 plant is still there. I did not seek to obtain work
- 16 records, which would not be particularly helpful
- 17 anyway for folks that have passed on.
- 18 Let's talk a little bit about the
- 19 exposure that you detailed relating to the first
- 20 husband at General Tire. Can you describe the nature 20 Mr. Ward passed away?
- 21 of asbestos exposure that he had and then the
- 22 secondary exposure to Ms. Wiman?
- 23 So based on the descriptions of the
- 24 co-workers, there was asbestos insulation from pipes
- 25 in the roof that were in the warehouse area, which

- 1 working there I believe it was in 1960 he started
- 2 working at General Tire.

22 they were married.

- Q. For the exposures that were relevant to
- 4 Ms. Wiman, if it starts in 1960 at his employment, at
- 5 what point in time do you cut off his workplace
- 6 exposures at General Tire with respect to whether or
- 7 not they're relevant to Ms. Wiman?
- 8 MS. LONG: Objection to form.
- 9 MR. GAULT: Object to form.
- I believe around 1980 they moved from
- 11 the south warehouse to the north warehouse where
- 12 there was less asbestos or no asbestos being used, so
- 13 his exposure would have diminished if he was no
- 14 longer working in that area. I think it's unclear
- 15 exactly where he was working during that time, if he
- 16 was never going back into the south warehouse, but at
- 17 one point they did move to a cleaner environment from
- 18 the asbestos standpoint.
- 19 What is your understanding of when
- 2.1 A. I think he passed away around 2004 or
- 22 2005.
- 23 What is your understanding of when
- 24 Mr. Ward and Ms. Wiman got divorced?
- 25 They never got divorced, he died.

1 Q. I apologize. With respect to the job

- 2 change in 1997, what were you referring to?
- 3 A. He retired.
- 4 Q. Understood, but then I thought you said
- 5 something with respect to that would not have
- 6 impacted Ms. Wiman's exposure; did I mishear you?
- A. She didn't have any exposure after he
- 8 retired. His General Tire exposure closed in 1997
- 9 since he wasn't working there anymore.
- 10 Q. Do you have an opinion as to the types
- 11 of asbestos that Mr. Ward would have been exposed to
- 12 in his job?
- 13 A. It was a combination of amosite and
- 14 chrysotile.
- 15 Q. Do you have an opinion as to how much of
- 16 that exposure was amosite as opposed to chrysotile?
- 17 A. I did not do the sampling. There's a
- 18 comprehensive sampling included in there of whatever
- 19 was in the pipes at whatever time they did the
- 20 sampling, but I don't know the exact percentage.
- Q. Did that sampling material that you
- 22 reviewed inform the opinions that you're offering in
- 23 this case?
- 24 A. To the extent that it demonstrated that
- 25 the pipes had asbestos insulation.
- Page 11
- 1 Q. Does it matter to your opinions in this
- 2 case the level of, for example, amosite that was
- 3 present in the insulation?
- 4 A. If you're trying to get a long-winded
- 5 way of asking me if all types of asbestos causes
- 6 mesothelioma, they do. Certainly his exposures to
- 7 asbestos are what counted. If there's pipe
- 8 insulation, then you say there's exposure to both
- 9 amphibole and chrysotile.
- 10 Q. That wasn't a long-winded way of getting
- 11 at whether they all cause it, I know your opinions in
- 12 that regard, but you also have opinions with respect
- 13 to potency as between the different types of asbestos
- 14 fibers; is that accurate?
- 15 A. On a fiber per fiber basis with respect
- 16 to mesothelioma, yes.
- 17 Q. With respect to your opinions in this
- 18 case, does it matter to you how much amosite Mr. Ward
- 19 was exposed to as opposed to how much chrysotile he
- 20 was exposed to in his job?
- A. Only to the extent that if there's a
- 22 higher percentage of amosite there might be a higher
- 23 fiber per fiber risk of developing mesothelioma, but
- 24 because it's a combined exposure it exists in a
- 25 combined manner, so you'd look at both. It's just

- Page 10
 - 1 something that you note that there was both
 - 2 chrysotile and amosite. I think there was more
 - 3 chrysotile than amosite. If you got something that's

- 4 four times as potent or two and a half times as
- 5 potent but you've got four times as much of the less
- 6 potent, then they're sort of equivalent, so it all
- 7 evens out in the wash, so to speak, as long as you
- 8 don't shake it.
- Q. Have you attempted to quantify the
- 10 exposure to asbestos that Mr. Ward experienced in his
- 11 job?
- 12 A. I personally have not.
- Q. Do you have a view on, let's say, the
- 14 fibers per cc or fiber per cc years how much asbestos
- 15 exposure Mr. Ward experienced in his job?
- 16 A. I don't have a specific opinion with a
- 17 quantitative value associated with it. I would defer
- 18 to Dr. Ellenbecker if he's going to do that. I think
- 19 it's challenging when there was no air testing done,
- 20 which they certainly could have done when they were
- 21 doing the surveys, but I don't have the data to be
- 22 able to do that.
- 23 I could tell from a qualitative
- 24 standpoint their descriptions of asbestos in the air
- 25 being disturbed led to a significant exposure.
 - Page 13
- 1 Q. Are you able to provide any additional
 - 2 opinion with respect to the exposure beyond that it 3 was significant?
 - 4 MS. LONG: Objection to form.
 - 5 A. There's no numbers that were done;
 - 6 there's no air measurements that were done so one
 - 7 could look to the literature and say what the
 - 8 exposures would be from disturbing pipe insulation
 - 9 and come up with an estimate that way. I have not
 - 10 done a quantitative measurement.
 - 11 Q. Do you have any citations to that
 - 12 literature that you just referenced that you would
 - 13 look at if you wanted to actually come up with a
 - 14 quantitative estimate?
 - 15 A. Balzer and Cooper is one of the
 - 16 classics.
 - 17 Q. Any others come to mind?
 - 18 A. I would have to look at my reference
 - 19 list. There's a number of studies. I'm sure
 - 20 Dr. Ellenbecker would be able to provide you with
 - 21 that information as an industrial hygienist.
 - 22 Q. Let's talk about your opinions with
 - 23 respect to the exposure to asbestos that Ms. Wiman
 - 24 had in connection with her husband's work. What are
 - 25 your opinions with respect to that?

- 1 A. That her exposure is from laundering his
- 2 dust-ladened clothes. She shook out his clothes
- 3 before she washed them, after she washed them, after
- 4 she dried them. She liked to shake clothes and after
- 5 shaking out the clothes it caused asbestos to become
- 6 airborne. She was exposed in that fashion.
- 7 Q. Do you have an opinion that that
- 8 exposure would be to both amosite and chrysotile?
- 9 MR. GAULT: Object to form.
- 10 A. Based on the pipe insulation contents, 11 yes.
- 12 Q. Have you done any kind of quantitative
- 13 exposure assessment that Ms. Wiman had from
- 14 laundering and shaking out the clothes?
- 15 A. I have not done a numerical value from
- 16 that. There are references in the literature. I'm
- 17 not sure. There are a number of studies that have
- 18 measured it. I don't know if it's in Anderson or
- 19 Vianna and Polan and a number of other take-home 20 exposures.
- 20 exposures.
- 21 Q. Do you have an opinion as to the
- 22 frequency with which Ms. Wiman would have been
- 23 exposed to asbestos in the laundering of her
- 24 husband's work clothes?
- 25 A. She stated that she laundered -- she did

1 A. Yes.

- Q. What is contained in those binders generally?
- 4 A. Medical records. There's a whole list

Page 16

- 5 of what's in the binders. You have that. I think
- 6 it's deposition transcripts of co-workers, her
- 7 daughter, her sister. There's the asbestos survey
- 8 that was done at the plant. There's Dr. Longo's
- 9 deposition. There's Dr. Ellenbecker's deposition.
- 10 Q. Have you reviewed all of the materials
- 11 that are contained in the three binders that were
- 12 brought with you today?
- 13 A. Yes.
- 14 Q. Are there any case-specific materials
- 15 that you reviewed in this case that are not contained
- 16 within those three binders?
- 17 A. No.
- 18 Q. Have you spoken with any other expert
- 19 witnesses in connection with your opinions in this 20 case?
- 21 A. No.
- Q. Have you spoken with Ms. Wiman?
- A. I have not.
- Q. Did you ask counsel for the opportunity
- 25 to speak with Ms. Wiman?

- 1 laundry approximately twice a week, but also it
- 2 contaminates the household or the area where she was
- 3 doing the laundry, so it could have been additional,
- 4 but she did laundry twice a week based on her
- 5 description.
- 6 Q. Do you recall Ms. Wiman testifying that
- 7 her husband would not take off his clothing when he
- 8 immediately returned home from work?
- 9 A. I think in general he did not, on some
- 10 occasions he did.
- 11 Q. The testimony that Mr. Ward left his
- 12 work clothes on when he came home, in your opinion 12
- 13 would that have led to additional exposure to
- 14 asbestos that Ms. Wiman experienced?
- 15 MR. GAULT: Object to form.
- 16 A. Absolutely if she's interacting with
- 17 him, if he's contaminating the house, the dust gets
- 18 on the floor and she's cleaning the house. It would
- 19 be additional exposure not just from laundering his
- 20 clothes, if dust falls down or she's greeting him and
- 21 hugging him has potential to breathe in asbestos from
- 22 other encounters.
- Q. Let's talk about what you reviewed
- 24 specifically for this case. You brought with you I
- 25 see three binders today; is that fair?

- Page 17
 A. I didn't because I noted that Dr. Longo
- 2 had spoken to her. She's quite ill and I felt that
- 3 it would be duplicative in terms of some of the
- 4 questions we might be asking and I did not want to
- 5 call a very ill woman out of the blue. If Dr. Longo
- 6 had not reached out to her and asked her some of the
- 7 questions that I would have asked that were not
- 8 specifically asked in her deposition, then I would
- 9 have asked for that opportunity.
- 10 Q. Have you spoken with any of Ms. Wiman's
- 11 family members?
- 2 A. I have not spoken to her family members.
- 13 I've not spoken to her treating physician.
- 14 Q. Have you spoken with any of Mr. Ward's
- 15 co-workers at General Tire?
- 6 A. Apple Jaw seems like a very interesting
- 17 person, but I have not spoken to any of the
- 18 co-workers. He has the best name of a witness I have
- 19 ever seen.
- Q. When were you retained as an expert in
- 21 this case?
- A. I don't know. It was many months ago.
- 23 I think the case was initially scheduled to move
- 24 forward a little sooner and then it was delayed. It
- 25 was several months ago, but I began reviewing the

Page 18 Page 20 1 MR. EWALD: The initial binder. Let's 1 materials within the past few weeks. 2 go ahead just for the record mark this as Exhibit 1, Q. When was the first time that you started 3 reviewing materials in connection with this case? 3 please. 4 (Whereupon, deposition notice was I would say about two weeks ago. 5 received and marked Moline Exhibit 1, for Do you have any record of when you would 6 identification, as of this date.) 6 have been retained in this case? 7 Q. Doctor, I am handing you what's been It would have been in the cover letter 8 that is included in the binders since I didn't throw 8 marked as Exhibit 1. Have you seen this before? A. I glanced at it briefly. I think it was 9 anything away. You're looking in the wrong one. Q. I appreciate the help. There's a letter 10 included in one of the binders, but I basically noted 11 it was there, but didn't go through it 11 enclosing additional records dated November 7, 2019. Those were sent to me whatever that date 12 comprehensively. 13 was. The binder you have there was the original one 13 MR. EWALD: For the record, this is the 14 deposition notice, the amended deposition notice, 14 and I don't know if the cover letter is in there or 15 Exhibit 1. 15 not, but it was somewhere around February, the end of 16 Q. Let's talk about the reference and 16 February I believe, but I didn't review anything 17 until more recently. 17 reliance list. 18 MR. EWALD: If you could mark this as 18 February 2019? 19 I believe so. I think there was one 19 Exhibit 2. 20 20 binder sent and then additional binders were sent (Whereupon, Dr. Moline's Reference & 21 Reliance List received and marked Moline Exhibit 2, 21 more recently. I'm sure the Kazan firm or whoever 22 wrote it can provide that correspondence. 22 for identification, as of this date.) Doctor, I am handing you what's been MR. EWALD: We would request a copy of 23 24 that initial correspondence enclosing the materials 24 marked as Exhibit 2. What is that? 25 25 that are in one of the three binders. The original It is a reference list. It is missing Page 19 Page 21 1 set of materials. 1 the second part, which is the reliance documents, but 2 They didn't do a good job of labeling. 2 during a break I can pull that. It's a list of 3 MS. LONG: Counsel, will you send me a 3 references that I've been adding as I read more 4 letter or Kazan's firm a letter? 4 articles that I've been complying for a number of 5 MR. EWALD: Sure. No problem. 5 years. In this binder there is a -- I'll hand When was this reference list prepared? 6 Q. 7 7 this to you to take a look. It says documents sent A. It's an iterative documents. 8 8 to Moline; is that something counsel prepared or that When is the last time you updated it? Q. 9 you prepared? A. Probably within the last couple of 10 A. I don't refer to myself in the third 10 weeks. 11 person. 11 Q. Do you recall what's been added to the 12 Q. Some people do. 12 list? The president does, but I don't 13 MS. LONG: Objection to form. 14 personally myself. I don't appreciate not having a 14 I don't specifically recall what might 15 doctor in front of that, but anyway, I will raise 15 have been added in the past two weeks. I work with 16 that with the person who provided this. I did not 16 one of my colleagues who helps me manage my 17 provide this. This was provided by the law firm. 17 references. 18 Just to clarify, these were included in 18 Which colleague is that? O. 19 the binders. I took them out because I read them at 19 Her name is Elizabeth Salas (phonetic). 20 20 different times, so it was just for ease of not I may be mistaken, but I believe the 21 carrying a binder. 21 last time I saw a reference list it was numbered 202 22 MR. EWALD: For the record, Dr. Moline 22 and this one is 436. Has there been a significant 23 is referring to Exhibits 9 and 10 from one of the 23 addition of references within the last couple of

I don't know when the 202 came from, but

25

24 months?

A.

24 three binders.

A.

It was from the initial binder.

Page 22 1 it's been significantly more than 202 for a while.

- 2 Going through the reference list I realized that I
- 3 was missing certain types of articles, whether it was
- 4 on the stack of articles related to different types
- 5 of exposure. I didn't have some of the take-home
- 6 exposures at one point so I made sure they were
- 7 added, and then there were some articles I referenced
- 8 on asbestos cement that weren't on there, so we added
- 9 those, and then I add some related to ovarian cancer
- 10 at some point.
- I just mostly am keeping one list and
- 12 allowing you to earn more time as you go through the
- 13 list, so you should thank me.
- 14 MR. EWALD: Can you please mark this as
- 15 Exhibit 3, please.
- (Whereupon, Dr. Moline's Curriculum
- 17 Vitae was received and marked Moline Exhibit 3, for
- 18 identification, as of this date.)
- Dr. Moline, I am handing you what's been
- 20 marked as Exhibit 3. What is that?
- 21 It's a copy of my CV dated
- 22 November 11th.
- 23 2019? Q.
- 24 A. Correct.
- 25 What additions, revisions did you make Q.

- 1 Johnson & Johnson talc products?
 - A. I have not done a dose estimate. It
 - 3 would be a gross estimate in the sense that there was
 - 4 no air monitoring done, but I did not attempt it. In
 - 5 this particular case I was not asked to do a dose
 - 6 calculation.
 - 7 Q. As between potential asbestos exposures
 - 8 that Ms. Wiman had from Johnson & Johnson products
 - 9 and from her husband's work at General Tire, do you
 - 10 have an opinion as to which was more offensive?
 - 11 A. Certainly years-wise her exposure to
 - 12 Johnson & Johnson was more extensive. It was
 - 13 something she used from early childhood to very
 - 14 recently, but in terms of relative exposure I have
 - 15 not attempted to do a relative contribution. They're
 - 16 both cumulative and it's specious to try to separate
 - 17 them.
 - 18 Do you have an opinion as to what role,
 - 19 if any, genetics played in contributing to
 - 20 Ms. Wiman's mesothelioma?
 - 21 MS. LONG: Objection to form.
 - 22 There's certainly a family history of
 - 23 cancer. There's no evidence of any genetic testing;
 - 24 so it's speculative. There's no history of
 - 25 mesothelioma in the family, but there are other

Page 23

- 1 cancers that may indicate there's a genetic
- 2 predisposition to certain types of cancers.
- Q. You indicated a family history of
- 4 cancer. What family history of cancer are you aware
- 5 of with respect to Ms. Wiman?
- That her mother had breast cancer, her
- 7 sister had breast cancer, and another sister had
- 8 ovarian cancer, her father had pancreatic cancer, and
- 9 her brother had lung cancer.
- 10 Did you also review testimony that her
- 11 mother had colon cancer?
- 12 Yes, I believe she also did. I think
- 13 the breast cancer was not something that she died
- 14 from. I think she died from her colon cancer.
- 15 MR. EWALD: I'm going to mark this as
- 16 Exhibit 4.
- 17 (Whereupon, Dr. Moline's Attorney
- 18 Deposition/Trial List was received and marked Moline
- 19 Exhibit 4, for identification, as of this date.)
- 20 Q. Dr. Moline, I'm showing you what's been
- 21 marked as Exhibit 4. Please identify what that is.
- 22 A. It's a list of deposition and trial
- 23 testimony over the past four years.
- 24 Is it current as of today?
- 25 I don't include today's deposition, but

Page 25

- 1 to your CV for this version? 2 At what point in time?
- It's dated November 11, 2019. I'm
- 4 asking basically when you revised it on or around
- 5 that date, what changes did you make?
- A. Added some new interviews. Added some
- 7 new publications. Let's see if they incorporated
- 8 that I became president of the New York Occupational
- 9 and Environmental Medicine Association. That
- 10 occurred the week before or, no, actually the month
- 11 before.
- 12 Q. You said if they incorporated, who is
- 13 they?
- I'm smart enough not to attempt to mess
- 15 with a formatted document, so I have my assistant
- 16 help me.
- 17 What opinions are you offering in this
- 18 case with respect to Ms. Wiman's exposure to Johnson
- 19 & Johnson talc products?
- 20 That she used talc products for
- 21 virtually her entire life that were Johnson & Johnson
- 22 products and they contributed to her cumulative
- 23 asbestos exposure that led to her mesothelioma.
- Q. Have you attempted to quantify
- 25 Ms. Wiman's exposure to asbestos from her use of

Page 26 Page 28 1 yes. 1 7, for identification, as of this date.) Q. Fair enough. Dr. Moline, you've Q. Doctor, I'm handing you what's been 3 reviewed medical records of Ms. Wiman in connection 3 marked as Exhibit 7. Can you please identify that 4 with this case, correct? 4 for the record. It's an accepted manuscript entitled Are you aware of any medical records 6 Mesothelioma Associated with the Use of Cosmetic Talc O. 7 where a medical provider attributes Ms. Wiman's 7 that I am the first author of. 8 mesothelioma to her talc use? Whose idea was it to draft this article? There's no mention of her talc use in 9 MS. LONG: Objection to form. 10 the medical records in any way, shape or form, 10 Α. To write this article? 11 whether she even used it that I recall, no medical 11 Q. Yes. 12 provider mentioned talc. 12 It was something I've been thinking Q. The medical records do identify asbestos 13 about doing for a long time, to do a case series, and 14 exposure from the husband; is that correct? 14 at some point I had a conversation with Ron Gordon 15 15 and we decided to collaborate. Yes. 16 MR. EWALD: Mark this please as 16 Q. So you had the idea for the article and 17 Exhibit 5. 17 talked to Dr. Gordon about writing it with you? 18 (Whereupon, Dr. Moline's handwritten A. They were actually in parallel. I had 18 19 notes were received and marked Moline Exhibit 5, for 19 the idea of writing a case series for a long time. 20 identification, as of this date.) 20 Dr. Gordon and I, in the course of a discussion, it Q. Dr. Moline, I'm handing you what has 21 came up and we said why don't we collaborate on an 22 article. He had done tissue digestion in several 22 been marked as Exhibit 5. What is that, please? They are my handwritten notes that I 23 cases that I realized that I had also reviewed and 24 took as I reviewed the various documents contained in 24 that's how it came about. 25 the three binders that we discussed. 25 When you say that you had been thinking Page 27 Page 29 1 about doing a case series for a long time, how long a 1 Do you want to take a break? 2 2 time are we talking about? Q. Yes, I'm about to switch topics. I was A. A couple of years at least. I'm an 3 going to say let's take a break. 4 academic physician, I'm always thinking about what 4 (A recess was taken.) 5 MR. EWALD: Could you please mark this 5 kind of articles I can write. As I was reviewing 6 more and more cases of mesothelioma with cosmetic 6 as Exhibit 6, please. 7 talc exposure I felt it was important to get it into (Whereupon, Dr. Moline's Materials 8 the medical literature. 8 Reviewed/Relied on was received and marked Moline 9 Exhibit 6, for identification, as of this date.) Q. So at some point after 2017; is that 10 correct? 10 Q. I'm handing you what's been marked as 11 A. I can't give you an exact time. It 11 Exhibit 6. What is that, please? It's the reliance list that should have 12 would have been at some point in all likelihood in 13 been included in Exhibit 2. It's just a general 13 2017, yes. 14 reliance list for talc-related issues. 14 Just for the record, you were reviewing 15 your list of cases that's been marked as Exhibit 4? 15 Q. Do you recall when that list was last Correct, because that's when I began 16 updated? 17 reviewing more cases of talc exposure and started 17 A. I don't. I think the last -- it may 18 putting my academic hat on in addition to my other 18 need to be updated if there's been an additional 19 report, but certainly it was updated at some point 19 hats. 20 The title, Mesothelioma Associated with 20 after August 27, 2019. MR. EWALD: Please mark this as 21 the Use of Cosmetic Talc, who came up with that 22 title? 22 Exhibit 7. 23 I did. 23 (Whereupon, accepted copy of manuscript A. 24 Q. Was that the same title in the draft 24 entitled Mesothelioma Associated with the Use of

25 that was sent to the peer reviewers?

25 Cosmetic Talc was received and marked Moline Exhibit

Page 30 Page 32 1 Α. Yes. 1 with you in connection with your litigation 2 Was there a different title in earlier 2 consulting? Q. 3 drafts of the article? A. Never. There was no title in the earlier drafts 4 I failed to ask, apologies. How did 5 of the article. 5 Ms. Bevilacqua come to be involved in connection with 6 this article? O. When did you come with the title? 7 7 A. Around the time that we submitted it. A. I asked her if she would be interested. 8 8 Titles are not as important as what's in the content. Q. Why did you ask her? I hear you. Your co-author is Kristen Because I knew she was going into 10 Bevilacqua; is that correct? 10 epidemiology, she's a brilliant woman, and she's good 11 A. Yes. 11 with things like IRB, and also she's a phenomenal 12 O. What is her educational background? 12 researcher, so it was someone to assist me in some of 13 She has a Master's of Public Health 13 the aspects of the paper. 14 degree and she is currently in graduate school for a Jumping around a little bit, but in the 15 Ph.D. 15 paper it states that the study was conducted with the 16 Q. What role did Ms. Bevilacqua play in 16 approval of the Northwell Health Feinstein Institute 17 connection with this article? 17 for Medical Research. What does that mean? She assisted in compiling some of the A. It means that we submitted an 18 19 tables, working with me as we went through the cases, 19 application describing the protocol and it was 20 assisted in some of the -- we worked together on 20 accepted and reviewed by our institutional review 21 developing the background and section of the paper 21 board. 22 and she did more of the -- helped submit the IRB 22 Is it your understanding that the 23 application. Actually, she is actually the one who 23 approval would have been required in order for the 24 submitted the IRB application. 24 article to be written? 25 Has Ms. Bevilacqua in the past assisted 25 I felt that it was necessary since there Page 31 Page 33 1 you with your litigation consulting work? 1 are humans involved and it's a publication that has 2 2 personal health information. Actually, there's no A. 3 To your knowledge, has Ms. Bevilacqua 3 identifiable personal health information in the 4 been involved at all in consulting for litigation? 4 paper, but because we were writing a case series, I 5 felt that it was important to ensure that we were A. Maya Alexandri is also listed as a 6 abiding by all requirements for the protection of 6 Q. 7 co-author, correct? 7 human subjects. Q. What was the nature of the application 8 A. Correct. 9 Q. What is her educational background? that was provided to Northwell Health? 10 She was a lawyer, but she's a medical 10 They have a list of questions about what 11 student now. Her legal degree was immaterial in the 11 the project entails and what kind of data is going to 12 writing of this paper, but she is a medical student 12 be collected, how the data is going to be stored, 13 at the Hofstra School of Medicine and she assisted in 13 things along those lines. Was there any request or communications 14 some of the writing of the paper, not in the data 14 15 from Northwell Health after you submitted your 15 collection. How did Ms. Alexandri come to be 16 application for approval? 16 17 involved in connection with this paper? 17 Apart from getting the approval? 18 She has done rotations with me. She has 18 Apart from getting the approval. 19 an interest in occupational medicine. We worked 19 I don't know. I don't recall that they 20 together on another case report that she presented to 20 asked for any revisions or clarifications. I 21 the medical students research day, and was interested 21 honestly don't recall. I don't think -- if they did 22 in continuing to work with me on any projects and it 22 it wasn't substantive. 23 just so happened she had some free time over the 23 Would that request have been made to you 24 summer and assisted us. 24 or one of your co-authors?

Ms. Bevilacqua is the one who

25

Has Ms. Alexandri previously assisted

Page 34 1 spearheaded it. I would have been cc'd as the

- 2 principal investigator. I don't think there were
- 3 significant requests for anything to be changed.
- You mentioned a conversation with
- 5 Dr. Gordon that you had in connection with proceeding
- 6 with the paper; is that accurate?
- 7 A. Yes.
- 8 Q. Do you recall when that conversation
- 9 was?
- 10 It was probably at some point in 2017,
- 11 2018. I don't recall. Probably early 2018.
- 12 Do you recall where the conversation
- 13 took place?
- I'm pretty sure it was a phone A.
- 15 conversation.
- Q. You talked to Dr. Gordon about
- 17 proceeding with this case series. What did
- 18 Dr. Gordon have to say about it?
- He wanted to collaborate. He realized
- 20 he needed a clinician in order to flesh out the case
- 21 reports since he is not somebody who could describe
- 22 the clinical courses of the patients. I've known
- 23 Dr. Gordon for many, many years and it just was a
- 24 natural conversation that we had when we realized
- 25 that we had a common interest in publishing work
- Page 35

- 1 related to these cases.
- What role did Dr. Gordon play in
- 3 connection with this article?
- He did all the tissue digestions. 4
- 5 There are six tissue digestions that are
- 6 identified in the article, correct?
- 7 A. Yes.
- 8 So beyond the tissue digestions, what Q.
- 9 work did he do?
- 10 Described the methodology that he used,
- 11 also provided information about the control samples
- 12 that are described in the paper, as well as obviously
- 13 the results of the tissue digestion.
- 14 What role did you play with respect to
- 15 the drafting of the article?
- A. I was the principal author in drafting
- 17 it. I provided -- I worked very closely with
- 18 Ms. Bevilacqua in drafting it, but we talked about
- 19 what kind of topics to include in the background and
- 20 then I drafted the case reports, and then in writing
- 21 up the results and then the discussion, it was a
- 22 combination of the two of us writing it together.
- When you say you drafted the case report
- 24 descriptions, is that you physically typing on the
- 25 computer?

- I might have written it on a piece of
 - 2 paper and then typed what I wrote. Sometimes I write
 - 3 longhand and sometimes I write directly into the
 - 4 computer. I don't remember. I think some were on
 - 5 the computer and some I might have transcribed.
 - The manuscript was ultimately accepted
 - 7 by the Journal of Occupational and Environmental
 - 8 Medicine, correct?
 - 9 A. Yes.
 - 10 Q. Why did you decide to submit the article
 - 12 Well, it's a journal in my field, it's a
 - 13 journal that has published articles on cosmetic talc,
 - 14 and it's also a journal that publishes case series.
 - 15 Did you submit the manuscript to any
 - 16 other journals?
 - 17 A. No.
 - 18 Do you know any of the members of the
 - 19 editorial board at that journal?
 - 20 I'm sure I do. I don't know who's on
 - 21 the board of the journal. I know the
 - 22 editor-in-chief.
 - 23 Who's the editor-in-chief? Q.
 - 24 A. Paul Brandt-Rauf.
 - 25 How do you know him? Q.
- Page 37

- A. I've known him since 1991 when he was at
- 2 Columbia and I spent time meeting with him. He might
- 3 have even taught some classes and then our career
- 4 paths have overlapped. I think he might have been a
- 5 mentor when I did my fellowship on biomarkers. I
- 6 know we had specific conversations about cancer
- 7 biomarkers in 1992, 1993, 1994.
- Do you know who reviewed your paper?
- 9 The peer review process is anonymous or
- 10 is blinded. I have no idea.
- Just making sure. Did you make any 11
- 12 changes to the article as a result of the peer review
- 13 process?
- 14 A.
- 15 What changes were made?
- 16 They asked that we -- they felt that
- 17 some of the background and discussions were
- 18 duplicative. They asked for some clarification in
- 19 certain areas. I think they wanted some clarity on
- 20 how the methodology was described for the tissue
- 21 digestion. Those are the main things that I
- 22 remember.
- 23 When you say clarification in certain
- 24 areas to identify the methodology of the tissue
- 25 digestion, any other areas that you can recall that

Page 38 1 the peer reviewer requested clarification on?

- 2 A. I think there were a couple of comments
- 3 that some sentences were fragments that they wanted
- 4 us to rewrite. I don't recall all the specific
- 5 changes that were requested.
- 6 Q. Do you still have a record of
- 7 communications with the journal that you received
- 8 with respect to the peer review process?
- 9 MS. LONG: Objection to the form.
- 10 A. I might have, I think I do have a copy 11 of the initial review, yes.
- MR. EWALD: We would just ask at this
- 13 point in time that you maintain that copy and we will
- 14 discuss it with counsel.
- 15 Q. I believe you said you have a copy of --
- 16 what did you call it, initial review?
- 17 A. There was one review. I have a copy of
- 18 the actual review.
- 19 Q. Were there any other communications with
- 20 the journal that you and/or your co-authors had with
- 21 respect to the article?
- MS. LONG: Objection to form.
- A. Only they submitted -- they sent us the
- 24 proofs for us to make changes subsequent to the
- 25 online publication. So there was communication at

1 in passing.

Q. What did you tell Dr. Brandt-Rauf about 3 the paper when you had that initial conversation with

Page 40

Page 41

- 4 him?
- 5 A. I asked if they would be interested in
- 6 publishing a case series and I explained why I
- 7 thought it was a value to the readers of the journal
- 8 and that was basically it. He said send it on in.
- 9 Q. Do you remember approximately when this 10 conversation occurred?
- 11 A. It was at some point in 2018, but I
- 12 don't recall when it was.
- 13 Q. Do you recall approximately when the
- 14 paper was actually submitted to the journal?
- 15 A. It was late summer.
- 16 Q. Of 2019?
- 17 A. '19. I had a little hiccup in 2018 that
- 18 delayed me.
- 19 Q. I recall. I take it from your testimony
- 20 that before the article was accepted for publication
- 21 by the Journal of Occupational and Environmental
- 22 Medicine that you did not communicate with any
- 23 lawyers with respect to the article?
- A. I did not. I did not include it in any
- 25 conversations and they were not even aware it had

- 1 that point where we fixed a couple of grammatical
- 2 errors. The final manuscript when it is published
- 3 will not be substantively changed, but will not be
- 4 verbatim.
- 5 Q. I can't find it right now, I'm sure I'll
- 6 find it later. There was a double negative there
- 7 somewhere; did you see that one?
- 8 A. Yes. Yes, we took it out. Aren't you
- 9 the king and queen of double negatives being lawyers?
- 10 Q. We try not to be, but, yes, it ends up
- 11 coming out pretty awkward.
- Before the journal accepted the article
- 13 for publication, did you have any communications with
- 14 any individuals about the article outside of the
- 15 group of authors and the journal?
- 16 MS. LONG: Objection to form.
- 17 A. I called Dr. Brandt-Rauf when we were
- 18 envisioning writing the article to see if it would be
- 19 something that the journal would be interested in
- 20 publishing and he encouraged me to submit it. That's
- 21 something often you'll do, just say is this
- 22 appropriate because not all journals publish case
- 23 series. I have not had conversations with any other
- 24 individuals related to the paper except for my
- 25 colleagues in my department, but it would have been

- 1 been submitted.
 - 2 Q. I also take it from your testimony that
 - 3 the same answer with respect to any other individuals
 - 4 that serve as experts in asbestos and talc
 - 5 litigation, that you did not submit to them or have
 - 6 it submitted to them before the journal accepted the
 - 7 article for publication?
 - 8 MS. LONG: Objection to form.
 - A. I did not send drafts of the article to
 - 10 anyone for their opinion or review at all. I did not
- 11 have any conversations specific to the article.
- 12 Q. I just want to make sure those are two
- 13 separate things, right, there's the submitting of the
- 14 draft of the article and then there's having
- 15 conversations about the article, two separate things,
- 16 right?
- 17 A. Right, no one saw this article before it
- 18 was submitted. In a passing conversation I might
- 19 have said I'm about to submit something, but I don't
- 20 remember even who it was, but it was not somebody
- 21 that I have seen on a witness list where I have
- 22 testified.
- Q. You talked about a little bit early
- 24 passing conversations with your colleagues; is that
- 25 now what you're referring to as well?

4

5

6

1 MS. LONG: Objection to form.

- 2 A. People in my department know what
- 3 everyone is working on because we discuss those kinds
- 4 of things in faculty meetings, so that was what I was
- 5 discussing with respect to my colleagues.
- Q. What sort of things would you discuss at
- 7 a faculty meeting before the article was accepted for
- 8 publication?
- 9 MS. LONG: Objection to form.
- 10 That it was being submitted. We keep
- 11 people up to date on what kind of activities people
- 12 are doing including what manuscripts are being
- 13 written about what.
- 14 Q. On the funding it states, on the copy I
- 15 have, "no funds or external assistance were obtained
- 16 by any outside source in the development, writing,
- 17 analysis, conclusions of this manuscript."
- 18 Did I read that correctly?
- 19 A. You did.
- 20 Were there any changes that were made to
- 21 the funding disclosure?
- 22 A. No.
- 23 What are you trying to convey with that Q.
- 24 sentence?

1

25 MS. LONG: Objection to form. 11 identified in the copy I have as to describe

O.

- 10 The abstract, the objective is
- 12 exposures to talcum powder leading to mesothelioma

1 few hours, sometimes I worked on it for a shorter

Academic freedom is a beautiful thing.

Can you tell me whether it's, for

A. I can't even venture a guess. I don't

2 period of time. I honestly cannot give you an

3 estimate. I didn't need to count my hours.

Q. It must be nice.

7 example, less than 50 hours?

9 know how long it took.

Page 44

- 13 among 33 individuals as a non-occupational asbestos
- 14 exposure. Did I read that correctly?
- 15 A. Yes.
- 16 Q. You and your authors, co-authors use the
- 17 phrase leading to mesothelioma.
- 18 What do you mean by that?
- 19 It's just a semantic way. They had
- 20 exposure to talcum powder, they developed
- 21 mesothelioma. I wasn't leading anybody, like leading
- 22 a witness. It wasn't used in that context.
- 23 You have to also understand that the
- 24 rules of this journal are 150 words, so it's
- 25 truncated in terms of what can be put in the abstract

- That I was not paid to write this
- 2 article on behalf of plaintiff lawyers or defense
- 3 lawyers. I received no assistance from any outside
- 4 source to help me write it. I didn't have a company
- 5 author write it or a contractor write any part of
- 6 this article. The analysis and conclusions are
- 7 solely based on the authors', me included, 8 interpretation of the results.
- Q. In this context when you say analysis,
- 10 what are you referring to?
- A. Looking at the data and synthesizing it 11
- 12 all into an article.
- You had previously analyzed all 33 cases
- 14 in your capacity as an expert witness in litigation
- 15 before writing the manuscript, correct?
- A. They were all done separately and prior 16
- 17 to writing the manuscript, correct.
- 18 Q. And you were compensated at your hourly
- 19 rate by plaintiffs' attorneys for your analysis in
- 20 those 33 cases, correct?
- 21 For review of those, yes.
- 22 Do you have a sense of how many hours it
- 23 took you personally in working on this article?
- 24 A. I can't even begin to imagine. It was
- 25 done at various points and sometimes I worked on it a 25 included because she has not just exposure from

- Page 45 1 and there are guidelines as to what could be in, not
- 2 article specific, there has to be a particular
- 3 format.
- 4 Who did the drafting of this abstract? Q.
- 5 A. Ms. Bevilacqua and I did it together.
- You ultimately signed off on the content 6 O.
- 7 of the abstract, correct?
- 8 A. Yes.
- Q. Doctor, under the results of the
- 10 abstract the second sentence states, "talcum powder
- 11 usage was the only source of asbestos for all
- 12 33 cases." Did I read that correctly?
- 13 A. Yes.
- 14 Q. To your knowledge, is that going to
- 15 remain unchanged in the version that's been
- 16 published?
- 17 A. Yes.
- 18 Q. What do you mean by that sentence?
- 19 That in the 33 cases that were presented
- 20 in the article, that I was able to discern no other
- 21 exposure to asbestos.
- 22 For example, I would not have included
- 23 Ms. Wiman in this particular article. She's a
- 24 perfect case of somebody who would not have been

- 1 cosmetic talc, but also take-home exposure from her
- 2 husband. So that was the differentiation. This case
- 3 actually allows us to give you a stark example of
- 4 what I meant.
- 5 Q. Can you describe what the parameters you 6 used in choosing the individual cases for this 7 series?
- 8 MS. LONG: Objection to form.
- 9 A. Only in a general sense in that I went
- 10 through various cases and looked to see if there was
- 11 alternate exposures or additional exposures in
- 12 addition. For example, a spouse or they were
- 13 involved in home renovations or something along the
- $14\,$ like and excluded those cases from the $33\,I$ wrote
- 15 about.
- 16 Q. Were there any other general parameters
- 17 that you used in choosing the 33 that you write about
- 18 in the paper?
- 19 A. It was the cases that I had to choose
- 20 from testimony that we were writing the paper.
- 21 Certainly there have been other cases since the paper
- 22 was started that I did not include, but it was just
- 23 going through them sequentially basically.
- Q. Is it your understanding, Dr. Moline,
- 25 that Dr. Gordon was compensated for the tissue

,

- Page 47
 1 digestion work that he did as an expert witness in
- $2\,$ talc litigation for the six cases that are identified
- 3 here?
- 4 MS. LONG: Objection to form.
- 5 A. I have had no conversations with
- 6 Dr. Gordon regarding that.
- 7 Q. But do you have an understanding that
- 8 the six tissue digestions of his that are discussed
- 9 in this paper were done in the context as an expert
- 10 witness in asbestos litigation?
- 11 MS. LONG: Objection to form.
- 12 A. Yes, that was the initial manner by
- 13 which he was asked to do the tissue digestion. I
- 14 think we were pretty explicit in the article about
- 15 the providence of these cases.
- 16 Q. So there was six tissue digestions by
- 17 Dr. Gordon that are discussed in the paper, correct?
- 18 A. Correct.
- 19 Q. Did Dr. Gordon conduct any tissue
- 20 analysis of which you are aware in connection with
- 21 the other 27 cases discussed?
- A. I have not discussed that with him. We
- 23 decided to limit the number of cases to six. It
- 24 becomes overwhelming for a reader to read multiple
- 25 cases that are all very similar. I actually never

Page 48

- 1 had a discussion with him if he had ever done tissue
- 2 digestion on the other 27. We decided to write up
- 3 six cases and then describe other cases.
- 4 Q. How did you choose the six cases?
- 5 A. Again, it was six cases that Dr. Gordon
- 6 had, that he had done, and I had also reviewed those
- 7 cases and we realized in looking at those cases that
- 8 there had been no additional or no other sources of
- 9 asbestos apart from the cosmetic talc, so it was
- 10 looking at a list of these six cases and reviewing to
- 11 ensure there was no additional exposure.
- 12 O. Who selected the six cases?
- 13 A. Dr. Gordon. It was Dr. Gordon did the
- 14 tissue digestion was the starting point, so it was
- 15 these six cases that had no additional exposures.
- 16 Q. So Dr. Gordon identified these six cases
- 17 as ones where he did tissue digestions and you said
- 18 basically yes, we'll focus on these six cases?
- MS. LONG: Objection to form.
- 20 A. Yes, I believe he had given me a list of
- 21 eight or nine cases, but there were some that had
- 22 questionable additional exposures so we did not
- 23 include them. I don't remember the list.
- Q. The ones that were not included, are you
- 25 saying they weren't included amongst the six or they

- 1 weren't included amongst the 33 overall?
- 2 A. They weren't included in either.
- Q. But you did not tell Dr. Gordon that you
- 4 wanted to focus on one of the other 33 cases that are
- 5 listed in the article?
- 6 MS. LONG: Objection to form.
- 7 A. Do you mean one of the other 27?
- 8 O. Yes.
- 9 A. I did not. It was the cases he had
- 10 done, the cases I also reviewed. I did not discuss
- 11 the others.
- 12 Q. Was it Dr. Gordon that thought that six
- 13 was the right number to focus on?
- 14 A. No, it was my choice to limit it to six.
- 15 Q. You testified that there were a couple
- 16 cases that you excluded because of potential
- 17 alternative exposures, right?
- 18 A. Yes, at least one. There was one. I
- 19 don't know if there were additional.
- Q. Of the 33 that ended up being discussed
- 21 in your article, are there any that Dr. Gordon
- 22 presented to you as being one of the six that you
- 23 said no, we should not use that as one of the six?24 MS. LONG: Objection to form.
- A. No, the only cases that I'm aware of

- 1 that Dr. Gordon had any involvement with is the six.
- 2 It is possible that he did a tissue digestion on the
- 3 others, but if he did, I did not focus on that
- 4 because I decided that we were going to stop at six.
- Do you have let's call it a key that
- 6 matches up with each of the 33 case studies with the
- 7 litigation plaintiff's name?
- MS. LONG: Objection to form.
- Are you asking if I identified the
- 10 listing of the cases?
- 11 Q. Yes.
- 12 A. There is an identified case listing.
- 13 You will not get it.
- 14 Why is that?
- 15 Because it's protected under IRB and
- 16 HIPAA and it's protected health information.
- 17 Q. What is the basis of your understanding
- 18 for that?
- 19 A. That this is a research endeavor and we
- 20 did not solicit consent with the understanding that
- 21 they would be anonymous and not identified by name in
- 22 the article or other identifying features apart from
- 23 age of diagnosis and occupation or other things along
- 24 those lines.

1

25 Q. Why did you choose 33 as a number?

- Because I'm a history of science major.
- 2 Q. You reference the Wagner paper; is that
- 3 the reason you chose 33?
- A. I thought it was a beautifully
- 5 symmetrical way to describe a -- since Dr. Wagner in
- 6 1960 made the connection or the widely accepted
- 7 connection between mesothelioma and asbestos based on
- 8 a case series of 33 individuals that has been widely
- 9 accepted in the medical literature, I thought it was
- 10 only fitting to use that same number in an article
- 11 almost 60 years later that's describing an exposure
- 12 that heretofore had not been comprehensively
- 13 described in the medical literature. It's of a
- 14 historical reference. I could have picked another
- 15 number, but I like the historical implications.
- Q. At the time that you were selecting
- 17 which cases to use in your case series, how many
- 18 cases did you have available to select from?
- A. More than 33. I don't remember the
- 20 exact number. I have not counted the exact number of
- 21 cases I've reviewed, so I can't give you an actual
- 22 number.
- 23 Do you have a sense of how many cases
- 24 you excluded from the series on the basis that they
- 25 were essential asbestos exposures separate and apart

1 from the talc usage?

- 2 A. I don't recall the exact number. It was
- 3 something initially going through the various cases
- 4 that I reviewed, which is many more than 33 over the

Page 52

- 5 past years. Honestly, I can't give you an exact
- 6 number. I can't say it was 50 percent. I can't say
- 7 25 percent. I don't know because I wasn't cataloging
- 8 my exclusions.
- For those cases where you did not Q.
- 10 identify a potential other source of asbestos from
- 11 the cosmetic talc, what criteria did you use to
- 12 choose your 33?
- 13 A. I'm sorry. I lost you.
- 14 You talked about excluding some from the
- 15 case series where you identified a potential asbestos
- 16 exposure.
- 17 A. Ms. Wiman, for example.
- 18 Without would not have been available to
- 19 you I don't think at the time you were drafting the 20 article, fair?
- 21 MS. LONG: Right. It should be clear
- 22 that you're using Wiman as an example of the type.
- 23 She was not considered, nor excluded,
- 24 but because we're here, hopefully going to get back
- 25 to the case at some point in my life, she's a prime
 - Page 53

Page 51 1 example of someone who would not have been included

- 2 because she had a second exposure or potentially
- 3 others. So that was the same type of analysis that I
- 4 went through; if in the course of either my interview
- 5 or the deposition transcripts or other information
- 6 available there was identification of an alternate
- 7 exposure, then they would have been excluded.
- Q. So my poorly worded question earlier,
- 9 this isn't much better, my question then is, of the
- 10 cases available to you at the time you were selecting
- 11 your 33 that did not in your estimation have a other
- 12 potential source of asbestos exposure, what criteria
- 13 did you use to use amongst those for your 33?
- A. It was basically sequential. I went
- 15 through the various reports that I've written or
- 16 cases that I've reviewed and began compiling those
- 17 that are cosmetic talc. It wasn't like I said
- 18 73 percent women and 27 percent men. I didn't have
- 19 exclusion criteria along those lines apart from
- 20 having an additional exposure to asbestos or
- 21 potential asbestos exposure.
- 22 If I'm hearing you correctly, once you
- 23 got to 33 as you're going down the list where there
- 24 wasn't, in your estimation, other potential source of
- 25 asbestos exposure you stopped?

Page 54

A. Yes. I could have continued, but I

- 2 wanted my 33 number. If I were to write the paper
- 3 and include all of them, the number would be much
- 4 higher.

1

- 5 Q. Do you have an estimate of how much
- 6 higher it would be?
- 7 A. I don't know. I haven't looked. There
- 8 certainly are cases I've reviewed since then where
- 9 their sole exposure to asbestos has been to cosmetic
- 10 talc that are not included or were not considered in
- 11 the manuscript, but I can't give you a number.
- Q. I believe I know the answer to this
- 13 question based on your answer to the previous
- 14 question, but I'll ask it anyway.
- 15 In selecting the cases for your case
- 16 series, did it matter to you the type of mesothelioma
- 17 that the individual had been diagnosed with?
- 18 A. Define type.
- 19 Q. I will be very general with respect to
- 20 peritoneal, pericardial or pleural.
- 21 A. You mean location of tumor?
- 22 Q. Sure.

2

- 23 A. That is the anatomically correct
- 24 question rather than type because type could mean --
- 25 do you mean biphasic? Do you mean sarcomatoid? Do
 - Page 55
- 1 somehody who worked in an as
- Q. Sure.A. I did not pay attention or I did not2 were not living in an 3 renovations, they have
- 4 differentiate based on anatomical location or first
- 5 presentation of tumor.

1 you mean epithelioid?

- 6 Q. If we are using your definition of type,
- 7 I take it you did not differentiate based on the type
- 8 of mesothelioma?
- 9 A. I did not differentiate based on
- 10 pathological classification either.
- 11 Q. You did not differentiate in choosing
- 12 your 33 cases as between whether or not the
- 13 individual was a male or female?
- 14 A. No.
- 15 Q. When you submitted the manuscript for
- 16 publication, did it have 33 cases?
- 17 A. Yes.
- 18 Q. Was there any peer review process,
- 19 comments about the number of cases that you had
- 20 chosen?
- 21 A. No.
- Q. Is it accurate that you did not
- 23 encounter any of the 33 individuals referenced in the
- 24 article in the course of your clinical practice?
- 25 A. Are you asking me if any of them came to

- 1 me on their own as opposed to being referred in by a
- 2 lawyer? Is that what you're asking me?
- 3 Q. Yes.
- 4 A. No one came to me directly.
- 5 Q. All of these came to you via lawyers in
- 6 connection with litigation?
- 7 A. Correct.
 - Q. When you say in the Background section,
- 9 "for all 33 cases, other potential exposures to
- 10 asbestos were considered, with no identified source
- 11 apart from the talcum powder."
- Did I read that correctly?
- 13 A. Yes.
- 14 Q. What information did you consider in
- 15 determining whether or not there were other potential
- 16 exposures to asbestos?
- 17 A. I think it's described later in the
- 18 manuscript and I think we've talked about it already.
- 19 It was whether they had any household exposure, they
- 20 worked in an occupation where there was asbestos
- 21 exposure apart from the use of cosmetic talc.
- For example, there are three
- 23 hairdressers, so they had occupational exposure to
- 24 cosmetic talc, but it was all cosmetic talc, they
- 25 didn't have take-home exposure from living with
 - Page 57

- 1 somebody who worked in an asbestos profession, they
- 2 were not living in an home or participating in home
- 3 renovations, they had no identifiable source of
- 4 asbestos exposure.
- 5 Q. I understand it may be different, the
- 6 specifics may be different as to each individual of
- 7 the 33. I'm trying to get a sense of your process
- 8 overall, so I'll start general.
- 9 In reviewing materials for other
- 10 potential asbestos exposures, did you or your
- 11 co-authors do any new investigation for any of the
- 12 cases that had not already been done in litigation?
- 13 A. No.
- 4 Q. In reviewing other potential asbestos
- 15 exposures, did you review any data other than that
- 16 which you reviewed at the time of your deposition in
- 17 that particular case?
- 18 A. I have no idea how to answer that
- 19 question. I don't know what you're asking me. If
- 20 you're asking me if I was deposed in case A, I would
- 21 have been asked what I reviewed at that deposition.
- 22 Maybe I was provided something subsequent which would
- 23 have been in a supplemental report if there was one,
- 24 but I don't recall any specifically with these
- 25 33 cases.

Page 58 Q. It's not a trick question.

2 No, I understand. I don't really know

- 3 what you're asking me. I hadn't been provided with
- 4 any other information that I recall apart from the
- 5 information that had initially been provided that I
- 6 used in generating my reports.
- 7 Q. Let's take not a hypothetical case,
- 8 let's just take one of the cases, typically in one of
- 9 your talc cases you will receive materials from
- 10 counsel as you prepare your opinions in that case,
- 11 correct?

1

- 12 A. Correct.
- 13 Q. That could include medical records,
- 14 correct?
- 15 A. Yes.
- 16 Q. It can include expert reports both from
- 17 the plaintiffs' side and from the defense side,
- 18 correct?
- 19 A. Occasionally, not always. I rarely get
- 20 defense reports.
- 21 It can include the plaintiff's Q.
- 22 depositions?

A.

Q.

10 correct?

2

4

5

8 9

11

25

23 It always includes the plaintiff

1 talking about exposure information, correct?

3 information like a very close friend.

In general, yes.

- 24 depositions if they're alive.
- And any family member that may be 25

Or other individuals that may have

Or a co-workers, for example, correct?

In some jurisdictions you will issue a

And then you are usually deposed,

Page 60

- 1 Let me finish my question before you say you won't 2 comment.
- 3 A. Okay.
- 4 Q. Thank you. Hypothetically if one of the
- 5 33 cases went to trial, I'm not saying they did or
- 6 they didn't, would you have reviewed your trial
- 7 testimony in that case?
 - MS. LONG: Objection to form.
- A. In general I never look at my trial
- 10 testimony once I've uttered the words unless I'm 11 asked a question about it in a subsequent trial where
- 12 I'm impeached on my prior trial testimony. I did not
- 13 include any of my personal testimony in consideration
- 14 for any cases in this.
- 15 In reviewing potential other exposures
- 16 apart from cosmetic talc to asbestos, would you have
- 17 reviewed testimony at trial of other witnesses if it
- 18 existed?

8

- 19 MS. LONG: Objection form.
- 20 I would not have reviewed other
- 21 testimony at trial. I don't believe I'm allowed to
- 22 do that, certainly not before I testify.
- I'm talking about, and it does depend on
- 24 the jurisdiction, but I'm talking about in connection
- 25 with this report, with this article.

Page 59

With respect to this article I did not

- 2 look at any trial testimony, it was only based on the
- 3 initial information provided to me in order to keep
- 4 it as uniform as possible.

- 7 the 33 cases, would you have reviewed that as you
- 8 were assessing for this article whether that
- 9 particular case had other potential sources of
- 11 A. In some jurisdictions thankfully I'm
- 12 not. So I would not be deposed in certain
- 13 jurisdictions, other jurisdictions, unfortunately,
- 14 I'm deposed, which makes you happy because you get to
- 15 sit in this airless room.

7 written report, correct?

Correct.

- 16 Q. This does not make me happy.
- With a lovely court reporter who is 17 A.
- 18 among the best.
- 19 Q. Is it fair that some of these 33 cases
- 20 ultimately went to trial?
- 21 Do not know, will not comment.
- 22 Well, are you saying that --
- 23 I will not comment on any specific case
- 24 included in the paper.
 - I'm not asking about a specific case.

- To the extent that you had given a
- 6 deposition or depositions in connection with one of

- 10 asbestos exposure?
- A. I did not review any of the transcripts
- 12 of my personal depositions in the generation of this
- 13 article.
- 14 If we go to Case Histories under
- 15 Materials and Methods, it talks about there in the
- 16 middle of that first paragraph, "exposure data was
- 17 obtained from sworn testimony by the cases, which
- 18 included extensive questioning regarding all sources
- of asbestos exposure." Did I read that correctly?
- 20 A. Yes.
- 21 Q. In connection with this article, did you
- 22 review any exposure data apart from sworn testimony
- 23 of the individual and the family member?
- 24 Only if it had been provided to me, but
- 25 in all likelihood it would have included alternate

Page 62 Page 64 1 exposures that would not have led to them being 1 That was based in fact, not on hypothesis or 2 included in this particular manuscript. 2 conjecture. But if it had been present, for example, Q. I appreciate all that, but how would you 4 if I had been provided with evidence that an 4 have been able to assess whether those other 5 potential exposures were, as you say, hypothetical or 5 individual had asbestos exposure from sampling done 6 legitimate if it was raised for the first time at 6 in their home that showed that there was asbestos 7 from construction materials and they described home 7 your deposition and you didn't review your deposition 8 renovations, then that would have been considered and 8 transcript in connection with the writing of this 9 I would have included that individual. article? Q. I do apologize, but in there did you 10 MS. LONG: Objection to form. 11 Again, I don't recall that this happened 11 talk about it coming out in testimony? One of the 12 questions I have of you is, did you review in 12 with respect to any of these cases and I don't recall 13 connection with this article and these 33 patients that I was presented with hard evidence of exposure. 14 14 anything apart from the testimony that's identified I've been presented with some really 15 creative potential exposures just because someone 15 here and medical records? 16 lived in an area with no air sampling, with no proof 16 MS. LONG: Objection, asked and 17 answered. 17 that what was claimed actually transpired in 18 manufacturing plants and that was claimed as an 18 A. Again, what I reviewed is included. If 19 there was additional information provided then I alternate exposure that had no basis in fact and I 20 would have reviewed it. Again, chances are if there 20 would not have included because there was no 21 information. I'm just speaking hypothetically. We 21 was additional information provided, they would not 22 be included in the paper because that would have 22 were limited to the data we had in hand with respect 23 prevented them from not having any other source of 23 to what was described. 24 exposure. For the cases included in this paper, they 24 Q. Is it your testimony that as you sit 25 here today you can't recall a single time in cosmetic 25 would not have had an alternative exposure for which Page 65 Page 63 1 talc litigation where you found out for the first 1 exposure data was presented. 2 time at your deposition of a legitimate potential Q. If in evaluating potential asbestos 3 asbestos exposure? 3 exposures in giving your opinions in a particular 4 Legitimate? 4 case you did not identify a potential source of A. 5 asbestos exposure until you were asked about it at 5 Legitimate. Meaning there was air testing, air 6 your deposition, would that have been reviewed in 7 sampling, air monitoring, there was proof that the 7 connection with this article? 8 individual was there? I don't recall a specific 8 MS. LONG: Objection to form. It depends on the timing of when the 9 instance where I have seen specific I was in a plant, 10 my spouse was in a plant that I didn't know used 10 deposition might have been. If I was asked about a 11 exposure, the question is, was it a real exposure or 11 asbestos and they brought it home to me that was 12 was it a hypothetical exposure that might not have 12 real. 13 had any basis in provable fact that I am often 13 I have been provided with various 14 confronted with in depositions. 14 exposure scenarios based on someone living in a 15 15 community where -- that they live in a city that has So if I had any question whether there 16 buildings and being asked if that was a risk factor 16 was exposure to an alternate source at the time I was 17 without any evidence that the individual had specific 17 writing this paper, I would have excluded them. I 18 exposure to asbestos and I'm supposed to assume just 18 don't recall that that occurred in any of these 19 33 cases, but if it did, on further consideration I 19 because a person lived in a city that that provided 20 them with exposure to asbestos above what the 20 would have substituted in another individual for whom 21 there was no additional exposure. 21 background might be. I don't recall if I've been 22 provided with credible information. 22 I honestly don't recall that happening, 23 To circle back to your full question so 23 but that's what I would have done. My scientific

24 you won't say I'm not responsive, I don't recall

25 specifically. I've been in too many depositions

24 reputation is on the line. This is to the best of my

25 understanding, the cases had no alternative exposure.

- 1 clearly. I don't recall specifically and certainly
- 2 not for these 33 cases where I've been provided with
- 3 credible, measurable asbestos exposure in a
- 4 deposition.
- 5 Q. In your article under that same
- 6 paragraph you talk about in the context of sources of
- 7 asbestos exposure residents --
- 8 A. What page are you on?
- 9 Q. It's under Materials and Methods under
- 10 Case Histories.
- 11 A. There are page numbers at the bottom.
- 12 Q. I have an un-paginated copy because I
- 13 got it hot off the presses.
- 14 A. Page six.
- 15 Q. Page six. On page six under Case
- 16 Histories it talks about potential sources of
- 17 asbestos exposure, "residence in an area that might
- 18 have had asbestos industry leading to possible
- 19 environmental exposures." Did I read that correctly?
- 20 A. Yes.
- 21 Q. Is it your testimony that you would only
- 22 consider such exposures if there was what data
- 23 available?
- MS. LONG: Objection to form.
- 25 A. If there's actual data available. I've

- 1 these results are not presented in this paper.
 - Why did you not, as part of your review
 - 3 of these 33 cases and potential sources of asbestos
 - 4 exposure, review any other tissue analysis that might

Page 68

- 5 have been done in a particular case by an
- 6 investigator other than Dr. Gordon?
- 7 A. Because we felt it important to have the
- 8 same lab do all the analysis of the cases that we
- 9 presented in detail and other labs might have used
- 10 different tissue methodology or analysis, and for
- 11 consistency sake we chose the six cases, but there
- 12 might have been others, I don't recall, and I
- 13 certainly don't know who, if any, but it's possible
- 14 that there were tissue digestion done on some of the
- 15 other cases.
- 16 Q. As you sit here today, do you know
- 17 whether any of the 33 had tissue digestion done by
- 18 someone other than Dr. Gordon?
- 19 A. I can't answer that question with any
- 20 degree of certainty. It's possible, but we wanted to
- 21 make sure that we said that it's possible that there
- 22 might have been tissue analysis, I just was not
- 23 presenting a detail case report with any of that
- 24 information.
- Q. One of the points that you emphasize in

- 1 had individuals, not included in this paper, who
- 2 describe asbestos on their front lawn or on their car
- 3 from a plant that was in their community. That would
- 4 be sufficient for me to say that the asbestos
- 5 industry led to a potential exposure to asbestos.
- 6 Q. A little bit further up it says, "all
- 7 cases were reviewed by an occupational physician with
- 8 experience evaluating exposure in thousands of
- 9 patients"; is that you?
- 10 A. Yes.
- 11 Q. Skipping around a little bit, but just
- 12 trying to stay on topic, on page 31, let me know when
- 13 you're there.
- 14 A. Yes.
- 15 Q. I'm looking at the asterisk under the
- 16 table that reads, "tissue analysis presented done by
- 17 author. Tissue analysis might have been done in some
- 18 cases by other investigator, these results are not
- 19 presented in this paper." Did I read that correctly?
- 20 A. Yes.
- Q. The author, just for the record, that's
- 22 Dr. Gordon, correct?
- 23 A. Correct.
- 24 Q. It talks about tissue analysis might
- 25 have been done in some cases by other investigator,

- Page 69
 1 the discussion is that amosite and crocidolite were
- 2 not found in any of these cases; is that accurate?
- 3 A. In the six cases, yes.
- 4 Q. The six cases. To the extent that there
- 5 was amosite or crocidolite found by an investigator
- 6 in tissue digestion other than Dr. Gordon, you would
- 7 not have reviewed that in connection with this
- 8 article, correct?
- 9 A. Correct.
- 10 Q. You talk about how your reputation as a
- 11 scientist is on the line with this paper, right? You
- 12 made that reference earlier.
- 13 A. Any time someone publishes you are
- 14 basing it to the best of your ability, which is why
- 15 we put paragraphs about limitations of a paper in
- 16 there because there are opportunities for us to
- 17 get -- there's always opportunities in any paper,
- 18 there's always limitations. I would not knowingly
- 19 put out anything that was not to the best of my
- 20 knowledge correct.
- Q. In that vein, if in one of these
- 22 33 cases there was a tissue digestion done by
- 23 multiple analysts that identified crocidolite, as a
- 24 scientist writing this paper why would you ignore
- 25 that?

MS. LONG: Objection to form.

- 2 A. That's assuming I had it available prior
- 3 to writing up the cases and, again, I'm using
- 4 Dr. Gordon's analysis.

1

- Q. When you say available to you, you
- 6 certainly have access to other defendant expert
- 7 reports or plaintiff expert reports in connection
- 8 with the cases in which you're testifying, correct?
- 9 A. At certain points during the litigation 10 possibly.
- 11 Q. Certainly if in connection with the
- 12 Wiman case you want to look at a defense expert
- 13 report submitted in the case, you're confident, I
- 14 take it, that you can ask plaintiff's counsel and she
- 15 would give it to you, right?
- 16 A. I'm sure she would.
- 17 Q. So in trying to reach your scientific
- 18 conclusions, why, as a scientist, did you not look at
- 19 data that bore directly on the questions presented by
- 20 your article?
- 21 MS. LONG: Objection to form.
- 22 A. Again, if you're speaking about a tissue
- 23 digestion then that would have been under
- 24 Dr. Gordon's realm and I would have expected that he 24
- 25 would have looked at whatever data were available

Page 70 Page 77

- 1 a particular case that was one of these 33, would you
- 2 also have reviewed that and any materials cited in 3 that report?
- 4 A. If they existed; I don't recall that
- 5 they did.Q. I'm not saying that there is one.
- 7 A. I don't think there was. It's certainly
- 8 not in the generation of the 33.
- 9 Q. As you noted, there are some cases in
- 10 which you don't or didn't provide a written report,
- 11 how in preparing this article would you have
- 12 identified the materials to review?
- 13 A. I think there was only one case that I
- 14 had not provided a report in and the other one would
- 15 have been going through notes.
- 16 Q. So the one where you didn't provide a
- 17 report, you would have gone through notes similar to
- 18 what you have done for Ms. Wiman in this case?
- 19 A. Correct.
- Q. For the other 32, in assessing potential
- 21 alternative asbestos exposures you would have
- 22 reviewed your report and anything referenced in that
- 23 report, correct?
- at he 24 A. Correct.

1

Q. Would you have reviewed anything else?

Page 71

- 1 with respect to tissue digestion. I don't recall the
- 2 specific -- I don't know what case you're speaking
- 3 about.
- 4 Q. I can show you.
- 5 A. Well, I'm not going to discuss whether
- 6 that person is included in the paper or not.
- 7 Q. Okay.
- 8 A. But was that something that Dr. Gordon
- 9 found and that would be a question you can ask
- 10 Dr. Gordon, why might someone have found something
- 11 that he didn't, but we were basing it on the initial
- 12 tissue digestion or the only tissue digestions that
- 13 we were aware of at the time that these cases were
- 14 written up, which was in 2018.
- 15 Q. Talk more about your process of
- 16 evaluating the potential other asbestos sources. If
- 17 it was a jurisdiction in which you had authored a
- 18 written report, would you have reviewed that in
- 19 connection with this paper?
- 20 A. Yes.
- 21 Q. In those cases where you had authored a
- 22 written report, what else would you have reviewed?
- A. The materials leading up to the
- 24 generation of that report.
- 25 Q. If you authored a supplemental report in

Page 73 Whatever materials were referenced in

- 2 the report is what I have reviewed.
- 3 Q. That was part of my question. Apart
- 4 from the report and any materials referenced in the
- 5 report, would you have reviewed anything else with
- 6 respect to those 32 cases?
- 7 A. Not that I can think of. Certainly not
- 8 at the time that we wrote the manuscript.
- 9 Q. So if there was an alternative source of
- 10 exposure that was raised with you after you issued
- 11 your report in those 32 cases, whether it be a
- 12 deposition or a trial or otherwise, you would not
- 13 have considered that in connection with this article,
- 14 correct?
- MS. LONG: Objection to form.
- 16 A. The cases were written when the cases
- 17 were written. They were written fairly early on. I
- 18 did not go back and revise it based on any further
- 19 activities that might have transpired in a deposition
- 20 or in a trial. I will not comment on any further
- 21 cases that might or might not be included in the
- 22 paper.
- 23 Q. I understand that maybe you find out --
- 24 you write the case report description and then you
- 25 find out some new stuff afterwards, but what I'm

Page 74 Page 76 1 talking about is a situation in which you are deposed 1 Do you recall talking about that? 2 in a particular case, an alternative exposure to A. I think I was talking about it in your 3 asbestos is identified to you for the first time in 3 hypothetical, what might be presented to me in a 4 that deposition, if that deposition occurred before 4 deposition based not on fact but on conjecture with 5 you started writing this article, you would not have 5 no information that the exposures were above 6 considered the alternative exposure in this article, 6 background, correct. 7 correct? Q. My question is, in the article it talks 8 MS. LONG: I'm going to object to the 8 about just whether or not there were other potential 9 form. I just want to make sure we're speaking now in 9 asbestos exposures and doesn't mention whether or not 10 hypothetical terms because the more that you lay out 10 they are above background, correct? 11 specific situations and represent that maybe that's 11 I don't use that terminology in the 12 the way things went, I think by asking Dr. Moline to 12 paper. 13 comment on them, then it becomes difficult for her to 13 Okay. So my question then is, in 14 maintain the anonymity of the subject. 14 assessing whether there were other potential asbestos 15 Again, just to make sure that's in a --15 exposures, did you look for any potential alternative 16 if that were to happen and if hypothetically this was 16 asbestos exposures or only ones you determined would 17 the situation I think, Dr. Moline, you can answer to 17 be above background? 18 the extent you understand the question. 18 MS. LONG: Objection to form. The cases were written up at the 19 I looked at the information that was 20 beginning of the first thing that we did, which was 20 provided to me based on the questioning which was 21 to pick six cases for which there is a longer case --21 more extensive than one would typically get from a 22 were done -- that was done -- that was the easy part 22 standard questionnaire in general from these cases. 23 23 for me because I'm writing up a clinical case, and So I took any exposures that were 24 that was done at the beginning of when we embarked on 24 assessed whether it be eight brake changes that they 25 this endeavor, and they were not revised based on any 25 accompanied their spouse with. I would have not Page 75 Page 77 1 tried to quantify that exposure, but I would have 1 additional information apart from what was done to 2 excluded that individual from the report because 2 make it consistent with all of the articles. 3 3 there was a potential exposure. When are we going to stop because we've Q. If I'm hearing you correctly, if during 4 been going for an hour and a half? 5 MS. LONG: Do you want to do a lunch 5 your review of the materials you reviewed in 6 connection with this article, if you identified a 7 MR. EWALD: Sure. 7 potential source of asbestos exposure that one of the 8 33 patients suffered -- one of the patients was 8 (A recess was taken.) 9 9 exposed to, that you would have removed that patient (Time noted: 12:40 p.m.) ******** *#0 from the case series regardless of whether or not 10 11 that exposure to asbestos was above background? 11 AFTERNOON SESSION ************* 12 I wasn't assessing in my analysis if 13 there was any suggestion that someone had an 13 (Time noted: 1:15 p.m.) 14 CONTINUED EXAMINATION 14 additional exposure based on their deposition 15 transcripts or other information provided to me, I 15 BY MR. EWALD: 16 did not include them in the 33 based on the Q. Doctor, do you agree that the only 17 information I had at the time I wrote the paper. 17 potential asbestos exposures you considered in 18 You talked about how every scientific 18 connection with your article are those referenced in 19 your expert reports or your case notes for each 19 article has limitations, right? 20 A. Yes. 20 individual case? 21 21 In your paper, specifically on page 21 22 and 22, you discuss the limitations in which the case 22 At some point in our back and forth, in 23 series should be understood, correct? 23 our discussion before lunch, at some point in time 24 Correct. 24 you were talking about whether or not the potential A. 25 In that discussion of the paper's 25 asbestos exposures were exposures above background. Q.

1 limitations, you do not discuss as one limitation the 1 part of your clinical practice that has mesothelioma, 2 possibility of other tissue digestions for the 33 2 you typically take an extensive exposure history, 3 patients that were not considered in this article, 3 right? 4 4 correct? A. Correct. 5 A. I did not specifically mention that in You previously testified that taking a 6 proper exposure history is a crucial element of the 6 the limitations, that is correct. 7 7 work that occupational medicine doctors do, right? I'm almost certain I know how you're 8 going to answer, but I'm just going to make my record A. Correct. 9 and then we can move along and deal with it later. Q. For the 33 cases discussed in your It's my intent, if counsel permits it on 10 article, how many, if any, did you personally take an 11 plaintiffs and if Dr. Moline answers, to show 11 asbestos exposure history of the patient for 12 rendering the opinion that their mesothelioma was 12 Dr. Moline expert reports that she has previously 13 authored and use those expert reports to match up the 13 caused by talcum powder? 14 identities of some or all of the 33 cases that are 14 A. I don't recall how many. 15 identified in the article. 15 Q. As you sit here today do you recall any? My question to I guess you is, if I 16 I know there were some, but I can't 16 A. 17 proceed with that, will you answer my questions? 17 recall and I will not comment further. 18 On page seven before you get into the I will not. 19 MR. EWALD: Counsel, do you I guess --19 case descriptions of the six, you talk about how 20 MS. LONG: Am I following the witness' 20 these six case reports are presented in greater 21 advice? 21 detail; their clinical course was similar to all 33 22 MR. EWALD: Yes. 22 cases evaluated and the same rigor with respect to 23 MS. LONG: Yes. Dr. Moline has a right 23 obtaining information related to any asbestos 24 not to testify about information protected by HIPAA 24 exposure as applied to all 33 cases. 25 and by restrictions put in place by her internal 25 Did I read that correctly? Page 79 1 review board, and certainly she's made her position 1 A. Yes. 2 clear on where she feels comfortable testifying about 2 How are you able to make a 3 the article and where she doesn't. 3 determination, comparative determination as to the I agree that matching up the reports to 4 rigor by which asbestos exposure information was 5 specific people in the article would go further than 5 obtained across the 33 cases? 6 she feels is correct under the privileges and A. It was referring to the same rigor that 7 protections that she cited, so I'm not going to 7 I used, meaning that the same methodology used in the 8 instruct her to answer contrary to her ethics and 8 six cases was used to evaluate the other 27. 9 guidelines on that. Q. Why you can't or won't or both tell me 10 MR. EWALD: I appreciate that, Counsel. 10 how many of the 33 patients you personally did 11 Just for the record I will note that we disagree with 11 exposure history of, you would agree with me that 12 that position and that we will take it up later, but 12 there are many of the 33 in which you did not conduct 13 certainly reserve our rights to ask those questions 13 any exposure history, correct? 14 if the Court permits or we otherwise reach some other 14 MS. LONG: Objection to form. 15 agreement. Thank you both for that. 15 A. First of all, I honestly don't remember Q. As part of your clinical practice you 16 how many, so I don't appreciate the can't or won't. 17 ordinarily take an extensive exposure history when 17 I honestly have no recollection of how many of them I 18 dealing with a patient that has mesothelioma, 18 did. 19 correct? 19 To be clear on that, I was saying the 20 Is that presupposing that I don't take 20 can't because you also say that somehow gets into the 21 an extensive exposure history when a patient doesn't 21 privacy concerns. That's all I was referring to. 22 present with mesothelioma? 22 I'm not suggesting that you are withholding

21 (Pages 78 - 81)

Page 81

24

23 information.

A.

25 no recollection.

I'm not trying to deceive you. I have

That is not at all what I'm saying. I'm

24 not trying to get every negative out there. I'm just

25 trying to say when you have a patient come to you as

1 Q. I was not suggesting otherwise.

- 2 A. Can I please have the question again.
- 3 Q. It's your recollection that at least,
- 4 we'll say at least one, I'm not saying there was one,
- 5 but at least one of the 33 you have a recollection of
- 6 personally taking an asbestos exposure history of
- 7 that patient, right?
- 8 A. It's potential.
- 9 Q. Let's say as you sit here today, do you
- 10 remember any of it that you know you took exposure
- 11 history of those 33?
- 12 A. Yes.
- 13 Q. Conversely, there are at least some
- 14 patients where you did not personally take an
- 15 exposure history of that are discussed in this
- 16 article, correct?
- 17 A. Yes.
- 18 Q. In those circumstances where you did not
- 19 personally take the exposure history, who are you
- 20 relying on to obtain that exposure history?
- 21 A. I think it's spelled out either two or
- 22 three times in the article that the information was
- 23 obtained through deposition transcripts of the
- 24 individual, the family members or anyone who had
- 25 personal knowledge of the individual using the talcum
 - Page 83
- 1 powder.
- Q. So the questioning in that circumstancewhere you did not personally conduct exposure history
- 4 would have been done by lawyers, correct?
- 5 A. Correct.
- 6 Q. You talk about how in the article that
- 7 even some med students don't know how to take proper
- 8 occupational exposure histories, correct?
- 9 A. I don't know if I said that med
- 10 students. I discussed that there's very little
- 11 discussion in the medical school curriculum in
- 12 general about occupational histories. I don't recall
- 13 that I said med students don't know how to take
- 14 occupational histories.
- 15 Q. Do you have any knowledge as to the
- 16 medical training of any of the lawyers that
- 17 questioned the patients or their family members or
- 18 people with relevant knowledge at deposition in the
- 19 33 cases that you rely on?
- A. It's not really medical knowledge that's
- 21 important for an exposure history per se. I'm not
- 22 familiar with the educational background of the
- 23 various questioners. I was more evaluating the
- 24 questions and answers to see how comprehensive they
- 25 were and using the information that was available to

- 1 me.
 - 2 Q. Understood. My question is, you
 - 3 testified today and previously that one of the major
 - 4 specialties that you bring to the table as an
 - 5 occupational medicine doctor is your knowledge of
 - 6 these potential asbestos exposures, correct?
 - 7 A. Particularly in a case where there's no
 - 8 identifiable source, yes.
 - 9 Q. Presumably you're not aware of any of
 - 10 the lawyers that questioned the patients or their
 - 11 family members in connection with this article, the
 - 12 33 plaintiffs, have any training as an occupational
 - 13 medicine doctor, correct?
 - 14 A. Presumably not.
 - 15 Q. So when you're talking about the rigor
 - 16 with which the questioning of these 33 cases for a
 - 17 potential alternative exposures, you're relying on
 - 18 lawyers for that rigor, correct?
 - 19 A. The term rigor was used with respect to
 - 20 my evaluation of the cases was the same for all 33.
 - 21 That's where I use the term rigor as we discussed
 - 22 earlier today. With respect to the questioning, it's
 - 23 dependent on the questions and answers asked of the
 - 24 individual or their family members, that is correct.
 - O. Let's talk a little bit about the
- Page 8

Page 84

- 1 discussion of control samples on page 17. There's a
- 2 paragraph on page 17 under control samples right
- 3 before the Results section, was this paragraph
- 4 drafted by Dr. Gordon?
- 5 A. It was drafted by Dr. Gordon and then I
- 6 and Ms. Bevilacqua did some wordsmithing, but this
- 7 was based on Dr. Gordon's controls and this is his
- 8 data.
- 9 Q. In connection with the drafting of this
- 10 article, did you discuss with Dr. Gordon details
- 11 regarding his control set?
- 12 A. I had been aware of his control set well
- 13 before this paper. From conversations he had
- 14 discussed wanting to include the control samples in
- 15 the paper as a way of -- because there had been a
- 16 1 1 6 1 1 1 1 1 1 1 1 1 1 1
- 16 dearth of control samples in the medical literature
- 17 and including that in this paper.
- 18 Q. Do you have an understanding as to
- 19 whether Dr. Gordon modified his control sample
- 20 universe in connection with this article than what
- 21 had previously been published about it?
- A. My understanding -- this is a question
- 23 for Dr. Gordon.
- Q. I'm asking your understanding.
 - A. My understanding is that these control

4

- 1 samples predated any discussion of certainly this
- 2 paper and, in fact, I'm aware that they predated any
- 3 discussion and actually probably predated any
- 4 consideration of talc.
- I understand that -- I'm going to hold
- 6 you to your understanding of what the situation is,
- 7 but we'll ask Dr. Gordon the particulars.
- In that paragraph it states that
- 9 "exposure histories had been obtained by treating
- 10 pulmonologists or surgeons from all individuals; all
- 11 were screened for asbestos exposure for personal use,
- 12 family exposure, and personal or family use of talcum
- 13 powder."
- 14 Is it your understanding that the
- 15 control group was asked about personal or family use
- 16 of talcum powder?
- Based on Dr. Gordon's -- this is from 17 A.
- 18 Dr. Gordon.
- 19 O. I'm asking you.
- 20 I don't know other than what Dr. Gordon
- 21 contributed to the article and what he wrote. I know
- 22 that he was explicit in including that in this
- 24 in the past, about 20 years ago he published, and it
- 25 may be related to that, but these are questions that

1 I don't have any further information beyond what is

2 in the text regarding Dr. Gordon's control samples.

Q. I'm entitled and so I wanted to know

4 what your level of understanding is, so I'm not going 5 to go beyond that, but if it turns out that some or

6 all of the control group were not questioned about

7 their use of talcum powder, does that, in your view,

A. I think his control population was to

8 limit the usefulness of this control sample?

- 1 investigation that is described in that paragraph of 2 potential asbestos exposures was more extensive than

Page 88

- 3 you did with the 33, fair?
 - MS. LONG: Objection to form.
 - With respect to the people as they were
- 6 collecting their tissue, they would have spoken to
- 7 the treating doctor, so yes, in most cases I did not
- 8 speak to the treating doctor.
- Q. In any cases did you speak to the
- 10 treating doctor?
- 11 It's possible, but not that I A.
- 12 specifically recall.
- 13 On page 21, in talking about, again, the
- 14 limitations of the article, it talks about how the
- 15 depositions were thorough and included both
- 16 exhaustive questioning about alternative sources of
- 17 asbestos exposure.
- 18 On what basis do you and your co-authors
- 19 conclude that the depositions included, quote,
- 20 exhaustive questioning about alternative sources of
- 21 asbestos exposure?
- 22 A. I read the depositions in these cases
- 23 section. Dr. Gordon has written about talcum powder 23 where people are asked questions over and over again.
 - 24 It's my description of the depositions and the
 - 25 questioning that took place.

Page 87

- Page 89 But you're not in a position to make an 1
 - 2 assessment that all potential sources of asbestos
 - 3 exposure were, in fact, discussed at the patient's
 - 4 depositions, correct?
 - 5 MS. LONG: Objection to form.
 - You're asking me a hypothetical. That's 6
 - 7 unknowable. They asked as many as were in these
 - 8 categories.
- MS. LONG: Objection to form. 9 I take it also that Dr. Gordon was the Q.
 - 10 person responsible for creating table three on page
- 11 talk about a general control population of
- 12 individuals who had no known exposure to asbestos, so
- 13 if they did have exposure to talcum powder, then that
- 14 would not be a full control group.
- 15 Then it goes on to say that, "for those
- 16 patients in whom there was any question of asbestos
- 17 exposure, from any source, the pathologists conferred
- 18 with the treating clinician to make ensure there was
- 19 no known asbestos exposure."
- 20 Did I read that correctly?
- 21 A. You did.

- 22 That is your understanding of what
- 23 happened with respect to the control population?
- 24 From Dr. Gordon, yes, that's correct.
- 25 Based on your testimony today, the Q.

- 11 33?
- 12 It was a collaboration. We worked on it
- 13 to just make it more presentable, but the data are
- 14 all directly from Dr. Gordon. We just worked on it
- 15 together to make it so it was a more concise table.
- 16 Do you know what protocol Dr. Gordon
- 17 used in connection with his analysis of the control
- 18 population?
- 19 A. Only what's described in the paper.
- 20 Again, this is Dr. Gordon's section of the paper.
- 21 I appreciate that. I'm asking what you
- 22 independently know.
- 23 He described his protocols.
- 24 I guess my question to you, and I Q.
- 25 appreciate that, is I interpreted his discussion of

1 the tissue sample analysis to be his protocol for the

- 2 six analyses here. I didn't necessarily interpret
- 3 that as the same protocol used for the control group.
- 4 Do you have an you understanding one way
- 5 or the other on that?
- 6 A. No. My assumption was that they were
- 7 the same, but that would be a question you would have
- 8 to pose to him.
- 9 Q. Understood. Before you leave page 33
- 10 there is that note A, "all fibers that were counted
- 11 were always one micrometer or less in length."
- Did I read that correctly?
- 13 A. Where are you?
- 14 Q. Page 33. "All fibers that were counted
- 15 were always one micrometer or less in length."
- Did I read that correctly?
- 17 A. Yes.
- 18 Q. Again, I'm going to ask Dr. Gordon, but
- 19 I want to know what your understanding is, is that
- 20 consistent with your understanding of what was
- 21 counted with respect to the control population?
- 22 A. Yes, that's what he described, wrote in
- 23 his tables. That's based on Dr. Gordon.
- Q. Do you have an understanding that in the
- 25 tissue digestions for the six at issue in your

- Page 90
 1 with no history of asbestos exposure, correct?
 - 2 A. Yes.
 - 3 Q. In the paper you also talk about how

Page 92

Page 93

- 4 there were findings of chrysotile amongst the six
- 5 patients we discussed, correct?
- A. Yes.
- 7 Q. You also, I believe, state that that is
- 8 consistent with exposure to talc products, correct?
- 9 A. Yes, chrysotile has been found in
- 10 various talc products.
- 11 Q. Are you, as part of the article,
- 12 concluding that any chrysotile found in the six
- 13 patients' tissue analyses was from talc?
- MS. LONG: Objection to form.
- 15 A. Well, I think it was only found in one
- 16 of the individuals that we reported in the paper.
- 17 It's consistent with their history of exposure to
- 18 talc and that's all we can say from that.
- 9 Q. Would it also be, in your opinion,
- 20 consistent with exposure to background levels of
- 21 chrysotile, correct?
- MS. LONG: Objection to form.
- 23 A. Potentially, except I've never heard of
- 24 fibrous in platy talc also being present in
- 25 background ambient general air, which was also found

Page 91

1 article, whether or not Dr. Gordon counted everything

- 2 five micrometers or more in his analysis?
- 3 A. He in his methods described that they
- 4 were more than five micrometers.
- 5 O. So based on what Dr. Gordon describes as
- 6 the method for the six tissue digestions at issue in
- 7 the paper, Dr. Gordon would not have counted any
- 8 fibers that were one micrometer or less in length,
- 9 correct?
- 10 A. In these six patients, no.
- 11 Q. In looking at the control group, still
- 12 on table three at the end, do you agree with me that
- 13 chrysotile is the most common type of asbestos that
- 14 was identified in the lung tissue or in the tissue
- 15 burdens of the control population?
- 16 A. In this table, yes.
- 17 Q. Is that consistent with your
- 18 understanding of chrysotile and its use and its
- 19 presence in the background?
- MS. LONG: Objection to form.
- A. It's consistent with my understanding of
- 22 the fact that 95 percent of commercial asbestos in
- 23 the United States is chrysotile.
- Q. So from that you would expect to find
- 25 chrysotile in this control population of individuals

- 1 when they did the same evaluation of the tissue.
- Q. Then are you suggesting that the
- 3 presence of talc found in the tissue analyses means
- 4 that the chrysotile that's also found must have come
- 5 from the talc?
- 6 A. No, you're conflating two sentences.
- 7 I'm just saying they also found talc and I'm unaware
- 8 of talc being in the general background, fibrous talc
- 9 being in the general background.
- 10 Q. If I wanted to look for the ultimate
- 11 conclusion of this paper, is that the final sentence
- 12 on page 22?
- 13 Just for the record it states, "this
- 14 paper provides evidence that mesothelioma cases once
- 15 considered idiopathic may be attributable to
- 16 asbestos-contaminated cosmetic talcum powder usage
- 17 and that the elicitation of a history of such usage
- 18 is imperative to obtaining a full exposure history in
- 19 all patients presenting with mesothelioma."
- 20 MS. LONG: Objection to form.
- 21 A. Yes.
 - Q. You would agree that this paper does not
- 23 conclude that cosmetic talcum powder causes
- 24 mesothelioma?
- 25 A. I think we're very careful to say that

- 1 based on the study design it provides evidence that
- 2 it can cause, but because it's a case series,
- 3 although case series do have greater value in
- 4 evaluating a rare disease such as mesothelioma that
- 5 is associated with an exposure, that we were very
- 6 careful in our wording.
- 7 Q. If you would go to page 18, the last
- 8 sentence before Discussion. It's one of the I
- 9 thought maybe a double negative. Can you state for
- 10 the record what you understand this sentence is
- 11 supposed to read, how it's supposed to read?
- 12 A. What are you referring to?
- 13 Q. "No aluminum silicates, aluminum
- 14 magnesium silicates and silica crystals, all
- 15 components of talcum powder identified in our
- 16 patients, were not found in the control population
- 17 that did not use talcum powder."
- 18 A. I believe it should say were found.
- 19 Q. FDA testing 2019. What have you
- 20 reviewed in connection with the 2019 testing on
- 21 behalf of FDA of Johnson's baby powder?
- A. I've seen articles that have been
- 23 written about it. I believe I've seen the FDA
- 24 report, but I need to take a look at it.
- 25 (Whereupon, AMA Analytical Services,

- at 1 sufficient latency period for the results of this
 - 2 test to impact Ms. Wiman personally.
 - 3 Q. To the extent that there's a discussion
 - 4 of Chinese talc deposit in this case, generally how
 - 5 does the FDA testing of Johnson's baby powder inform

Page 96

Page 97

- 6 your opinions with respect to whether or not there is
- 7 asbestos in Johnson & Johnson's Chinese talc deposit?
- A. They're finding that there's asbestos in
- 9 the finished product. It's consistent with other
- 10 findings I've seen, asbestos being found in Chinese
- 11 sourced Johnson & Johnson baby powder.
- 12 Q. Are you aware of any previous findings
- 13 of chrysotile in the Johnson & Johnson Chinese talc
- 14 deposit?
- 15 A. The only testing that I recall seeing
- 16 was not testing for chrysotile because the
- 17 methodology used would not -- explicitly states that
- 18 they cannot analyze for chrysotile, so I have not
- 19 seen chrysotile specifically that I recall in the one
- 20 document that I'm thinking of.
- Q. You see in the document I've shown you
- 22 that's been marked as Exhibit 8 under the mass
- 23 concentration of chrysotile, you would agree with me
- 24 the highest concentration by weight listed is
- 25 0.00002 percent?

Page 95

- Inc. Certificate of Analysis was received and marked
 Moline Exhibit 8, for identification, as of this
- 2 Moline Exhibit 8, for identification, as of this
- 3 date.)
- 4 Q. Dr. Moline, I'm showing you show you
- 5 what's been marked as Exhibit 8.
- 6 Have you seen this before?
- 7 A. Yes, I have seen it.
- 8 Q. I think it would be helpful if you can
- 9 just state your understanding based on what you've
- 10 reviewed of the status of the FDA's testing with
- 11 respect to Johnson's baby powder, what they found.
- 12 What was your understanding?
- 13 MS. LONG: Objection to form.
- 14 A. The FDA speaks for itself. I don't know
- 15 why you're asking me what the FDA said when they've
- 16 come out with statements and press leases. The FDA's
- 17 comments are the FDA's comments.
- 18 Q. I'll ask a question. How does the FDA's
- 19 comments that you reviewed inform your opinions in
- 20 this case?
- 21 A. I think this was from a bottle that
- 22 would be outside the time period of Ms. Wiman, it
- 23 would not have impacted Ms. Wiman's exposure because
- 24 she was not exposed to a bottle that was from this
- 25 vintage, meaning this time period, and there's not a

- 1 A. Yes.
- Q. Do you have an opinion as to whether or
- 3 not exposure to talc that contains 0.00002 percent by
- 4 weight chrysotile asbestos would be an above
- 5 background exposure?
- MS. LONG: Objection to form.
- 7 A. I would need someone to convert it
- 8 into -- this is a bulk sample. I would need it to be
- 9 converted into a fiber per cc value in order for me
- 10 to make an appropriate assessment.
- 11 Q. As you sit here today, you don't have an
- 12 opinion one way or another about whether or not
- 13 exposure to talc that contained 0.00002 percent
- 14 chrysotile asbestos would result in above background
- 15 exposure?
- 16 A. Again, I would need the calculation
- 17 converted into a fiber per cc value to make that
- 18 statement.
- MR. EWALD: Let's go ahead and mark this
- 20 as Exhibit 9.
- 21 (Whereupon, Johnson & Johnson press
- 22 release was received and marked Moline Exhibit 9, for
- 23 identification, as of this date.)
- Q. There you go, Dr. Moline. Dr. Moline,
- 25 we marked as Exhibit 9. It is identified for the

Page 98 Page 100 1 record as a Johnson & Johnson press release dated 1 done. 2 October 29, 2019, with a title 15 New Tests from the 2 MS. LONG: In 2019? 3 Same Bottle of Johnson's Baby Powder Previously 3 MR. EWALD: Yes. 4 Tested by FDA Find No Asbestos. 4 I had no knowledge that the FDA was I'm going to ask you, Doctor, have you 5 testing it. I had no knowledge that Johnson & 6 seen this press release before? 6 Johnson was going to retest it apart from what was 7 A. I have not seen the entire press 7 reported in the press. That's the extent of it. I 8 release. I've seen an excerpt, but I have not seen 8 had no insider information, no one was feeding me 9 the entire press release. 9 that this was being tested or retested or any other What do you recall in seeing the 10 information. I read it when everyone else did. 11 previous excerpt that you read with respect to this Since you read it you haven't since 12 become privy to information that you did not hear 12 press release? A. That Johnson & Johnson retested it and 13 publically? 14 they said through their testing labs they did not 14 A. I didn't hear the last couple of words. 15 find the asbestos. 15 Q. That you did not hear publically. Q. How does that, if at all, inform your 16 I don't have any other information. A. 17 opinions with respect to whether or not Johnson & Do you have any opinions based on your 17 Q. 18 Johnson Chinese talc has asbestos in it? 18 review of the press release and any other expertise MS. LONG: So this statement, how does 19 as to the conclusion by RJ Lee that there was 20 that --20 contamination in some initial samples? 21 21 MR. EWALD: Yes. MS. LONG: Objection to form. 22 A. I took it at face value from the company 22 A. I don't think that that's included in 23 that has a vested interest in not finding anything, 23 this press release. I have not seen RJ Lee's 24 that has a documented history on my reliance list of 24 testing. My understanding of RJ Lee is they've been 25 misinforming results to federal agencies before. 25 criticized by the EPA for their methodology. Page 99 Page 101 1 Q. What does that mean with respect to your MR. EWALD: Let's mark this as 1 2 Exhibit 10, please. 2 opinions? 3 3 A. I took it in saying they had it tested (Whereupon, Accepted copy of Exponent 4 and they didn't find anything. We have one lab 4 manuscript was received and marked Moline Exhibit 10, 5 finding it and another lab that's paid by someone who 5 for identification, as of this date.) 6 has a vested interest in not finding it not finding Q. Dr. Moline, I'm handing you what's been 7 it. I took it at face value. 7 marked as Exhibit 10. Can I ask you, Doctor, if Q. What does that mean in this context, 8 you've seen this before? 9 taking it at face value? 9 A. Yes. 10 10 A. Just what I said. The company who has a Q. What is it? 11 financial interest in not finding asbestos in their 11 It's an accepted manuscript by Exponent A. 12 powder didn't find asbestos in their powder. 12 employees. Q. I won't argue with you about what face Have you reviewed this article before? 13 13 14 value means in that context. 14 I read parts of this article before. I 15 15 read through the article. I haven't critically Do you have any knowledge about the FDA 16 testing of Johnson's baby powder and any subsequent 16 reviewed it. 17 testing by Johnson & Johnson of that same bottle and Based on what you have reviewed, how, if 17 18 lot apart from what you've read publically? 18 at all, does it inform your opinions as to whether or MS. LONG: You're just talking about 19 not Johnson & Johnson's Vermont talc can cause 20 this testing of the two last exhibits? 20 mesothelioma? 21 MR. EWALD: No, I'm asking more broadly. 21 A. My recollection is that they discuss 22 Q. I'm trying to get an understanding of 22 finding one mesothelioma at least and possibly a 23 the source of your knowledge about the FDA testing of 23 second, which might be the mysterious talc man that 24 Johnson's baby powder in 2019 and any follow-up 24 was referred to in the paper by Lamm. 25 25 testing that Johnson & Johnson and other labs have My recollection was that there was

- 1 another mesothelioma in the miners and it was a
- 2 follow-up of a very small cohort, that was a very
- 3 small cohort when Sullivan started it, but they did
- 4 find one meso or two in this group.
- 5 Q. First let's deal with that last point
- 6 you mentioned. This is not numbered. It's about
- 7 16 pages in, at the top it says, "In the updated
- 8 cohort of Vermont workers."
- 9 A. Okay.
- 10 Q. If you look there in the next paragraph
- 11 it talks about the one death was attributed to
- 12 mesothelioma as noted on the death certificate for
- 13 this worker. "This worker was employed in the talc
- 14 industry for less than five years and death occurred
- 15 30 years following employment, leaving open the
- 16 John Stand and Company and
- 16 possibility of exposure to asbestos in other
- 17 occupations or possible exposure to ionizing
- 18 radiation." Did I read that correctly?
- 19 A. Yes.
- Q. It goes on to say, "the death
- 21 certificate explicitly mentioned exposure to
- 22 asbestos. This single death due to mesothelioma
- 23 occurred after 1975, after the end of follow-up in
- 24 the Selevan, et al. study." Selevan is
- 25 S-e-l-e-v-a-n.

1

- Page 103
- It's Selevan just so you know.
- Q. "While Selevan, et al. 1979 did not
- 3 mention mesothelioma, Lamm and Starr in 1988 reported
- 4 there was one death from mesothelioma in the Vermont
- 5 cohort before 1975; however, no information was
- 6 provided regarding this worker so we are unable to
- 7 verify this claim or identify how this death was
- 8 coded in the present study."
- 9 Did I read that correctly?
- 10 A. Yes.
- 11 Q. Let me first ask you from the
- 12 perspective of this. You've previously given
- 13 opinions with respect to the Lamm article, correct?
- 14 A. Yes.
- 15 Q. Does the Fordyce 2019 article inform
- 16 your previously stated opinions with respect to the
- 17 Lamm article in any way?
- 18 A. No, they have no additional information,
- 19 so he remains the talc man.
- Q. Do you have any information regarding
- 21 the single death due to mesothelioma occurring after
- 22 1975 reference in the article apart from what is
- 23 stated in the article itself?
- 24 A. No, I have no personal knowledge of the
- 25 death certificate of this individual.

Page 104

- 1 Q. You have no knowledge with respect to 2 any prior potential exposure to asbestos separate
- 3 from any talc work at the Vermont mine?
- 4 A. Correct, if there was any.
- A. Correct, if there was an
- 5 Q. If there was.
- 6 A. There was?
- 7 Q. If there was. I was agreeing with you.
- 8 A. Okay.
- 9 Q. Would you agree with me that based on
- 10 the information provided in this article it is not
- 11 possible to conclude whether the single death due to
- 12 mesothelioma involves a talc worker that worked at
- 13 Johnson & Johnson Vermont talc mines?
- 14 A. Sorry, can you say that again?
- 15 Q. Sure. Would you agree with me that it
- 16 is not possible based on the information provided in
- 17 the Fordyce article about the single death due to
- 18 mesothelioma that occurred after 1975 to conclude
- 19 that that talc worker worked at the Vermont talc
- 20 mines used by Johnson & Johnson?
- 21 A. They described him as working in the
- 22 talc industry. I don't know what other talc
- 23 industries there were that he could have worked in,
- 24 but I have no way of -- they're very vague about it
- 25 for this particular individual so I have no

- 1 additional information.
- 2 Q. If you look at the last paragraph before
- 3 the references, the conclusion paragraph, let me know
- 4 when you're there. It states, "In conclusion, this
- 5 study provides further evidence that excess deaths
- 6 among Vermont miners and millers are due largely to
- 7 excess mortality from non-malignant respiratory
- 8 disease; there is no evidence of increased risk of
- 9 respiratory cancer." Did I read that correctly?
- 10 A. You did.
- 11 Q. Do you agree with that conclusion?
- 12 A. Well, I think if you look at the first
- 13 sentence of the page, I think one of the limitations
- 14 of this study is pointed out about the fact that
- 15 there's concern that it lacked adequate statistical
- 16 power to detect an increase in rare diseases like
- 17 mesothelioma. I would say that before I would say
- 18 there's no evidence, I would make sure that that was
- 19 more evident because they have inadequate, as they
- 20 say, statistical power to make such a sweeping
- 21 characterization.
- Q. Do you agree that the study does not
- 23 provide any evidence of increased risk of respiratory
- 24 cancer?
- 25 A. They do not have -- they have a very

- 1 close to statistically significant increase, it is
- 2 elevated, but it is not statistically significant.
- 3 If they were to be truly comprehensive they would say
- 4 there was an increase, although it did not reach
- 5 statistical significance.
- Q. Just so I'm clear on what you mean by
- 7 that, could you just explain in a little bit more
- 8 detail what you mean by saying that it was not
- 9 statistically significant?
- 10 They report on all deaths, all causes of 11 death with an elevated standardized mortality ratio
- 12 of 133.4 that they say is statistically significant
- 13 because the confidence interval does not include 100.
- 14 The rates of cancers of the respiratory
- 15 system are 137.4 and of the bronchus, trachea and
- 16 lung are 143.9 with a confidence interval that
- 17 approaches 100 but does not make it so that it is
- 18 technically not statistically significant, but it is
- 19 close to statistically significant especially if you
- 20 were to look at, for example, the confidence interval
- 21 for cancer of the kidney, which is based on three
- 22 cases and has a very wide confidence interval, but
- 23 ranges from 36 to 500. This one ranges from 98.4 to
- 24 203, which is lot closer to 100, so while it does not
- 25 approach the statistically significant values, it is
 - Page 107
- 1 elevated and they do not mention that in their 2 conclusion.
- Q. Have you consulted with any statistician 4 in connection with the findings of this article?
- I have not.
- Have you been provided any information Q.
- 7 from counsel by a statistician in connection with
- 8 this article?
- 9 MS. LONG: I'm going to -- it's fine.
- 10 A. I don't recall specifically related to
- 11 this article. It may have been in a report that I
- 12 read, but I don't recall if there was an analysis of
- 13 this article. I have seen other statistical analyses
- 14 of the Vermont talc cohort. I don't recall whether
- 15 it included an analysis of this article. To be
- 16 complete in my answer, I can't recall whether the
- 17 statistical report included this article.
- 18 We've been going for a little more than
- 19 an hour. I'm finished with that line of questioning.
- 20 I have some sort of odds and ends I want to ask. Why
- 21 don't we take a quick break. Off the record.
- 22 (A recess was taken.)
- 23 MR. EWALD: Mark as Exhibit 11, please.
- 24 (Whereupon, copy of article entitled
- 25 Health Effects of Censored Elongated Mineral

- Page 108
- 1 Particles was received and marked Moline Exhibit 11,
- 2 for identification, as of this date.)
- Q. Dr. Moline, I'm handing you what's been 4 marked as Exhibit 11. Have you seen this document
- 5 before?

- A. I've seen it.
- 7 Q. Can you identify it for the record,
- 8 please?
- MS. LONG: Do you have a copy for me? 9
- 10 MR. EWALD: Sure. I'm not sure I'm
- 11 going to ask any questions about it.
- 12 The article is Health Effects of
- 13 Censored Elongated Mineral Particles: A Critical
- 14 Review. The first author is Egilman.
- 15 You said you have seen it before. Are
- 16 you relying on this article for your opinions in this 17 case?
- 18 I have this on the top of my reading
- 19 list, which is why I have seen it. It is literally
- 20 an article that I have in my possession. It's on my
- 21 to-do list for this week so I can't answer any
- 22 questions about the article.
- That's fair. My only statement on the 23
- 24 record is, to the extent that you do read it and you
- 25 intend to rely on it for your opinions in this case,
- Page 109 1 that you tell counsel and we can discuss whether or 2 not an additional deposition will be necessary.
- 3 I'm happy to.
- 4 Would you agree with me that you, when
- 5 testifying at trial in Simon Greenstone cases, use
- 6 more PowerPoint slides than when you testify in,
- 7 let's say, Levy Konigsberg cases?
- I think that's a mischaracterization. 8 A.
- 9 Q. Okay.
- 10 I think it depends on the lawyers'
- 11 preferences. For example, I believe in a case that I
- 12 testified for Levy Konigsberg recently with Ms. Long
- 13 it was a very limited PowerPoint which just provided
- 14 some background information. I think in the past
- 15 Simon Greenstone has asked that we prepare a more 16 comprehensive PowerPoint.
- 17 That's fair. I didn't mean to be so
- 18 reductive in the question. I guess how does that
- process typically work when you're testifying at
- 20 trial? Do you create the slides yourself?
- Just like I don't touch my CV, I will go
- 22 over them with the lawyers the content to be included
- 23 and then I allow them to work with the program since
- 24 they are more facile than I.
- 25 Maybe not the lawyer.

Page 110 Page 112 1 Or their paralegal or somebody who is 1 Α. Correct. 2 much better at PowerPoint presentations than me, but 2 Why did you present to the jury in 3 Weirick the J&J adult and diapering estimate and then 3 there are a couple of standard background slides that

- Just so the record is clear, when you
- 6 talked about your CV, the actual work of the document
- 7 was by your assistant, right?

4 seem to be in circulation now.

- I provide them the content, they just
- 9 type it.
- 10 For your CV, an assistant, like the
- 11 assistant that you work with here in your job,
- 12 correct?
- 13 Correct.
- 14 Then in the context of the slides, you
- 15 provide counsel with the content, is your testimony,
- 16 and then counsel or somebody working for counsel puts
- 17 together the slides?
- We're often sitting together when it's
- 19 being done but yes.
- 20 MR. EWALD: Mark this as Exhibit 12,
- 21 please.
- 22 (Whereupon, copy of PowerPoint slide was
- 23 received and marked Moline Exhibit 12, for
- 24 identification, as of this date.)
- 25 I'm going to mark one more thing and

- 4 not do so in the Weirick case?
- You said Weirick twice.
 - I knew it. Why did you present to the
- 7 jury in the Cabibi case the J&J adult and J&J
- 8 diapering estimate reflected on Exhibit 12 and not in
- 9 the Weirick case?
- 10 Because there has been overwhelmingly
- 11 conflicting testimony from the Johnson & Johnson
- 12 corporate representative with respect to what the 4.5
- 13 plus fibers per cc meant and whether it was fibers or
- 14 fibers per cc.
- 15 Based on information, he had previously
- 16 stated that it represented 4.5 fibers per cc and then
- 17 he changed his testimony in subsequent depositions.
- 18 So after I became aware of that I felt that it was
- 19 important to just leave it out because there is so
- 20 much uncertainty as to whether what that actual
- 21 testing reflected so I did not include that in
- 22 subsequent PowerPoints.
- 23 So going forward, are you affirmatively
- 24 relying on the J&J, what's listed here as the J&J
- 25 adult and diapering estimates for the opinions that

Page 111

- 1 we're going to talk briefly about it. Let's mark
- 2 this as Exhibit 13, please.
- (Whereupon, copy of PowerPoint slide was
- 4 received and marked Moline Exhibit 13, for
- 5 identification, as of this date.)
- Q. I'm showing you what's been marked as
- 7 Exhibit 13. For the record, I will represent that
- 8 Exhibit 12 was from slides that you presented in the
- 9 Cabibi, C-a-b-i-b-i, case. Exhibit 13 was from
- 10 slides you presented in the Weirick case.
- Do these look like slides that you
- 12 previously presented?
- 13 A. Yes.
- On Exhibit 12 there's a listing for the
- 15 J&J adult estimate and the J&J diapering estimate.
- 16 Do you see that?
- 17 A. Yes.
- 18 When you look at the slide in Weirick on
- 19 13 with the same title and some of the same figures,
- 20 the J&J adult estimate and the J&J diapering estimate
- 21 do not appear, correct?
- 22 A. Yes.
- 23 The two additions to the chart on
- 24 Weirick relate to two MAS exposure studies, below the
- 25 waist and baby diapering, correct?

- 1 you're offering in this case?
- 2 MS. LONG: Objection to form.
- A. Not until I think there's a straight
- 4 answer from the corporate representative. It doesn't
- 5 change depending on the wind, so I will not be
- 6 relying on that particular number.
- 7 You can set that aside.
- 8 (Whereupon, a copy of PowerPoint slide
- 9 received and marked Moline Exhibit 14, for
- 10 identification, as of this date.)
- 11 Q. I'm showing you what has been marked as
- 12 Exhibit 14. We'll represent because I was there that
- 13 you used this slide in connection with your Weirick
- 14 testimony. Does that look familiar?
- 15 A. Yes.
- 16 My question to you is when it said what
- 17 was known, you would agree that's in the passive
- 18 voice?
- 19 You know my son is taking grammar and
- 20 I'm not anymore, but, yes, I believe it is passive.
- 21 It's ambiguous to me, the reader, about
- 22 who is being referred to here. So my question is,
- 23 when are you talking about what was known, who knows?
- 24 Well, it's not talking about who. It's
- 25 talking about what. Why does it have to say who?

Page 114 Page 116 1 And he's not on first. What's on second. 1 MR. EWALD: I'm going to pass the 2 witness in a second while I look over my notes. I Q. When you're offering opinions about what 3 was known, are you offering an opinion that Johnson & 3 assume that counsel on the phone has at least a 4 couple of questions, but before I do I just wanted to 4 Johnson should have known these things at these 5 state on the record that I discussed with counsel off 5 various points in time? 6 the record about the three binders that Dr. Moline MS. LONG: Objection to form. 7 7 brought with her. I do not have the intention to A. First of all, this might be used for 8 have the court reporter copy all of the contents of 8 non-Johnson & Johnson. It's basically talking about 9 the health hazards of when there was an 9 those three binders, but I do want to ensure that we 10 identification that asbestos was a health hazard and 10 have a clear record of all the materials that 11 Dr. Moline considered in this case and I don't think 11 when there was an identification that asbestos may be 12 found with talc and the health effects of talc. 12 that there is a single page that currently reflects 13 So it's basically just to give a 13 that. 14 I am open to any number of solutions, 14 reference point in terms of saying what was known in 15 but I would propose that we make Exhibit 15 a 15 the '30s or what was known in the '40s and the '50s 16 placeholder to then reach agreement with counsel on 16 and '60s, and they stop in the '60s because there was 17 what contents are included within those three binders 17 an explosion of growth in the asbestos literature. 18 and put that there. Q. Are you talking about what was known in 19 the scientific community? MS. LONG: I just want to make sure I'm 20 clear on what you're proposing. 20 Yes, the scientific or medical 21 21 community. MR. EWALD: Sure. You gave testimony actually in the 22 MS. LONG: Are you proposing that 23 Exhibit 15 will eventually be a copy of the binders 23 Weirick trial in sum and substance that asbestos can 24 remain in the air for hours, if not days, before it 24 or some sort of list? 25 MR. EWALD: Just a list. 25 settles; is that consistent with your opinions in Page 115 Page 117 1 this case? MS. LONG: Okay. I think we can work 1 2 MS. LONG: Objection to form. 2 that out. 3 MR. EWALD: Great. With that I will A. In general, yes. What do you rely on for the opinion that 4 pass the witness, look over my notes and see where we 5 asbestos can remain in the air for essentially days? A. It's something that I learned way back (Whereupon, list of contents of 7 when. I don't even know if I can point you to a 7 documents in three binders will be provided and 8 marked Moline Exhibit 15, for identification, as of 8 source. It's just one of those things that I'm aware 9 of from industrial hygiene courses where it may have 9 this date.) 10 been discussed. There have been area studies I know 10 EXAMINATION BY 11 from joint compound, for example, where asbestos has 11 MR. GAULT: 12 been measured at the time it's been used and then at 12 0. Dr. Moline, can you hear me okay? 13 various times later to measure how long asbestos may 13 A. 14 be present in the air after its use. 14 My name is Patrick Gault. I represent 15 Continental in this case. Do you have an But as you sit here today, you can't 16 identify any authority that you rely on for the 16 understanding that General Tire was acquired by 17 Continental Tire? 17 proposition that asbestos can remain in the air for 18 days? 18 Yes. A. 19 MS. LONG: Objection to form. 19 I'm just going to refer to it as the 20 General Tire plant regardless of the time period or A. It may be in the Anderson paper. It may 21 be in a Fischbein paper. Those are the joint 21 who actually owned the plant; is that okay? 22 22 compound papers that I'm thinking of. It could That's fine. 23 actually be in a Rohl/Langer or a Nicholson paper 23 First, this may be a little bit of an 24 from the '70s where they were measuring asbestos 24 odd question, but do you recall a radiologist by the 25 name of Dr. Ray Herrin? 25 content.

Page 118 Page 120 I saw a medical report from him. I've 1 transcript.

- 2 never met him. I've never heard of him before I saw
- 3 this report, but yes, I saw a B reading and a listing
- 4 of pulmonary function tests on Mackey Ward.
- But you don't know anything about him
- 6 losing his medical license, being sanctioned by the
- 7 court or anything like that?
- I know nothing. I don't know the name.
- Obviously Dr. Ellenbecker is involved in
- 10 this case. You mentioned that earlier if I'm not
- 11 mistaken. Did you review his deposition?
- 12 Yes.
- 13 Did you review two volumes or three
- 14 volumes or just the first volume?
- A. I reviewed I think it was two volumes.
- 16 I know I reviewed two volumes. I don't remember that
- 17 there was a third.
- 18 Q. In fairness, I just got it e-mailed to
- 19 me today, so you wouldn't have had time to see it.
- 20 What specific General Tire documents did
- 21 you receive and review? I know you mentioned I think
- 22 the 1991-'92 asbestos survey.
- 23 Correct.

1

7

10

15

17

Q.

A.

14 provided with.

12 Mackey Lyn Ward?

18 you mean, Counsel?

8 deposition?

24 Did you receive or review any General

Only that were attachments to

2 depositions that may have been a site map. That's

You mentioned Apple Jaw, that's Kenneth

Did you review John Paul Simmons'

What other depositions, co-worker

11 depositions did you review? And I mean co-workers of

Those were the only two that I was

MR. GAULT: Yes, ma'am.

21 and I didn't make any comments that would be

22 relatable to the case. Sometimes I'm jotting

A. I did not make any. I don't highlight

23 something that has nothing to do with it just because

24 I need to write a number down, but there's nothing on

25 Tire-specific documents?

3 the extent that I recall.

5 Simmons; is that correct? Correct.

I did.

16 notes on those transcripts?

- 2 Q. Other than you've already mentioned,
- 3 what specific articles will you rely on to comment
- 4 with regard to Mackey Lyn Ward's potential for
- 5 exposure to asbestos at General Tire, if any?
- I mentioned a couple earlier which is
- 7 the Anderson, and the Vianna and Polan, and then an
- 8 article, I think it's Magnani from Casale Monferrato
- 9 talking about take-home exposure. I'm not sure if
- 10 there is an article that Nicholson did where he
- 11 measured exposure in the home. There are others on
- 12 my reference list that talk about take-home
- 13 exposures. I would have to go through the list.
- All those articles, I'm just generally
- 15 speaking, the exposure to the individual who
- 16 allegedly brought home the asbestos on his or her
- 17 clothing would have been exposed to a much greater
- 18 degree than Mackey Lyn Ward was exposed potentially
- 19 at General Tire; is that fair?
- 20 MS. LONG: Objection to form.
- 21 A. It depends on the circumstances of their
- 22 exposure. There are cases reported from take-home
- 23 exposure of individuals in brake manufacturing
- 24 plants. There are other reports in the literature of
- 25 take-home exposure that may not have been extensive.

Page 119

- With respect to the Italian study on the
 - 2 asbestos cement plants, yes, in all likelihood they
 - 3 had a higher exposure.
 - Have you ever been in a tire facility,
 - 5 tire manufacturing facility?
 - No, not that I recall.
 - Do you recall ever testifying on behalf
 - 8 of a plaintiff who worked in a tire manufacturing
 - 9 facility?
 - 10 I have certainly reviewed other cases of
 - 11 individuals who worked in tire manufacturing
 - 12 facilities. I am not sure if I've actually testified
 - 13 on those cases or I've just written reports.
 - 14 Were those cases involving asbestos or
 - 15 some kind of chemical or do you recall?
 - 16 They would have been asbestos cases.
 - 17 There are chemicals in tire plants, but I would have
 - 18 been asked to comment on the asbestos.
 - 19 Sorry to jump around on you a little
 - 20 bit, but I forgot to ask you about Dr. Herrin. You
 - 21 said you did have that ILO form and the PFT on Mackey
 - 22 Lyn Ward.
 - 23 A.
 - 24 You're not going to testify at trial Q.
 - 25 that Mr. Ward in fact did have what is shown in those

Did you do any highlighting or make any MS. LONG: On the transcript themselves

- 25 them. I take notes. I don't make comments on the

Page 122 1 medical records, are you?

- 2 MS. LONG: Objection to form.
- 3 A. I just noted it in my notes. I don't
- 4 have any -- I will answer the questions I'm asked. I
- 5 do know that Ms. Wiman referenced that her husband
- 6 had been diagnosed with asbestosis, but I don't know
- 7 from where she derived that data, if it was from this
- 8 physician or it was from other sources or her own
- 9 personal physician.
- 10 Q. Without additional information or even
- 11 the X-ray to review or have someone review it, you
- 12 can't come to that conclusion independently just
- 13 based on those records; is that fair?
- 14 A. The records speak for themselves. The
- 15 PFTs are the PFTs. I don't know how you can fudge a
- 16 diffusing capacity. Apart from that, again, I know
- 17 nothing about this physician and whether it's
- 18 something that one would, based on information -- I'm
- 19 relying on you to discuss this particular physician.
- 20 I would have to get some further information before I
- 21 would testify or take a look at the film myself or
- 22 have another B reader look at it if this gentleman
- 23 has been discredited.
- 24 Q. That's fair enough. You mentioned that
- 25 some of the General Tire documents you may have seen

Page 124

- 1 warehouses were a large part, but I don't recall that
- 2 there was a specific description of the acreage or
- 3 the square footage of the warehouse, just that the
- 4 warehouses were huge.
- 5 Q. The document we were talking about, it
- 6 has a legend in the upper left-hand corner that lists
- 7 the square footage of all the buildings. I added it
- 8 up and it looks like it was 638,900 square feet. You
- 9 have no way to agree or disagree with that
- 10 calculation I'm assuming?
- A. Correct, I didn't look at the legend, I
- 12 didn't try to figure it out.
- Q. If I said it appears that the warehouses
- 14 were over 14 acres in size, the warehouses combined
- 15 total, does that seem about correct?
- 16 MS. LONG: Objection to form.
- 17 A. I'm not sure how you convert square feet
- 18 to acreage.
- 19 Q. Google and a calculator.
- 20 A. I'm sure that's the way we all do it
- 21 now, but I can't tell you off the top of my head. My
- 22 farming days have long passed.
- Q. They're huge warehouses, that's fair to
- 24 say?
- 25 A. That's what the description was.

Page 123

- 1 were the ones attached to the deposition of the
- 2 co-worker depositions and I think you specifically
- 3 referenced a schematic I think you called it of the
- 4 plant.
- 5 A. It wasn't schematics per se. I think it
- 6 was actually like an architectural drawing of the
- 7 plants. I didn't pay much attention to it since I'm
- 8 not an architect.
- 9 Q. Do you know where the General Tire plant
- 10 at issue is located?
- 11 A. I don't think it exists anymore. I
- 12 think it moved to Mexico.
- 13 Q. What do you base that on, deposition
- 14 testimony?
- 15 A. Correct. I think it was in Mayfield,
- 16 Kentucky, I believe was the town.
- 17 Q. Do you have an idea in terms of the size
- 18 of the facility in terms of acres? I mean the plant
- 19 itself, not the property around it.
- 20 A. There were some references to 45 to
- 21 60 acres for the plant. I don't know if that's true
- 22 or not. Those were just the numbers I recall.
- Q. Do you have an idea or a concept of the
- 24 size of the warehouses?
- 25 A. From the descriptions I saw the

- Q. Did you see distinctions between the
- 2 north and the south warehouses?
- 3 A. There was a description of the north and
- 4 the south, that something was built over a creek, so
- 5 there was definitely a distinction, yes.
 - Q. Did you get the understanding that the
- 7 warehouses were only connected to the production area
- 8 by two aisles where you could drive a couple of fork
- 9 trucks back and forth?
- 10 A. That I don't recall.
- 11 Q. Did you happen to match up the asbestos
- 12 survey to the warehouses in terms of where there was
- 13 asbestos-containing material located?
- 14 A. I did not. I assumed that would be
- 15 something that Dr. Ellenbecker was going to do. I
- 16 just skimmed through it and noted that there was
- 17 reports of asbestos being present.
- 18 Q. Did you get the understanding that the
- 19 only material that may have contained asbestos in the
- 20 warehouses was from the steam pipes up in the ceiling
- 21 that fed the steam heaters in the warehouse?
 - A. That was what I gleaned, although it's
- 23 unclear whether there was also insulation around the
- 24 Banbury or other equipment, but there was no
- 25 information apart from I think a passing reference to

Page 125

1 that.

- 2 Q. I'm specifically talking about the
- 3 warehouse. The Banbury is in the production area.
 - A. Correct. My understanding is it was
- 5 from the steam pipes, correct.
- 6 Q. Dr. Moline, you don't have any opinion
- 7 in terms of whether or not Mr. Ward was exposed to
- 8 industrial talc at General Tire, do you?
- 9 A. There was a passing mention in one of
- 10 the depositions, but there wasn't enough information
- 11 for me to be able to give an opinion to a reasonable
- 12 degree of medical certainty.
- My understanding from the tire
- 14 manufacturing is that industrial talc can be used,
- 15 but I don't know if it was used at General Tire and I
- 16 did not see any specific information to that effect.
- 17 Q. There was no asbestos material used in
- 18 the construction of tire manufacturing that you saw
- 19 from these depositions anyway?
- 20 A. I don't know what you mean by
- 21 construction of tire manufacturing.
- Q. That no asbestos products are utilized
- 23 in the production process of manufacturing a tire.
- A. Unless there was industrial talc that
- 25 contains asbestos, but, again, there wasn't

Page 128

- 1 insulation falling from the ceiling of the warehouse?
- 2 A. Correct.
 - Q. Mr. John Paul Simmons testified that
- 4 he'd run over it and sometimes he'd end up cleaning
- 5 it up himself. Do you remember that?
- 6 A. Yes.

3

- 7 Q. Do you remember Kenneth Simmons
- 8 testifying that if pipe insulation fell from the
- 9 ceiling of the warehouse, he would call the
- 10 janitorial or his supervisor would call the
- 11 janitorial staff and they would come clean it up.
- Do you recall that?
- 13 A. Yes.
- 14 Q. He never personally cleaned it up; is
- 15 that fair?
- 16 A. Not when he was in the warehouse.
- 17 Q. Right, he used to be in the janitorial
- 18 department. Do you remember the first testimony,
- 19 co-worker or eyewitness testimony about Mackey Lyn
- 20 Ward being present in the warehouse came from John
- 21 Paul Simmons and that wasn't until the mid-1970s?
- 22 A. Correct.
- Q. Neither John Paul Simmons or Kenneth
- 24 Simmons testified that Mackey Lyn Ward was in the
- 25 area of the warehouse when pipe insulation fell from

Page 127

- 1 sufficient information to know whether that was used
- 2 in this plant or not, but other than that, I'm not
- 3 aware of any asbestos products being used in tire
- 4 manufacturing.
- 5 Q. Did you see some testimony about roofing
- 6 material in the warehouses?
- 7 A. Yes.
- 8 Q. If Dr. Ellenbecker testified that the
- 9 roofing material -- if the roofing material did
- 10 contain asbestos, it would be considered non-friable,
- 11 would you agree with that?
- 12 A. If it were intact then it would not be
- 13 friable. If it were cut or broken apart or parts of
- 14 the roof fell down, then it had potential to become
- 15 friable.
- 16 Q. How would that be?
- 17 A. Well, if a tornado comes through and
- 18 knocks off part of the roof and then breaks off bits
- 19 of the roof and the tar paper, then it could
- 20 conceivably become friable. I think Apple Jaw
- 21 described that. I think Mr. Kenneth Simmons
- 22 described all sorts of dust including dust from the
- 23 roof during the tornado.
- Q. You obviously recall both Kenneth
- 25 Simmons and John Paul Simmons testifying about pipe

- 1 the ceiling; is that correct?
- 2 A. Yes.
- 3 MS. LONG: Objection to form.
- 4 A. No, I don't recall that. I recall that
- 5 they discussed that the insulation was falling from
- 6 the ceiling and they saw it with respect to it
- 7 occurring when he was there as well. That wasn't my
- 8 read of their depositions. I thought that they were
- 9 describing that the pipe insulation fell in the
- 10 warehouse during the times that they were working
- 11 with him.
- 12 Q. Correct. When they were working on the
- 13 same shift, but I mean actually Mr. Ward physically
- 14 being present when pipe insulation fell?
- 15 A. I think they were not concentrating on
- 16 what was falling on Mr. Ward, they were probably
- 17 concentrating on what was falling on them, so I don't
- 18 think they were able to answer what specifically
- 19 might have fallen, but they were describing the
- 20 environment at the same time he was working in there.
- 21 Q. Let me see if you agree or disagree with
- 22 what Dr. Ellenbecker says. I asked him, "so what I
- 23 gather, you correct me, that Mr. John Paul Simmons
- 24 assumed Mackey Lyn Ward experienced those same25 things, but he couldn't testify as to firsthand

Page 130 Page 132 1 knowledge witnessing that occurring by Mackey Lyn 1 O. There were several truck bay doors too, 2 Ward?" He said, "that's my recollection of his 2 correct? 3 deposition." 3 A. Yes. 4 Okay. Dr. Ellenbecker could have said Q. Do you recall the testimony about 5 leaving those open and the ventilation that would 5 that. I had a slightly different read, but 6 Dr. Ellenbecker is entitled to his opinion. 6 come through because of that? Q. Dr. Ellenbecker described Mackey Lyn 7 A. Yes. 8 Ward's potential exposure to asbestos from this 8 0. There were also roof exhaust fans in the 9 falling pipe insulation as episodic. warehouse too. Do you remember that? Would you agree with that? 10 10 There was some mention of it, yes, and 11 11 there was also a description of heaters and blowers 12 In other words, it didn't happen on a 12 blowing dust. 13 daily basis; is that fair? 13 Q. I'm sorry. 14 MS. LONG: Objection to form. We're 14 I recall that they also described 15 talking now just about the falling or any exposure 15 blowers that blew dust around within the warehouse. 16 from the material that had fallen? 16 I believe that was John Paul Simmons; is 17 MR. GAULT: That is a fair objection. 17 that to your recollection? Q. First let's start with the falling pipe 18 A. Yes. 19 insulation, that didn't happen every day? 19 He was talking about the blowers on the 20 20 steam heaters that even in the summertime the steam A. It might have occurred every day for a 21 period of time, but certainly it wasn't a 21 heater would be off, but they would leave the blower 22 five-day-a-week occurrence. 22 on; is that what you're recalling? Q. What about exposure to asbestos, can you I just remember they talked about 24 heaters and blowers and I didn't make that 24 testify whether or not that would have been a daily 25 occurrence? 25 distinction. Page 131 Page 133 1 A. Again, if there was disruption of the Q. Do you recall Kenneth Simmons testifying 2 pipe covering, whether it was from the forklifts and 2 about wet sweepers coming through the warehouse and 3 the pallets or from the asbestos on the floor, it 3 wet sweeping the aisles once a day? 4 sounds like it was not a daily occurrence but it was A. I remember him talking about wet 5 something that occurred with regularity. 5 sweepers coming through; I don't recall that it was Q. Neither Kenneth Simmons or John Paul 6 daily, but I don't recall that specific element. 7 Simmons could really quantify how often it happened; Q. If that is the case, if wet sweepers 8 is that fair? 8 swept the floors, the aisles every day, to the extent A. Correct. 9 there may be asbestos dust on the floor, that would 10 Q. If you'll assume for me that the south 10 help remove it; is that fair? 11 warehouse contained no asbestos-containing insulation A. If the sweepers are effective. What it 11

12 or material, would you agree with me then when

13 Mr. Ward was working in the south warehouses, he

14 wouldn't have been exposed to asbestos?

15 A. Correct.

16 Q. Do you have any concept of the

17 ventilation in the warehouses?

18 A. No, I don't think it was well described.

19 Q. Do you remember the testimony about they

20 could literally pull a freight train inside the

21 warehouse?

22 A. Meaning they could have a freight train

23 come into the warehouse?

24 Q. Correct.

25 A. Yes.

12 would also do is make it less likely to become

13 airborne.

14 Q. With a wet sweeper?

15 A. If the wet sweeper is wetting the

16 asbestos on the floor, yes, then it's less likely to

17 become airborne if it's wet.

18 Q. I thought you said more likely.

19 A. Sorry.

Q. That's why I asked again.

21 MS. LONG: You said less likely.

MR. GAULT: That's okay.

Q. Were you aware of a study that was

24 conducted, a joint study between the United Rubber

25 Workers union, General Tire and other tire

Page 134 Page 136 1 manufacturing companies, University of North Carolina 1 extent there may have been asbestos fibers on his 2 and Harvard joint study of potential health hazards 2 clothes, would that help decrease the amount that he 3 at tire manufacturing plants? 3 had on his clothes when he eventually went in the It sounds vaguely familiar. I didn't 4 house for the night? 5 MS. LONG: Objection to form. 5 review it in advance of this deposition. 6 I can't comment on whether it would Q. Do you know if you received it? It was 7 change the fibers imbedded in the fabric. I don't 7 produced by General Tire. A. I did not receive it as part of the 8 know. I've never seen a study that's compared 9 individuals with asbestos fiber on their clothes 9 materials given to me. 10 before and after going to work in a field. 10 Q. I'm sorry, just to clarify, did you say Q. Do you recall Ms. Wiman testifying that 11 you didn't review it or you didn't receive it? A. I definitely didn't receive it and I 12 Mr. Ward's clothes were much cleaner once he started 13 said I did not review it in conjunction with this 13 working in the warehouse or less dusty I should say? A. Well, he moved from working with carbon 14 particular case. I know I've read studies in the 15 black to no longer working directly with carbon black 15 past about tire or rubber workers. 16 so, yes, they were less dusty. Q. Would you find it surprising if that 17 study that started in the early '70s, went on 17 Do you recall the co-worker testimony 18 that the warehouse was the least dirty and dusty 18 throughout the '70s did not focus at all on asbestos 19 as a potential health hazard? place in the facility? 20 Yes, which doesn't necessarily say a 20 MS. LONG: Objection to form. 21 lot. That's compared to what? 21 A. It depends on what the hypothesis of the 22 study was. I would have to see what the 22 Q. Production. 23 23 comprehensive nature of the study was. A. Understood. 24 Q. If it's potential health hazards to tire 24 O. Do you recall Mr. Kenneth Simmons 25 testifying about how dust would blow in from the 25 manufacturing employees, does that change that at Page 135 Page 137 1 all? 1 parking lot into the warehouse through the truck 2 docks? 2 MS. LONG: Objection as to form. 3 A. Yes. 3 They might have been looking at the 4 So that would obviously increase the 4 immediate, not what might happen in the future. 5 Again, I would have to look at what they were 5 level of dust in the warehouse just from that alone? MS. LONG: Objection to form. 6 actually analyzing. 7 Q. Do you recall Kenneth Simmons testifying Q. Let me ask you this way, you're not 8 testifying that all the dust in the warehouse came 8 that when they finished their shift, they being the 9 forklift operators, would sometimes blow out their 9 from insulation on pipes; is that fair? 10 A. Correct. 10 clothes with an air hose before going home? 11 O. There were many sources for the dust and 11 I recall he mentioned that, yes. 12 If Mr. Ward would do that, that would 12 some of it could have even come from production? 13 MS. LONG: Objection to form. 13 certainly decrease the amount of asbestos fibers that 14 he may have had on his clothes when he went home; is 14 A. Correct. 15 15 that fair? MR. GAULT: Actually, strike that. 16 Q. Do you recall the testimony that when 16 A. Correct. 17 the pipe insulation fell from the pipes, do you 17 O. You testified earlier today about 18 sometimes when Mr. Ward came home he wouldn't change 18 recall how long or how long of sections of pipe 19 right away. Do you recall that? 19 insulation fell from the pipes? 20 20 I think it varied. I think one time A. Yes. 21 there was mention of eight feet and the rest of it Q. Do you recall Ms. Wiman testifying that 22 was different pieces that didn't have necessarily a 22 he often when he came home from work went right to 23 length associated with it. 23 work on the farm? 24 Q. If I'm getting beyond where you're 24 Yes. A.

25 comfortable testifying, you just tell me, but do you

25

Q.

Wouldn't that work on the farm, to the

1 know much about asbestos-containing thermal 1 Ms. Wim

- 2 insulation in terms of how it's applied on pipes?
- 3 A. More than most doctors, but it depends
- 4 on how it's applied and what product is applied.
- Q. If we say calcium silicate, let's say
- 6 Kaylo was applied to pipe insulation. First of all,
- 7 Kaylo comes in three-foot sections, is that fair, if
- 8 you know?
- A. I don't know what size it comes in.
- 10 Q. In terms of installing Kaylo or other
- 11 calcium silicate thermal insulation products on pipe,
- 12 do you know one way or the other when the insulators
- 13 initially installed it they would use stainless steel
- 14 wire or stainless steel straps to put it up?
- 15 MS. LONG: Objection to form.
- 16 A. I think it depends on the nature of how
- 17 they were doing it. I've seen it where it was
- 18 installed with chicken wire. I don't think it was
- 19 stainless steel. In other places they may have used
- 20 bands that might have been stainless steel. There
- 21 are all different ways of installing insulation. I
- 22 don't know what makes one insulator choose one method
- 23 versus another.
- 24 Q. But given what you said, how does it
- 25 make sense that an eight-foot section of pipe

Page 138 Page 140

- 1 Ms. Wiman would have had to asbestos as a result of
- 2 Mr. Ward being exposed to asbestos at General Tire
- 3 would be significantly less than Mr. Ward's actual
- 4 exposure at General Tire?
- A. In general, yes.
- Q. When I asked Dr. Ellenbecker if he could
- 7 put a percentage on that one exposure versus the
- 8 other, he cited an article, the Sammel, S-a-m-m-e-l,
- 9 article and said it would be about 20 percent of the
- 10 initial exposure.
- Do you agree or disagree or have a
- 12 different opinion?
- 13 MS. LONG: Objection to form.
- 14 A. I know I read that article, but I don't
- 15 recall the exact number.
- 16 Q. In terms of Dr. Ellenbecker, what areas
- 17 of your opinion do you rely on Dr. Ellenbecker's
- 18 opinion as an industrial hygienist? If that didn't
- 19 make sense, let me know.
- 20 A. Dr. Ellenbecker has expertise with
- 21 respect to the measurement of asbestos and other
- 22 industrial hazards, he can comment on what exposures
- 23 from the exposure standpoint could be within the
- 24 plant, so he can do an analysis of the amount of
- 25 asbestos that was used based on the survey that was

Page 139

1 insulation could fall from a pipe?

- 2 MS. LONG: Objection to form.
- 3 A. Well, pipes are sequential and they're
- 4 long and it could have been that there was a leak
- 5 around the eight-foot section of pipe insulation and
- 6 it got wet and it dried and it contracted and it all
- 7 fell. I don't know if Mr. Simmons was actually
- 8 measuring the piece. It may have looked like it was
- 9 a long piece. Once it's put together, they're
- 10 joined, the various pieces. It doesn't mean that it
- 11 necessarily -- if it has an external coating around
- 12 it, it could all come down at once.
- 13 Q. Obviously the insulation that fell to
- 14 the floor, whether or not it had asbestos in it, we
- 15 don't know; is that fair?
- 16 A. The actual insulation that fell on the
- 17 floor we don't know. We do know that there was
- 18 asbestos insulation based on the survey results on
- 19 the pipes.
- 20 O. I understand, but in terms of what
- 21 actually fell, we don't know whether it contained
- 22 asbestos or not?
- A. I don't recall that General Tire did any
- 24 measurements; so we don't know the exact amount.
- Q. Would you agree that any exposure

- 1 done.
- Q. Would you agree there's been no
- 3 testimony that a forklift operator, much less Mackey
- 4 Lyn Ward, actually hit one of the steam lines going
- 5 to the steam heaters?
- 6 A. No, the steam lines were above the
- 7 forklifts, but they described dust from the steam
- 8 lines on the top pallet.
- 9 Q. Right, but I guess I meant like stacking
- 10 pallets or something like that, there was no
- 11 testimony that any of the forklift operators actually
- 12 struck the steam line, the insulated steam line with
- 13 the forks or the palletizers or anything like that?
- 14 A. Correct.
- 15 Q. One of the areas in your disclosure said
- 16 that you are expected to testify that the defendants
- 17 were in violation of asbestos regulations promulgated
- 18 by state governments and the United States
- 19 government, and that defendants violated their duties
- 20 under the Occupational Safety and Health Act.
- Would you agree that you can't testify
- 22 that Mr. Ward was exposed above the then existing TLV
- 23 or PEL at any time at General Tire?
- 24 MS. LONG: Objection to form.
- 25 A. There's no information related to the

Page 142

- 1 measurements; so I wouldn't be able to testify to a 2 specific level.
- Q. So you can't testify in terms of
- 4 exposure to asbestos that General Tire violated
- 5 Kentucky OSHA or OSHA vis-à-vis Mr. Ward?
- 6 MS. LONG: Objection to form.
- A. Based on numerical values, that's 8 correct.
- 9 Q. Just a couple more things from your
- 10 disclosure. Would you agree with me that to the
- 11 extent Mr. Ward was exposed or was potentially
- 12 exposed to asbestos at General Tire, it would have
- 13 been as a bystander?
- 14 A. From his work in the warehouse, yes.
- 15 Q. Do you know when the General Tire
- 16 facility was built?
- 17 A. I seem to recall seeing something about
- 18 1960.

1

- 19 Q. Correct, it was started in '59 and
- 20 finished in '60; so that's correct. Do you know when
- 21 the north warehouse was constructed or finished?
- A. I think that was around 1979 or 1980.
- 23 Q. If the documents in this case show that
- 24 the north warehouse was finished in '73, do you
- 25 recall anything that leads you to disagree with that?
 - Page 143
 - A. I don't recall either way. I thought it
- 2 was later.
- 3 Q. In fairness, the south warehouses were
- 4 completed in '78; so that might have been what you
- 5 were thinking.
- 6 A. Okay. I think there was some testimony
- 7 somewhere that the warehouses expanded and kept
- 8 expanding and maybe that's where I'm confused, but I
- 9 don't know the years of the various warehouses.
- 10 Q. Actually, in fairness, I think some of
- 11 the testimony from the co-workers was based on their
- 12 recollection and I think they did say something about
- 13 those years, but the documents prove otherwise, but
- 14 whatever.
- 15 It says in your disclosure, Dr. Moline
- 16 is expected to testify when it was known that
- 17 bystander and household exposure were known to cause
- 18 disease. I think you talked a little bit about this
- 19 earlier, but when is that in your opinion?
- 20 A. I think the first time it was really
- 21 described was in 1963 by Newhouse where there was a
- 22 description of household exposure.
- 23 Q. What were the workers doing in the
- 24 Newhouse study that brought home the asbestos to
- 25 their house?

- 1 A. That I don't remember. Working with
 - 2 asbestos.
 - 3 Q. I guess the distinction is they weren't
 - 4 driving a forklift in a warehouse?
 - 5 A. I don't think there's any specificity
 - 6 regarding that, no.

11

- Q. When do you believe that General Tire
- 8 should have known that Mackey Lyn Ward could
- 9 potentially expose his family to asbestos in his job
- 10 as a forklift operator in a warehouse?
 - MS. LONG: Objection to form.
- 12 A. The health hazards of asbestos were
- 13 known in the 1950s in the United States after
- 14 articles were published in the Journal of the
- 15 American Medical Association. Certainly in the 1950s
- 16 there was knowledge in the major medical publications
- 17 that asbestos was a health hazard.
- 18 Q. My question actually was when should
- 19 General Tire have known that Mr. Ward could
- 20 potentially take home asbestos fibers to his house
- 21 and expose his family? When should General Tire have
- 22 known that given he's a forklift operator in a
- 23 warehouse?
- 24 MS. LONG: Objection to form.
- 25 Objection, asked and answered.

Page 145

- A. Again, I think that they should have
- 2 understood that after the plant was built in 1960 if
- 3 there was potential exposure of the employees to
- 4 asbestos, then they should have known at some point
- 5 in the '60s.
- 6 Q. Is that for all employees regardless of
- 7 where they're working in the plant?
- 8 MS. LONG: Objection to form.
- 9 A. They should be aware of the fact that
- 10 asbestos was present in the plant and been aware that
- 11 there was potential exposure, and also they should
- 12 have known the condition of the plant and the fact
- 13 that the insulation was falling down from leaks at
- 14 various points that could lead to exposure.
- 15 Q. Were you aware that Triangle Insulation
- 16 was a defendant in this case?
- 17 A. Only because I saw their name. I don't
- 18 know what they are. All I know is I saw their name
- 19 and I saw some people from Triangle asking questions
- 20 in depositions.
- 21 Q. Were you provided any depositions of
- 22 former Triangle employees taken in cases years ago?
- 23 A. No.
- Q. So you don't know what role, if any,
- 25 Triangle had in insulating any part of the General

D 446	P. 440
Page 146 1 Tire plant?	Page 148 1 being said I think we've taken care of that.
2 A. I do not.	
	,
	3 notes. I don't know if counsel has some follow-ups.
4 insulated the north warehouses, what kind of duty	4 That being said I appreciate your time.
5 would Triangle have in terms of using	5 MR. EWALD: No follow-up.
6 asbestos-containing pipe insulation?	6 MS. LONG: I think we're done.
7 MS. LONG: Objection to form. This is	7 MR. EWALD: Thanks.
8 not a question this witness is not here to make	8 (Time Noted: 3:35 p.m.)
9 legal conclusions as to what any defendant or	9
10 company's legal duty would be, that's not within her	10
11 disclosure or her expert opinion. It would be a	11
12 conclusion for a judge or a jury.	12
13 If you want to ask her about factual	13
14 questions or opinion on things within her expertise,	14
15 I think that's fine, but asking her what duty another	15
16 company had, which is a very loaded legal term, is	16
17 not appropriate for this witness.	17
MR. GAULT: Let me try to rephrase.	18
19 First of all, I appreciate your objection, but just	19
20 object to form would be fine. The doctor can say I	20
21 can't testify as to a duty.	21
22 A. I can't testify as to a duty.	22
Q. There we go. Dr. Moline, what is your	23
24 definition of a significant exposure to asbestos?	24
25 A. One that is above background, that's	25
P 147	
Page 147	Page 149
Page 147	Page 149 1 JURAT
_	
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein,
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background.	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein, 4 do hereby certify the foregoing testimony of the
 non-trivial. Q. I believe that's Dr. Ellenbecker's opinion too, anything above background. Your disclosure says that you're 	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein, 4 do hereby certify the foregoing testimony of the 5 pages of this deposition to be a true and correct
 non-trivial. Q. I believe that's Dr. Ellenbecker's opinion too, anything above background. Your disclosure says that you're expected to testify that the levels of asbestos to 	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein, 4 do hereby certify the foregoing testimony of the 5 pages of this deposition to be a true and correct 6 transcript, subject to the corrections, if any, shown
 non-trivial. Q. I believe that's Dr. Ellenbecker's opinion too, anything above background. Your disclosure says that you're expected to testify that the levels of asbestos to which the plaintiff was exposed during her use of and 	JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and	JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the	JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page. JACQUELINE MOLINE, M.D.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence.	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page. JACQUELINE MOLINE, M.D.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that,	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page. JACQUELINE MOLINE, M.D. JACQUELINE MOLINE, M.D.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein, 4 do hereby certify the foregoing testimony of the 5 pages of this deposition to be a true and correct 6 transcript, subject to the corrections, if any, shown 7 on the attached page. 8 9 JACQUELINE MOLINE, M.D. 10 11 12 Subscribed and sworn to before me
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown non the attached page. JACQUELINE MOLINE, M.D. JACQUELINE MOLINE, M.D. Subscribed and sworn to before me This day of 2019.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair?	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein, 4 do hereby certify the foregoing testimony of the 5 pages of this deposition to be a true and correct 6 transcript, subject to the corrections, if any, shown 7 on the attached page. 8 9 JACQUELINE MOLINE, M.D. 10 11 12 Subscribed and sworn to before me
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form.	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page. JACQUELINE MOLINE, M.D. JACQUELINE MOLINE, M.D. Subscribed and sworn to before me This day of 2019.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page. JACQUELINE MOLINE, M.D. JACQUELINE MOLINE, M.D. Subscribed and sworn to before me This day of 2019.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those	JURAT JURAT JURAT I, Jacqueline Moline, M.D., the witness herein, do hereby certify the foregoing testimony of the pages of this deposition to be a true and correct transcript, subject to the corrections, if any, shown on the attached page. JACQUELINE MOLINE, M.D. Subscribed and sworn to before me This day of 2019.
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I	1 JURAT 2 3 I, Jacqueline Moline, M.D., the witness herein, 4 do hereby certify the foregoing testimony of the 5 pages of this deposition to be a true and correct 6 transcript, subject to the corrections, if any, shown 7 on the attached page. 8 9 JACQUELINE MOLINE, M.D. 10 11 12 Subscribed and sworn to before me 13 This day of 2019. 14 15 NOTARY PUBLIC
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I 19 don't have numerical values for her actual exposure	JURAT JU
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I 19 don't have numerical values for her actual exposure 20 level so I would not testify to them, but there is no	JURAT JU
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I 19 don't have numerical values for her actual exposure 20 level so I would not testify to them, but there is no 21 PEL, that she is not covered under any PEL.	JURAT JU
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I 19 don't have numerical values for her actual exposure 20 level so I would not testify to them, but there is no 21 PEL, that she is not covered under any PEL. 22 Q. I agree with you, but the disclosure	JURAT JU
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I 19 don't have numerical values for her actual exposure 20 level so I would not testify to them, but there is no 21 PEL, that she is not covered under any PEL. 22 Q. I agree with you, but the disclosure 23 says you're expected to testify about what the	JURAT JU
1 non-trivial. 2 Q. I believe that's Dr. Ellenbecker's 3 opinion too, anything above background. 4 Your disclosure says that you're 5 expected to testify that the levels of asbestos to 6 which the plaintiff was exposed during her use of and 7 exposure to defendant's talcum powder products and 8 other products would have likely exceeded established 9 TLVs and PELs in many instances. I want to go to the 10 other products in that sentence. 11 We've already talked about that, 12 correct, you will not testify that Mr. Ward or 13 Ms. Wiman was exposed above the TLVs or PEL for 14 asbestos; is that fair? 15 MS. LONG: Objection to form. 16 A. Ms. Wiman is not covered by any TLV or 17 PEL because her exposures were household and those 18 are levels that are workplace exposure levels. I 19 don't have numerical values for her actual exposure 20 level so I would not testify to them, but there is no 21 PEL, that she is not covered under any PEL. 22 Q. I agree with you, but the disclosure	JURAT JU

	Page 150	
1	CERTIFICATE	
2	CTATE OF NEW YORK	
3	STATE OF NEW YORK)) ss:	
4	COUNTY OF NEW YORK)	
5	COUNTY OF NEW TORK)	
6	I, BRENDA FITZGERALD, a Shorthand	
	Reporter and Notary Public within and for the State	
8		
9		
	witness whose DEPOSITION was held on November 25,	
	2019, as hereinbefore set forth, was duly sworn by	
	me, and that this transcript of such Examination is a	
	true and accurate record of the testimony given by	
	such witness.	
15	I further certify that I am not related	
16	to any of the parties to this action by blood or by	
17	marriage, and that I am in no way interested in the	
18	outcome of this matter.	
19	IN WITNESS WHEREOF, I have hereunto set	
	my hand this 2nd day of December 2019.	
21		
	Frenda Fitzgrald	
22	,,,	
23		
	BRENDA FITZGERALD	
24		
25		
	Page 151	
1	Page 151 ERRATA SHEET	
1 2		
2	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925	
3 (ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 SSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019	
2 3 (ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos	
2 3 (4) 5	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 SSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019	
2 3 (4) 5	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 5	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 5	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 5	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 6 1 4 1 5 5 7 - 7 - 8 - 9	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (1) 4 \ 5 \ 7 \ - 3 \ 8 \ - 4 \ 9 \ - 10 \ - 1	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 6 1 4 1 5 5 7 - 7 - 8 - 9	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (1) 4 \ 5 \ 7 \ - 3 \ 8 \ - 4 \ 9 \ - 10 \ - 1	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (0 1 4 '1 5 5 7	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 5 5 7	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 11 5 5 7	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 5 5 7	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 11 5 5 7	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 4 5 5 6 7 8 9 10 11 12 13 14 15	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 15 5 16	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2 3 (4) 15 5 16	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline	
2	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline PAGE/LINE(S) CHANGE REASON	
2	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline PAGE/LINE(S) CHANGE REASON	
2	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline PAGE/LINE(S) CHANGE REASON	
2	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline PAGE/LINE(S) CHANGE REASON PAG	
2 3 (4) 4 (5) 5 (7) 7 (7) 7 (7) 10 (7) 11 (7) 12 (7) 13 (7) 14 (7) 15 (7) 17 (7) 18 (7) 19 (7) 20 (7) 21 (7) 22 (7)	ERRATA SHEET Priority-One Court Reporting/Veritext 718-983-1234 ASSIGNMENT NO. P1-3782925 CASE NAME: Wiman, Carolyn v. Asbestos DATE OF DEPOSITION: 11/25/2019 WITNESS' NAME: Dr Jacqueline Moline PAGE/LINE(S) CHANGE REASON PAG	

[**& - 78**] Page 1

0	127 / 106.15	2010 1.10 10.11 10	36 106:23
&	137.4 106:15 14 2:22 113:9,12	2019 1:18 18:11,18 22:23 23:3 27:20	36 106:23 3782925 1:24
& 2:8,17 3:6,7,11	124:14	40:16 94:19,20	3:35 148:8
5:15 20:20 23:19	124 :14 143.9 106:16	98:2 99:24 100:2	
23:21 24:1,8,12			4
96:7,11,13 97:21	15 2:23 98:2	103:15 149:13	4 2:3,10 25:16,19
98:1,13,17 99:17	116:15,23 117:8	150:11,20 151:22	25:21 29:15
99:25 100:5	150 44:24	202 21:21,25 22:1	4.5 112:12,16
101:19 104:13,20	16 102:7	203 106:24	40202 3:13
112:11 114:3,8	17 85:1,2	21 77:21 88:13	40 s 114:15
0	175 1:17	22 2:9 77:22 93:12	436 21:22
0.00002 96:25 97:3	18 1:10 94:7	25 1:18 2:10 52:7	45 123:20
97:13	19 40:17	150:10	5
00181 1:10	1950 8:24	26 2:11	_
07039 1:22	1950s 144:13,15	27 2:12,14 27:20	5 2:11 26:17,19,22
	1960 9:1,4 51:6	47:21 48:2 49:7	50 44:7 52:6
1	142:18 145:2	53:18 81:8	500 106:23
1 1:1 2:7 20:2,5,8	1963 143:21	29 98:2	50 s 114:15
20:15	1970s 128:21	290 1:22	51 3:7
10 2:18 19:23	1975 102:23 103:5	2nd 150:20	52nd 3:7
101:2,4,7	103:22 104:18	3	59 142:19
100 106:13,17,24	1979 103:2 142:22	3 2:9 22:15,17,20	6
10019-6142 3:8	1980 9:10 142:22	30 4:24 102:15	6 2:12 27:6,9,11
10022 3:3	1988 103:3	30s 114:15	60 51:11 123:21
101 2:18	1991 37:1 118:22	31 67:12	142:20
107 2:19	1992 37:7	32 72:20 73:6,11	60s 114:16,16
10:10 1:18	1993 37:7	33 43:13,20 44:13	145:5
11 2:19 23:3	1994 37:7	45:12,19 46:14,17	638,900 124:8
107:23 108:1,4	1997 8:20,20 10:2	49:1,4,20 50:6,25	7
11/25/2019 151:3	10:8	51:3,8,19 52:4,12	-
110 2:20	1:15 75:13	53:11,13,23 54:2	7 2:13 18:11 27:22
111 2:21	2	55:12,16,23 56:9	28:1,3
113 2:22	2 2:8 20:19,21,24	57:7,25 59:19	70s 115:24 134:17
117 2:4,24	27:13	60:5 61:7 62:13	134:18
11th 22:22	20 2:7,8 86:24	63:19 66:2 68:3	718 1:23
12 2:20 110:20,23	140:9	68:17 69:22 72:1	718-983-1234
111:8,14 112:8	2004 9:21	72:8 77:8,16 78:2	151:2
12:40 75:9	2005 9:22	78:14 80:9,21,24	73 53:18 142:24
13 2:21 111:2,4,7,9	2017 29:9,13 34:10	81:5,10,12 82:5,11	730 3:12
111:19	2017 23:3,13 34:10 2018 34:11,11	83:19 84:12,16,20	78 143:4
133.4 106:12	40:11,17 71:14	88:3 89:11 90:9	
	10.11,17 / 1.17	90:14	
		70.17	

[8 - answer] Page 2

8	acres 123:18,21	96:23 104:9,15	ama 2:15 94:25
	124:14	105:11,22 109:4	amber 3:4
8 2:15 95:2,5 96:22	act 141:20	113:17 124:9	ambient 92:25
800 3:3	action 150:16	127:11 129:21	ambiguous 113:21
	activities 42:11	130:10 131:12	amended 20:14
9	73:19	139:25 140:11	american 144:15
9 2:17 19:23 97:20	actual 6:4 38:18	141:2,21 142:10	amosite 10:13,16
97:22,25	51:21 66:25 110:6	147:22	11:2,18,22 12:2,3
92 118:22	112:20 139:16	agreeing 104:7	14:8 69:1,5
94 2:16	140:3 147:19	agreement 79:15	amount 8:7
9485 150:21	add 22:9	116:16	135:13 136:2
95 91:22	added 21:11,15	ahead 20:2 97:19	139:24 140:24
97 2:17	22:7,8 23:6,6	air 12:19,24 13:6	amphibole 11:9
98.4 106:23	124:7	24:4 64:16 65:6,6	analyses 90:2
983-1234 1:23	adding 21:3	65:7 92:25 114:24	92:13 93:3 107:13
a	addition 21:23	115:5,14,17	analysis 2:16
abiding 33:6	29:18 46:12	135:10	42:17 43:6,9,19
ability 69:14	additional 7:6	airborne 14:6	47:20 53:3 67:16
able 12:22 13:1,20	13:1 15:3,13,19	133:13,17	67:17,24 68:4,8,10
45:20 64:4 81:2	18:11,20 27:18	airless 59:15	68:22 70:4 77:12
126:11 129:18	46:11 48:8,11,15	aisles 125:8 133:3	89:17 90:1 91:2
142:1	48:22 49:19 53:20	133:8	95:1 107:12,15
absolutely 15:16	62:19,21 63:21	al 1:8 102:24	140:24
abstract 44:10,25	75:1 77:14 103:18	103:2	analysts 69:23
45:4,7,10	105:1 109:2	alexandri 31:6,16	analytical 2:15
academic 29:4,18	122:10	31:25	94:25
44:5	additions 22:25	alive 58:24	analyze 96:18
accepted 2:13,18	111:23	allegedly 120:16	analyzed 43:13
27:23 28:5 32:20	adequate 105:15	allow 109:23	analyzing 135:6
36:6 39:12 40:20	adult 111:15,20	allowed 60:21	anatomical 55:4
41:6 42:7 51:6,9	112:3,7,25	allowing 22:12	anatomically
101:3,11	advance 134:5	allows 46:3	54:23
access 70:6	advice 78:21	alternate 46:11	anderson 14:18
accompanied	affirmatively	53:6 61:25 63:16	115:20 120:7
76:25	112:23	64:19	anna 3:9
accurate 11:14	age 50:23	alternative 49:17	anonymity 74:14
34:6 55:22 69:2	agencies 98:25	62:25 63:25 72:21	anonymous 37:9
150:13	ago 17:22,25 18:4	73:9 74:2,6 76:15	50:21
acquired 117:16	86:24 145:22	84:17 88:16,20	answer 41:3 54:12
acreage 124:2,18	agree 75:16 79:4	aluminum 94:13	54:13 57:18 68:19
	81:11 91:12 93:22	94:13	74:17 78:8,17

[answer - assess] Page 3

	I	I	I
79:8 107:16	appropriate 39:22	101:15 103:13,15	102:22 104:2
108:21 113:4	97:10 146:17	103:17,22,23	114:10,11,17,23
122:4 129:18	approval 32:16,23	104:10,17 107:4,8	115:5,11,13,17,24
answered 62:17	33:16,17,18	107:11,13,15,17	118:22 120:5,16
144:25	approximately	107:24 108:12,16	121:2,14,16,18
answers 78:11	4:14 6:21 15:1	108:20,22 120:8	125:11,13,17,19
83:24 84:23	40:9,13	120:10 140:8,9,14	126:17,22,25
anybody 44:21	architect 123:8	articles 21:4 22:3	127:3,10 130:8,23
anymore 10:9	architectural	22:4,7 29:5 36:13	131:3,11,14 133:9
113:20 123:11	123:6	75:2 94:22 120:3	133:16 134:18
anyway 7:17	area 7:25 8:11,15	120:14 144:14	135:13 136:1,9
19:15 54:14	9:14 15:2 64:16	asbestos 5:8,9 6:5	138:1 139:14,18
126:19	66:17 115:10	6:9,12,13,16 7:21	139:22 140:1,2,21
apart 33:17,18	125:7 126:3	7:24 8:4,12,18	140:25 141:17
48:9 50:22 51:25	128:25	9:12,12,18 10:11	142:4,12 143:24
53:19 56:11,21	areas 6:9 37:19,24	10:25 11:5,7,13	144:2,9,12,17,20
58:4 60:16 61:22	37:25 140:16	12:10,14,24 13:23	145:4,10 146:6,24
62:14 73:3 75:1	141:15	14:5,23 15:14,21	147:5,14 151:3
99:18 100:6	argue 99:13	16:7 22:8 23:23	asbestosis 122:6
103:22 122:16	article 2:19 28:8	23:25 24:7 26:13	aside 113:7
125:25 127:13	28:10,16,22 30:3,5	41:4 44:13 45:11	asked 7:10 17:6,7
apologies 32:4	30:17 32:6,24	45:21 47:10 48:9	17:8,9 24:5 32:7
apologize 10:1	35:3,6,15 36:10	51:7,25 52:10,15	33:20 37:16,18
62:10	37:12 38:21 39:12	53:12,20,21,25	40:5 47:13 57:21
appear 111:21	39:14,18 40:20,23	54:9 56:10,16,20	60:11 62:16 63:5
appears 124:13	41:7,9,11,14,15,17	57:1,4,10,14 60:16	63:10 65:16 84:23
apple 17:16 119:4	42:7 43:2,6,12,23	61:10,19 62:5,6	86:15 88:23 89:7
127:20	45:2,20,23 47:14	63:2,5 65:3,11,18	109:15 121:18
application 30:23	49:5,21 50:22	65:20 66:3,7,17,18	122:4 129:22
30:24 32:19 33:8	51:10 52:20 55:24	67:2,4,5 68:3	133:20 140:6
33:16	60:25 61:1,8,13,21	71:16 72:21 74:3	144:25
applied 80:24	62:13 63:7 64:9	75:17,25 76:9,14	asking 11:5 17:4
138:2,4,4,6	66:5 69:8 70:20	76:16 77:7,11	23:4 50:9 55:25
appreciate 18:10	72:11 73:13 74:5	80:11,23 81:4	56:2 57:19,20
19:14 64:3 79:10	74:6 75:18 76:7	82:6 84:6 86:11	58:3 59:25 74:12
81:16 89:21,25	77:6,19 78:3,15	87:12,16,19 88:2	85:24 86:19 89:6
146:19 148:4	79:3,5 80:10	88:17,21 89:2	89:21 95:15 99:21
approach 106:25	82:16,22 83:6	91:13,22 92:1	145:19 146:15
approaches	84:11 85:10,20	93:16 96:7,8,10	aspects 32:13
106:17	86:21 88:14 91:1	97:4,14 98:4,15,18	assess 64:4
	92:11 101:13,14	99:11,12 102:16	

[assessed - blower] Page 4

assessed 76:24	attributed 102:11	97:5,14 109:14	believe 9:1,10
assessing 61:8	attributes 26:7	110:3 146:25	18:16,19 21:20
72:20 76:14 77:12	august 27:20	147:3	25:12 38:15 48:20
assessment 14:13	author 28:7 30:9	balzer 13:15	54:12 60:21 92:7
89:2 97:10	31:7 35:16 43:5	banbury 125:24	94:18,23 109:11
assignment 151:2	67:17,21 108:14	126:3	113:20 123:16
assist 32:12	authored 71:17,21	bands 138:20	132:16 144:7
assistance 42:15	71:25 78:13	base 123:13	147:2
43:3	authority 115:16	based 7:23 14:10	best 17:18 59:18
assistant 23:15	authors 33:24	15:4 43:7 51:7	63:24 69:14,19
110:7,10,11	38:20 39:15 43:7	54:13 55:4,7,9	better 53:9 110:2
assisted 5:21	44:16,16 57:11	61:2 64:1 65:14	bevilacqua 30:10
30:18,20,25 31:13	88:18	73:18 74:25 76:4	30:16,25 31:3
31:24,25	available 51:18	76:20 77:14,16	32:5 33:25 35:18
associated 2:14	52:18 53:6,10	85:7 86:17 87:25	45:5 85:6
12:17 27:24 28:6	66:23,25 70:2,5,25	90:23 91:5 94:1	beyond 6:19,22
29:20 94:5 137:23	83:25	95:9 100:17	7:6 13:2 35:8 87:1
association 23:9	avenue 1:22 3:3	101:17 104:9,16	87:5 137:24
144:15	aware 25:4 26:6	106:21 112:15	binder 18:13,20
assume 65:18	40:25 47:20 49:25	122:13,18 139:18	19:6,21,25 20:1
116:3 131:10	71:13 84:9 85:12	140:25 142:7	binders 2:24 7:2
assumed 125:14	86:2 96:12 112:18	143:11	15:25 16:2,5,11,16
129:24	115:8 127:3	basically 20:10	18:8,20,25 19:19
assuming 70:2	133:23 145:9,10	23:4 40:8 46:23	19:24 20:10 26:25
124:10	145:15	48:18 53:14 114:8	116:6,9,17,23
assumption 90:6	awkward 39:11	114:13	117:7
asterisk 67:15	b	basing 69:14	biomarkers 37:5,7
attached 123:1	b 111:9,9 118:3	71:11	biphasic 54:25
149:7	122:22	basis 8:1 11:15	bit 7:18 32:14
attachments 119:1	baby 94:21 95:11	50:17 51:24 63:13	41:23 67:6,11
attempt 7:5 23:14	96:5,11 98:3	64:19 88:18	84:25 106:7
24:4	99:16,24 111:25	130:13	117:23 121:20
attempted 12:9	back 9:16 52:24	bay 132:1	143:18
23:24 24:15	65:23 73:18 75:22	beautiful 44:5	bits 127:18
attention 55:3	115:6 125:9	beautifully 51:4	black 136:15,15
123:7	background 30:12	began 17:25 29:16 53:16	blew 132:15
attorney 25:17	30:21 31:9 35:19		blood 150:16
attorneys 3:2,6,11 43:19	37:17 56:8 65:21	beginning 74:20 74:24	blood 150:16
attributable 93:15	75:25 76:6,10,17	behalf 43:2 94:21	blow 135:9 136:25 blower 132:21
attibutable 95:15	77:11 83:22 91:19	121:7	152:21
	92:20,25 93:8,9	141./	

[blowers - certainly]

blowing 132:12 blue 17:5 board 32:21 36:19	25 59:2 3,8 ,21 2 ,24 (,9,22
board 32:21 36:19 c 1:2 3:1 4:1 111:9 34:17,20 35:20,23 68:3,8,11,15 6 69:3,4,22 70: 69:3,4,22 70: 71:13,21 72:9 73:6,11,16,16 69:3,4,22 70: 71:13,21 72:9 73:6,11,16,16 73:6,11,16,16 73:6,11,16,16 74:19,21 76:2 73:6,11,16,16 74:19,21 76:2 75:17,20 58:7,10 78:14 80:9,22 79:12,13 71:2 70:12,13 71:2 70:12,13 71:2 70:12,13 71:2 70:12,13 71:2 72:1,13,18 73:24 74:2,21,23 75:19 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:	59:2 3,8 4,21 2 4,24 4,9,22
36:21 79:1 36:21 79:1 36:14 39:22 40:6 69:3,4,22 70: bore 70:19 45:24 46:2 50:6 71:13,21 72:9 bottle 95:21,24 50:12 51:8,17 73:6,11,16,16 98:3 99:17 50:12 51:8,17 73:6,11,16,16 bottom 66:11 57:16 124:10 59:23,25 60:7 78:14 80:9,22 brandt 36:24 39:17 40:2 59:23,25 60:7 81:5,8 83:19 break 21:2 27:1,3 california 151:21 66:10,15 68:5,23 70:12,13 71:2 70:12,13 71:2 breaks 127:18 50:5 128:9,10 74:2,21,23 75:19 145:22 breaks 127:18 50:5 128:9,10 75:20 77:10,22 62 cataloging 52 breaks 127:18 50:5 128:9,10 75:20 77:10,22 62 cataloging 52 breaks 127:18 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 50:12 51:8,17 74:19,21 76:2 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 50:12 51:8,17 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 50:12 51:8,17 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 50:12 51:8,17 75:20 77:10,22 75	3,8 4,21 2 4,24 7,9,22
36:21 79:1 150:1,1 36:14 39:22 40:6 69:3,4,22 70: bore 70:19 cabibi 111:9 112:7 45:24 46:2 50:6 71:13,21 72:9 98:3 99:17 50:12 51:8,17 73:6,11,16,16 bottom 66:11 57:16 124:10 52:15,25 54:15 74:19,21 76:2 brake 76:24 61:9,14 63:4 78:14 80:9,22 150:1,1 69:3,4,22 70: 73:6,11,16,16 50:12 51:8,17 73:6,11,16,16 57:17,20 58:7,10 78:14 80:9,22 59:23,25 60:7 81:5,8 83:19 66:10,15 68:5,23 70:12,13 71:2 70:12,13 71:2 70:12,13 71:2 109:5,7 120:2 70:12,13 71:2 74:2,21,23 75:19 75:20 77:10,22 70:12,13 71:2 75:20 77:10,22 75:20 77:10,22 80:19,20 84:7 89:34,22 70:2 70:12,13 71:2 75:20 77:10,22 78:14 80:9,22 70:12,13 71:2 70:12,13 71:2 75:20 77:10,22 75:20 77:10,22 80:19,20 84:7 89:34,22 70:2 80:19,20 84:7 84:16,20 88:7 70:12,13 71:2 75:20 77:10,22 75:20 77:10,22 80:19,20 84:7 89:34,22 70:2 80:19,20 8	,21 ,2 ,24 ,9,22
bore 70:19 bottle 95:21,24 98:3 99:17 calcium 138:5,11 bottom 66:11 brake 76:24 120:23 calculator 124:19 brandt 36:24 39:17 40:2 calculator 124:19 break 21:2 27:1,3 call 17:5 38:16 50:5 128:9,10 70:12,13 71:2 70:12,13 71:2 93:14 106:22 50:5 128:9,10 72:1,13,18 73:24 74:2,21,23 75:19 74:2,21,23 75:19 breaks 127:18 called 1:15 39:17 75:20 77:10,22 cataloging 52 breaks 127:18 80:19,20 84:7 categories 89	,21 ,24 ,24 ,9,22
bottle 95:21,24 98:3 99:17 bottom 66:11 brake 76:24 120:23 brandt 36:24 39:17 40:2 break 21:2 27:1,3 75:6 107:21 breaks 127:18 breast 25:6,7,13 calcium 138:5,11 calculation 24:6 97:16 124:10 calculator 124:19	2 ,,24 ,,9,22 2
bottom 66:11 brake 76:24 120:23 brandt 36:24 39:17 40:2 break 21:2 27:1,3 75:6 107:21 breaks 127:18 breast 25:6,7,13 calculation 24:6 97:16 124:10 calculator 124:19 calculat	,,24 ,,9,22 ,2
bottom 66:11 97:16 124:10 57:17,20 58:7,10 78:14 80:9,22 brandt 36:24 calculator 124:19 59:23,25 60:7 81:5,8 83:19 brandt 36:24 california 151:21 66:10,15 68:5,23 93:14 106:22 break 21:2 27:1,3 75:6 107:21 75:5 128:9,10 74:2,21,23 75:19 125:20 77:10,22 breaks 127:18 123:3 23:3 23:3 80:19,20 84:7 20:17,20 58:7,10 59:23,25 60:7 81:5,8 83:19 84:16,20 88:7 93:14 106:22 109:5,7 120:2 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 75:20 77:10,22 <th>2,9,22</th>	2,9,22
brake 76:24 120:23 brandt 36:24 39:17 40:2 break 21:2 27:1,3 75:6 107:21 breaks 127:18 breast 25:6,7,13 calculator 124:19 calendering 8:11 california 151:21 call 17:5 38:16 50:5 128:9,10 called 1:15 39:17 123:3 cancer 22:9 24:23 calculator 124:19 61:9,14 63:4 66:10,15 68:5,23 70:12,13 71:2 70:12,13 71:2 72:1,13,18 73:24 74:2,21,23 75:19 75:20 77:10,22 cataloging 52 categories 89	2
120:23 calendering 8:11 61:9,14 63:4 84:16,20 88:7 brandt 36:24 66:10,15 68:5,23 93:14 106:22 39:17 40:2 call 17:5 38:16 70:12,13 71:2 109:5,7 120:2 break 21:2 27:1,3 50:5 128:9,10 72:1,13,18 73:24 121:10,13,14 breaks 127:18 123:3 75:20 77:10,22 cataloging 52 break 25:6,7,13 cancer 22:9 24:23 80:19,20 84:7 categories 89	2
brandt 36:24 california 151:21 66:10,15 68:5,23 93:14 106:22 break 21:2 27:1,3 75:6 107:21 75:6 107:21 75:21,13,18 73:24 74:2,21,23 75:19 121:10,13,14 breaks 127:18 123:3 75:20 77:10,22 cataloging 52 breaks 25:6,7,13 22:9 24:23 80:19,20 84:7 categories 89	
39:17 40:2 break 21:2 27:1,3 75:6 107:21 breaks 127:18 breast 25:6,7,13 call 17:5 38:16 50:5 128:9,10 called 1:15 39:17 123:3 cancer 22:9 24:23 70:12,13 71:2 72:1,13,18 73:24 74:2,21,23 75:19 75:20 77:10,22 cataloging 52 categories 89	
break 21:2 27:1,3 75:6 107:21 50:5 128:9,10 breaks 127:18 breast 25:6,7,13 50:5 128:9,10 74:2,21,23 75:19 75:20 77:10,22 cataloging 50:5 128:9,10 50:5 128:9,10 60:19,20 84:7 121:10,13,14 121:10,13,14 145:22	
called 1:15 39:17 74:2,21,23 75:19 145:22 cataloging 52	16
breaks 127:18 breast 25:6,7,13 123:3 75:20 77:10,22 cataloging 52 cancer 22:9 24:23 80:19,20 84:7 categories 89	
breast 25:6,7,13 cancer 22:9 24:23 80:19,20 84:7 categories 89	
handle 15.21 cancer 22.7 24.25 04.2 2.05.20 06.4 norms 11.11.0	8
breathe 15:21 25:4,4,6,7,8,8,9,11 94:2,3 95:20 96:4 cause 11:11 9	4:2
brenda 1:16 150:6 25:13,14 37:6 108:17,25 109:11 101:19 143:1	7
150:23 105:9,24 106:21 111:9,10 112:4,7,9 caused 14:5 8	0:13
brief 4:20 cancers 25:1,2 113:1 115:1 causes 11:5 9:	3:23
briefly 20:9 111:1 106:14 116:11 117:15 106:10	
brilliant 32:10 capacity 43:14 118:10 119:22 cc 12:14,14 97	
bring 84:4 122:16 133:/134:14 9/:1/112:13	14
broader 4:11 captioned 1:15 142:23 145:16 112:16	
broadly 99:21 car 67:2 151:3 cc'd 34:1	
broken 127:13 carbon 136:14 15 cases 28:23 29:6 ceiling 125:20	
bronchus 106:15 care 148·1 29:15,17 30:19 128:1,9 129:1	
brother 25:9 career 37.3 35:1 43:13,20 cement 22:8 1	
brought 15:24 careful 93:25 94.6 45:12,19 46:6,10 censored 2:19	
16:12 65:11 116:7 carolina 134·1 46:14,19,21 47:2 107:25 108:1	
120:16 143:24	
builder 8:11 48:3,3,4,5,7,7,10 37:19,23 59:1	2
building 6:10 carpenter 5:18 48:12,15,16,18,21 70:9 78:7	
buildings 65:16 6:11.7:1 49:4,9,10,16,25 certainly 11:6	
124:7 carrying 19:21 50:10 51:17,18,21 12:20 24:11,2	
built 125:4 142:16 casale 120:8 51:23 52:3,9 27:19 46:21 5	
145:2 case 1:10 4:12 23 53:10,16 54:8,15 60:22 66:1 68	
bulk 97:8 55:13.10:23.11:2 55:12,16,19.56:9 70:6,11.72:7	
11:18 15:24 16:14 57:12,25 58:8,9 79:1,13 86:1	

[certainly - compensated]

			Page 6
1	34:20	comfortable	79:2
		127.25	

121:10 130:21	92:12,21 93:4	clinician 34:20	comfortable 79:2
135:13 144:15	96:13,16,18,19,23	87:18	137:25
certainty 68:20	97:4,14	close 59:3 106:1	coming 39:11
126:12	ci 1:10	106:19	62:11 133:2,5
certificate 2:15	circle 65:23	closed 10:8	commencing 1:18
95:1 102:12,21	circuit 1:1	closely 35:17	comment 59:21,23
103:25	circulation 110:4	closer 106:24	60:2 73:20 74:13
certify 149:4	circumstance 83:2	clothes 14:2,2,4,5	80:17 120:3
150:8,15	circumstances	14:14,24 15:12,20	121:18 136:6
challenging 12:19	82:18 120:21	135:10,14 136:2,3	140:22
chances 62:20	citations 13:11	136:9,12	comments 38:2
change 10:2 113:5	cited 72:2 79:7	clothing 15:7	55:19 95:17,17,19
134:25 135:18	140:8	120:17	119:21,25
136:7 151:5	city 65:15,19	coating 139:11	commercial 91:22
changed 34:3 39:3	civil 1:16	coded 103:8	commission
112:17	claim 103:7	cohort 102:2,3,8	151:25
changes 23:5	claimed 64:17,18	103:5 107:14	common 34:25
37:12,15 38:5,24	clarification 37:18	collaborate 28:15	91:13
42:20 76:24	37:23 38:1	28:21 34:19	commonwealth
characterization	clarifications	collaboration	1:2
105:21	33:20	89:12	communicate
chart 111:23	clarify 19:18	colleague 21:18	40:22
chemical 121:15	134:10	colleagues 21:16	communication
chemicals 121:17	clarity 37:19	39:25 41:24 42:5	38:25
chicken 138:18	classes 37:3	collected 33:12	communications
chief 36:22,23	classics 13:16	collecting 88:6	33:14 38:7,19
childhood 24:13	classification	collection 31:15	39:13
chinese 96:4,7,10	55:10	colon 25:11,14	community 1:17
96:13 98:18	clean 128:11	columbia 37:2	65:15 67:3 114:19
choice 49:14	cleaned 128:14	combination	114:21
choose 46:19 48:4	cleaner 9:17	10:13 35:22	companies 134:1
50:25 52:12	136:12	combined 11:24	company 43:4
138:22	cleaning 15:18	11:25 124:14	98:22 99:10
choosing 46:6,17	128:4	come 13:9,13,17	146:16
55:11	clear 52:21 79:2	30:6 31:16 32:5	company's 146:10
chose 51:3 68:11	81:19 106:6 110:5	79:25 93:4 95:16	comparative 81:3
chosen 55:20	116:10,20	122:12 128:11	compared 136:8
chrysotile 10:14	clearly 66:1	131:23 132:6	136:21
10:16 11:9,19	clinical 34:22	137:12 139:12	compensated
12:2,3 14:8 91:13	55:24 74:23 79:16	comes 127:17	43:18 46:25
91:18,23,25 92:4,9	80:1,21	138:7,9	

[compiling - corporate]

compiling 30:18	conferred 87:17	constructed	contrary 79:8
53:16	confidence 106:13	142:21	contributed 23:22
complete 107:16	106:16,20,22	construction 62:7	86:21
completed 143:4	confident 70:13	126:18,21	contributing
completeness 6:17	conflating 93:6	consulted 107:3	24:19
complying 21:4	conflicting 112:11	consulting 31:1,4	contribution
components 94:15	confronted 63:14	32:2	24:15
compound 115:11	confused 143:8	contain 127:10	control 35:11 85:1
115:22	conjecture 64:2	contained 16:2,11	85:2,11,12,14,16
comprehensive	76:4	16:15 26:24 97:13	85:19,25 86:15
10:18 83:24 106:3	conjunction	125:19 131:11	87:2,6,8,10,11,14
109:16 134:23	134:13	139:21	87:23 89:17 90:3
comprehensively	connected 125:7	containing 6:12,13	90:21 91:11,15,25
20:12 51:12	connection 13:24	125:13 131:11	94:16
computer 35:25	16:19 18:3 26:3	138:1 146:6	controls 85:7
36:4,5	30:17 31:17 32:1	contains 97:3	conversation
conceivably	32:5 34:5 35:3	126:25	28:14 34:4,8,12,15
127:20	47:20 51:6,7 56:6	contaminated	34:24 40:3,10
concentrating	60:24 61:6,21	93:16	41:18
129:15,17	62:13 63:7 64:8	contaminates 15:2	conversations
concentration	69:7 70:7,11	contaminating	37:6 39:23 40:25
96:23,24	71:19 73:13 75:18	15:17	41:11,15,24 47:5
concept 123:23	77:6 84:11 85:9	contamination	85:13
131:16	85:20 89:17 94:20	100:20	conversely 82:13
concern 105:15	107:4,7 113:13	content 30:8 45:6	convert 97:7
concerns 81:21	consent 50:20	109:22 110:8,15	124:17
concise 89:15	consider 56:14	115:25	converted 97:9,17
conclude 88:19	66:22	contents 2:23	convey 42:23
93:23 104:11,18	consideration	14:10 116:8,17	cooper 13:15
concluding 92:12	60:13 63:19 86:4	117:6	copy 2:13,18,19,20
conclusion 93:11	considered 52:23	context 43:9 44:22	2:21,22 18:23
100:19 105:3,4,11	54:10 56:10 62:8	47:9 66:6 99:8,14	22:21 27:23 38:10
107:2 122:12	73:13 74:6 75:17	110:14	38:13,15,17 42:14
146:12	78:3 93:15 116:11	continental 3:12	44:11 66:12 101:3
conclusions 42:17	127:10	117:15,17	107:24 108:9
43:6 70:18 146:9	consistency 68:11	continued 54:1	110:22 111:3
condition 145:12	consistent 75:2	75:14	113:8 116:8,23
conduct 7:5 47:19	90:20 91:17,21	continuing 31:22	corner 124:6
81:12 83:3	92:8,17,20 96:9	contracted 139:6	corporate 112:12
conducted 32:15	114:25	contractor 43:5	113:4
133:24			

[correct - department]

correct 22:24 26:4 26:14 29:10,16	29:21 36:13 46:1 48:9 52:11 53:17	critical 108:13 critically 101:15	151:22 days 114:24 115:5
30:10 31:7,8 35:6	54:9 56:21,24,24	criticized 100:25	115:18 124:22
36:8 43:15,17,20	60:16 64:25 93:16	crocidolite 69:1,5	deal 78:9 102:5
45:7 47:17,18	93:23	69:23	dealing 79:18
54:23 56:7 58:11	counsel 7:7 16:24	crucial 80:6	dearth 85:16
58:12,14,18 59:1,4	19:3,8 38:14	crystals 94:14	death 102:11,12
59:7,8,10 67:22,23	58:10 70:14 78:10	cumulative 23:22	102:14,20,22
69:8,9,20 70:8	78:19 79:10 107:7	24:16	103:4,7,21,25
72:19,23,24 73:14	109:1 110:15,16	current 25:24	104:11,17 106:11
74:7 76:6,10	110:16 116:3,5,16	currently 30:14	deaths 105:5
77:23,24 78:4,6	119:18 148:3	116:12	106:10
79:6,19 80:4,8	count 44:3	curriculum 2:9	deceive 81:24
81:13 82:16 83:4	counted 11:7	22:16 83:11	december 150:20
83:5,8 84:6,13,18	51:20 90:10,14,21	cut 9:5 127:13	decide 36:10
84:24 87:24 89:4	91:1,7	cv 22:21 23:1	decided 28:15
91:9 92:1,5,8,21	county 150:4	109:21 110:6,10	47:23 48:2 50:4
103:13 104:4	couple 21:9,23	d	decrease 135:13
110:12,13 111:21	29:3 38:2 39:1	d 2:1	136:2
111:25 112:1	49:15 100:14	daily 130:13,24	defendant 3:6,11
118:23 119:5,6	110:3 116:4 120:6	131:4 133:6	70:6 145:16 146:9
123:15 124:11,15	125:8 142:9	data 12:21 31:14	defendant's 147:7
126:4,5 128:2,22	course 28:20 53:4	33:11,12 43:11	defendants 1:9
129:1,12,23 131:9	55:24 80:21	57:15 61:16,22	141:16,19
131:15,24 132:2	courses 34:22	63:1 64:22 66:22	defense 43:2 58:17
135:16 137:10,14	115:9	66:25 70:19,25	58:20 70:12
141:14 142:8,19	court 1:1,21 59:17	85:8 89:13 122:7	defer 12:17
142:20 147:12	79:14 116:8 118:7	date 18:12 20:6,22	define 4:10 54:18
149:5	151:1	22:18 23:5 25:19	definitely 125:5
corrections 149:6	cover 18:7,14	26:20 27:9 28:1	134:12
correctly 42:18	covered 147:16,21	42:11 95:3 97:23	definition 55:6
44:14 45:12 53:22	covering 131:2	101:5 108:2	146:24
56:12 61:19 66:19	create 109:20	110:24 111:5	degree 30:14
67:19 77:4 80:25	creating 89:10	113:10 117:9	31:11 68:20
87:20 90:12,16	creative 64:15	151:3	120:18 126:12
102:18 103:9	credible 65:22	dated 18:11 22:21	delayed 17:24
105:9	66:3	23:3 98:1	40:18
correspondence	creek 125:4	daughter 16:7	demonstrated
18:22,24	criteria 52:11	day 31:21 130:19	10:24
cosmetic 2:14	53:12,19	130:20,22 133:3,8	department 39:25
27:25 28:6 29:6		149:13 150:20	42:2 128:18

[depend - doors] Page 9

depend 60:23	131:18 132:14	differentiation	129:5
dependent 84:23	141:7 143:21	46:2	discussing 42:5
depending 113:5	describes 91:5	difficult 74:13	discussion 8:10
depends 63:9	describing 32:19	diffusing 122:16	28:20 35:21 48:1
109:10 120:21	51:11 129:9,19	diffusion 5:18	69:1 75:23 77:25
134:21 138:3,16	description 2:6	digestion 28:22	83:11 85:1 86:1,3
deposed 57:20	15:5 73:24 88:24	35:13 37:21,25	89:25 94:8 96:3
59:9,12,14 74:1	124:2,25 125:3	47:1,13 48:2,14	discussions 37:17
deposit 96:4,7,14	132:11 143:22	50:2 68:14,17	disease 94:4 105:8
deposition 1:6,15	descriptions 7:23	69:6,22 70:23	143:18
1:16 2:7,10 4:9	12:24 35:24 80:19	71:1,12	diseases 105:16
7:3,13 16:6,9,9	123:25	digestions 35:4,5,8	disruption 131:1
17:8 20:4,14,14	design 94:1	47:8,16 48:17	distinction 125:5
25:18,22,25 53:5	detail 4:15 68:9,23	71:12 78:2 90:25	132:25 144:3
57:16,21 61:6	80:21 106:8	91:6	distinctions 125:1
63:6,10 64:7,7	detailed 7:19	diminished 9:13	disturbed 12:25
65:2 66:4 73:12	details 85:10	direct 6:11	disturbing 13:8
73:19 74:4,4 76:4	detect 105:16	directly 36:3 56:4	division 1:1
77:14 82:23 83:18	determination	70:19 89:14	divorced 9:24,25
109:2 118:11	81:3,3	136:15	docks 137:2
119:8 123:1,13	determined 76:16	dirty 136:18	doctor 19:15 20:7
130:3 134:5 149:5	determining 56:15	disagree 79:11	20:23 28:2 45:9
150:10 151:3	developed 44:20	124:9 129:21	75:16 84:5,13
depositions 8:5	developing 11:23	140:11 142:25	88:7,8,10 98:5
58:22,24 61:6,12	30:21	discern 45:20	101:7 146:20
63:14 65:25 88:15	development	disclosure 42:21	doctors 80:7 138:3
88:19,22,24 89:4	42:16	141:15 142:10	document 23:15
112:17 119:2,10	diagnosed 54:17	143:15 146:11	96:20,21 108:4
119:11 123:2	122:6	147:4,22	110:6 124:5
126:10,19 129:8	diagnosis 50:23	discredited 122:23	documented 98:24
145:20,21	diapering 111:15	discuss 38:14 42:3	documents 2:23
derived 122:7	111:20,25 112:3,8	42:6 49:10 71:5	19:7 21:1,7 26:24
describe 7:20	112:25	77:22 78:1 85:10	117:7 118:20,25
34:21 44:11 46:5	died 9:25 25:13,14	101:21 109:1	122:25 142:23
48:3 51:5 67:2	different 11:13	122:19	143:13
described 35:10	19:20 22:4 30:2	discussed 4:23	doing 6:4,8 12:21
35:12 37:20 51:13	57:5,6 68:10	26:25 47:8,17,21	15:3 28:13 29:1
56:17 62:7 64:23	130:5 137:22	47:22 49:20 80:9	42:12 138:17
88:1 89:19,23	138:21 140:12	82:15 83:10 84:21	143:23
90:22 91:3 104:21	differentiate 55:4	85:14 89:3 92:5	doors 132:1
127:21,22 130:7	55:7,9,11	115:10 116:5	

[dose - et] Page 10

dose 24:2,5	drafts 30:3,4 41:9	effect 126:16	ended 49:20
double 39:6,9 94:9	drawing 123:6	effective 133:11	ends 39:10 107:20
dr 2:8,9,10,11,12	dried 14:4 139:6	effects 2:19 107:25	ensure 33:5 48:11
4:6 12:18 13:20	drive 1:17 125:8	108:12 114:12	87:18 116:9
16:8,9 17:1,5	driving 144:4	egilman 108:14	entails 33:11
19:22 20:20 22:16	dry 5:24	eight 48:21 76:24	enterprises 1:8
22:19 25:17,20	due 102:22 103:21	137:21 138:25	entire 23:21 98:7,9
26:2,18,21 27:7	104:11,17 105:6	139:5	entitled 2:13,19
28:17,20 34:5,16	duly 4:2 150:11	either 8:2 49:2	27:24 28:5 87:3
34:18,23 35:2	duplicative 17:3	53:4 55:10 82:21	107:24 130:6
39:17 40:2 46:24	37:18	143:1	entrainment 8:4
46:25 47:6,17,19	dust 8:7 14:2	element 80:6	environment 6:8
48:5,13,13,16 49:3	15:17,20 127:22	133:6	9:17 129:20
49:12,21 50:1	127:22 132:12,15	elevated 106:2,11	environmental
51:5 67:22 68:6	133:9 136:25	107:1	23:9 36:7 40:21
68:18 69:6 70:4	137:5,8,11 141:7	elicitation 93:17	66:19
70:24 71:8,10	dusty 136:13,16	elizabeth 21:19	envisioning 39:18
74:12,17 78:11,12	136:18	ellenbecker 7:10	epa 100:25
78:23 85:4,5,7,10	duties 141:19	12:18 13:20 118:9	epidemiology
85:19,23 86:7,17	duty 146:4,10,15	125:15 127:8	32:10
86:18,20,23 87:2	146:21,22	129:22 130:4,6,7	episodic 130:9
87:24 89:9,14,16	e	140:6,16,20	epithelioid 55:1
89:20 90:18,23	e 2:1 3:1,1,9 4:1,1	ellenbecker's 16:9	equipment 125:24
91:1,5,7 95:4	4:1 75:11,11	140:17 147:2	equivalent 12:6
97:24,24 101:6	102:25,25 118:18	elongated 2:19	errata 151:1
108:3 116:6,11	140:8 150:1,1	107:25 108:13	erroneous 6:20
117:12,25 118:9	earlier 30:2,4 53:8	embarked 74:24	errors 39:2
121:20 125:15	69:12 84:22	emphasize 68:25	especially 106:19
126:6 127:8	118:10 120:6	employed 102:13	esq 3:4,8,9,13
129:22 130:4,6,7	135:17 143:19	employees 101:12	essential 51:25
140:6,16,17,20	early 24:13 34:11	134:25 145:3,6,22	essentially 115:5
143:15 146:23	41:23 73:17	employment 9:4	established 147:8
147:2 151:4,20	134:17	102:15	estimate 13:9,14
draft 28:8 29:24	earn 22:12	enclosing 18:11,24	24:2,3 44:3 54:5
41:14	ease 19:20	encounter 55:23	111:15,15,20,20
drafted 35:20,23	easy 74:22	encountered 5:10	112:3,8
85:4,5	editor 36:22,23	encounters 15:22	estimates 112:25
drafting 35:15,16	editorial 36:19	encouraged 39:20	estimation 53:11
35:18 45:4 52:19	educational 30:12	endeavor 50:19	53:24
85:9	31:9 83:22	74:25	et 1:8 102:24
			103:2

[ethics - exposures] Page 11

ethics 79:8	115:11	expert 16:18 17:20	54:9 56:19,21,23
evaluate 81:8	exceeded 147:8	43:14 47:1,9	56:25 57:4 59:1
evaluated 80:22	excerpt 98:8,11	58:16 70:6,7,12	61:10,16,19,22
evaluating 63:2	excess 105:5,7	75:19 78:12,13	62:5,24,25 63:1,5
67:8 71:16 83:23	excluded 46:14	146:11 150:9	63:11,11,12,16,21
94:4	49:16 51:24 52:23	expertise 100:18	63:25 64:13,19
evaluation 84:20	53:7 63:17 77:2	140:20 146:14	65:3,14,18,20 66:3
93:1	excluding 52:14	experts 41:4	66:7,17 67:5,8
evens 12:7	exclusion 53:19	expires 151:25	68:4 73:10 74:2,6
eventually 116:23	exclusions 52:8	explain 106:7	77:1,3,7,11,14
136:3	exhaust 132:8	explained 40:6	79:17,21 80:2,6,11
evidence 24:23	exhaustive 88:16	explicit 47:14	80:24 81:4,11,13
62:4 64:13 65:17	88:20	86:22	82:6,10,15,19,20
93:14 94:1 105:5	exhibit 20:2,5,8,15	explicitly 96:17	83:3,8,21 86:9,11
105:8,18,23 146:3	20:19,21,24 22:15	102:21	86:12 87:12,13,17
evident 105:19	22:17,20 25:16,19	explosion 114:17	87:19 88:17,21
ewald 2:3 3:8 4:5	25:21 26:17,19,22	exponent 2:18	89:3 92:1,8,17,20
18:23 19:5,22	27:6,9,11,13,22,25	101:3,11	93:18 94:5 95:23
20:1,13,18 22:14	28:3 29:15 95:2,5	expose 144:9,21	97:3,5,13,15
25:15 26:16 27:5	96:22 97:20,22,25	exposed 8:18	102:16,17,21
27:21 38:12 75:7	101:2,4,7 107:23	10:11 11:19,20	104:2 111:24
75:15 78:19,22	108:1,4 110:20,23	14:6,23 77:9	120:5,9,11,15,22
79:10 97:19 98:21	111:2,4,7,8,9,14	95:24 120:17,18	120:23,25 121:3
99:21 100:3 101:1	112:8 113:9,12	126:7 131:14	130:8,15,23
107:23 108:10	116:15,23 117:8	140:2 141:22	139:25 140:4,7,10
110:20 116:1,21	exhibits 2:5 19:23	142:11,12 147:6	140:23 142:4
116:25 117:3	99:20	147:13,24,25	143:17,22 145:3
148:5,7	existed 60:18 72:4	exposure 5:11,17	145:11,14 146:24
exact 10:20 29:11	existing 141:22	5:20,25 6:3,5,16	147:7,18,19
51:20,20 52:2,5	exists 11:24	6:18,21,23,24 7:19	exposures 5:7,9,15
139:24 140:15	123:11	7:21,22 8:12 9:13	9:3,6 11:6 13:8
exactly 9:15	expanded 143:7	10:6,7,8,16 11:8	14:20 22:6 24:7
examination 1:6	expanding 143:8	11:24 12:10,15,25	44:12 46:11,11
1:15 2:2 4:4 75:14	expect 91:24	13:2,23 14:1,8,13	48:15,22 49:17
117:10 150:12	expected 70:24	15:13,19 22:5	51:25 56:9,16
examined 4:3	141:16 143:16	23:18,23,25 24:11	57:10,15 60:15
example 11:2 44:7	147:5,23	24:14 26:14 29:7	62:1 63:3 64:5,15
45:22 46:3,12	experience 67:8	29:17 44:14,20	66:19,22 72:21
52:17,22 53:1	experienced 12:10	45:21,25 46:1	75:17,25,25 76:5,9
56:22 59:4 62:3	12:15 15:14	48:11 51:11 52:16	76:15,16,23 84:6
106:20 109:11	129:24	53:2,7,12,20,21,25	84:17 88:2 120:13

[exposures - forgot]

140:22 147:17	fairly 73:17	feinstein 32:16	first 4:1 5:12 6:2
extensive 24:12	fairness 118:18	fell 8:1,2,2 127:14	7:19 18:2 28:7
61:18 76:21 79:17	143:3,10	128:8,25 129:9,14	55:4 61:16 64:6
79:21 80:2 88:2	fall 139:1	137:17,19 139:7	65:1 74:3,20
120:25	fallen 8:4 129:19	139:13,16,21	81:15 102:5
extent 10:24 11:21	130:16	fellowship 37:5	103:11 105:12
61:5 69:4 74:18	falling 128:1 129:5	felt 17:2 29:7	108:14 114:1,7
96:3 100:7 108:24	129:16,17 130:9	32:25 33:5 37:16	117:23 118:14
119:3 133:8 136:1	130:15,18 145:13	68:7 112:18	128:18 130:18
142:11	falls 15:20	female 55:13	138:6 143:20
external 42:15	familiar 83:22	fiber 11:15,15,23	146:19
139:11	113:14 134:4	11:23 12:14 97:9	firsthand 129:25
eyewitness 128:19	family 17:11,12	97:17 136:9	fischbein 115:21
f	24:22,25 25:3,4	fibers 11:14 12:14	fitting 51:10
f 75:11 150:1	58:25 61:23 82:24	90:10,14 91:8	fitzgerald 1:17
fabric 136:7	83:17 84:11,24	112:13,13,14,16	150:6,23
face 98:22 99:7,9	86:12,12,15 144:9	135:13 136:1,7	five 91:2,4 102:14
99:13	144:21	144:20	130:22
facile 109:24	fans 132:8	fibrous 92:24 93:8	fixed 39:1
facilities 121:12	farm 135:23,25	field 36:12 136:10	flesh 34:20
facility 121:4,5,9	farming 124:22	figure 124:12	floor 8:2 15:18
123:18 136:19	fashion 14:6	figures 111:19	131:3 133:9,16
142:16	father 5:17 25:8	film 122:21	139:14,17
fact 63:13 64:1,19	father's 6:3 7:1	final 39:2 93:11	floors 133:8
76:4 86:2 89:3	fda 94:19,21,23	financial 99:11	focus 48:18 49:4
91:22 105:14	95:14,15 96:5	find 39:5,6 73:23	49:13 50:3 134:18
121:25 145:9,12	98:4 99:15,23	73:25 91:24 98:4	folks 7:17
factor 65:16	100:4	98:15 99:4,12	follow 99:24 102:2
factual 146:13	fda's 95:10,16,17	102:4 134:16	102:23 148:3,5
faculty 42:4,7	95:18	finding 96:8 98:23	following 78:20
failed 32:4	features 50:22	99:5,6,6,11 101:22	102:15
fair 15:25 26:2	february 18:15,16	findings 92:4	follows 4:3
52:20 59:19 88:3	18:18	96:10,12 107:4	foot 138:7,25
108:23 109:17	fed 125:21	fine 107:9 117:22	139:5
120:19 122:13,24	federal 1:16 98:25	146:15,20	footage 124:3,7
124:23 128:15	feeding 100:8	finish 60:1	fordyce 103:15
130:13,17 131:8	feel 6:17	finished 96:9	104:17
133:10 135:15	feels 79:2,6	107:19 135:8	foregoing 149:4
137:9 138:7	feet 124:8,17	142:20,21,24	forenoon 1:18
139:15 147:14	137:21	firm 18:21 19:4,17	forgot 121:20

[fork - grammar] Page 13

fork 125:8	found 65:1 69:2,5	54:19 57:8 59:5	goes 87:15 102:20
forklift 135:9	71:9,10 92:9,12,15	60:9 76:22 83:12	going 4:18 9:16
141:3,11 144:4,10	92:25 93:3,4,7	87:11 92:25 93:8	12:18 22:2 25:15
144:22	94:16,18 95:11	93:9 115:3 117:16	27:3 32:9 33:11
forklifts 8:3 131:2	96:10 114:12	117:20 118:20,24	33:12 45:14 46:23
141:7	four 6:21 12:4,5	120:5,19 122:25	50:4 52:3,24
forks 141:13	25:23	123:9 126:8,15	53:23 71:5 72:15
form 5:5 6:6 7:8	fragments 38:3	133:25 134:7	74:8 75:3,4 78:8,8
9:8,9 13:4 14:9	free 31:23	139:23 140:2,4,5	79:7 86:5 87:4
15:15 21:13 24:21	freedom 44:5	141:23 142:4,12	90:18 98:5 100:6
26:10 28:9 38:9	freight 131:20,22	142:15 144:7,19	107:9,18 108:11
38:22 39:16 41:8	frequency 14:22	144:21 145:25	110:25 111:1
42:1,9,25 46:8	friable 127:10,13	generally 16:3	112:23 116:1
47:4,11 48:19	127:15,20	96:4 120:14	117:19 121:24
49:6,24 50:8 60:8	friday 4:21	generated 8:8	125:15 135:10
60:19 63:8 64:10	friend 59:3	generating 58:6	136:10 141:4
66:24 70:1,21	front 19:15 67:2	generation 61:12	good 4:6,7 19:2
73:15 74:9 76:18	fudge 122:15	71:24 72:8	32:10
81:14 87:9 88:4	full 65:23 87:14	genetic 24:23 25:1	google 124:19
89:5 91:20 92:14	93:18	genetics 24:19	gordon 28:14,17
92:22 93:20 95:13	function 118:4	gentleman 122:22	28:20 34:5,16,18
97:6 100:21 113:2	funding 42:14,21	getting 11:10	34:23 35:2 46:25
114:6 115:2,19	funds 42:15	33:17,18 137:24	47:6,17,19 48:5,13
120:20 121:21	further 63:19 67:6	give 29:11 44:2	48:13,16 49:3,12
122:2 124:16	73:18,20 79:5	46:3 51:21 52:5	49:21 50:1 67:22
129:3 130:14	80:17 87:1 105:5	54:11 70:15	68:6,18 69:6 71:8
134:20 135:2	122:20 150:15	114:13 126:11	71:10 85:4,5,10,19
136:5 137:6,13	future 135:4	given 48:20 61:5	85:23 86:7,18,20
138:15 139:2	g	103:12 134:9	86:23 87:24 89:9
140:13 141:24	gaseous 5:18	138:24 144:22	89:14,16 90:18,23
142:6 144:11,24	gather 129:23	150:13	91:1,5,7
145:8 146:7,20	gault 2:4 3:11,13	giving 63:3	gordon's 70:4,24
147:15	9:9 14:9 15:15	glanced 20:9	85:7 86:17 87:2
format 45:3	117:11,14 119:19	gleaned 125:22	89:20
formatted 23:15	130:17 133:22	go 7:14 20:2,11	government
former 145:22	137:15 146:18	22:12 61:14 73:18	141:19
forth 75:22 125:9	148:2	79:5 87:5 94:7	governments
150:11 forward 17:24	general 5:12,13	97:19,24 109:21 120:13 146:23	141:18
forward 17:24 112:23	7:20 9:2,6 10:8	120:13 146:23	graduate 30:14
114.43	15:9 17:15 24:9	141.7	grammar 113:19
	27:13 46:9,16		

[grammatical - identification]

grammatical 39:1	harvard 134:2	higher 11:22,22	house 15:17,18
graves 1:1	hat 29:18	54:4,6 121:3	136:4 143:25
great 1:17 117:3	hats 29:19	highest 96:24	144:20
greater 80:20 94:3	hazard 114:10	highlight 119:20	household 15:2
120:17	134:19 144:17	highlighting	56:19 143:17,22
greenstone 109:5	hazards 114:9	119:15	147:17
109:15	134:2,24 140:22	hipaa 50:16 78:24	huge 124:4,23
greeting 15:20	144:12	historical 51:14,15	hugging 15:21
gross 24:3	head 124:21	histories 61:14	human 33:7
group 39:15 86:15	health 1:17 2:19	66:10,16 83:8,12	humans 33:1
87:6,14 90:3	30:13 32:16 33:2	83:14 86:9	husband 5:11,12
91:11 102:4	33:3,9,15 50:16	history 24:22,24	5:13 7:20 15:7
growth 114:17	107:25 108:12	25:3,4 51:1 79:17	26:14 46:2 122:5
guess 44:8 78:16	114:9,10,12 134:2	79:21 80:2,6,11	husband's 13:24
78:19 89:24	134:19,24 141:20	81:11,13 82:6,11	14:24 24:9
109:18 141:9	144:12,17	82:15,19,20 83:3	hygiene 7:12
144:3	hear 30:9 100:12	83:21 92:1,17	115:9
guidelines 45:1	100:14,15 117:12	93:17,18 98:24	hygienist 7:13
79:9	heard 92:23 118:2	hit 141:4	13:21 140:18
h	hearing 53:22	hofstra 31:13	hypothesis 64:1
hairdressers 56:23	77:4	hold 86:5	134:21
half 12:4 75:4	heater 132:21	home 14:19 15:8	hypothetical 58:7
hand 19:6 64:22	heaters 125:21	15:12 22:5 46:1	63:12 64:5 74:10
124:6 150:20	132:11,20,24	46:13 56:25 57:2	76:3 89:6
handing 20:7,23	141:5	57:2 62:6,7 65:11	hypothetically
22:19 26:21 27:10	held 150:10	120:9,11,12,16,22	60:4 64:21 74:16
28:2 101:6 108:3	help 18:10 23:16	120:25 135:10,14	i
handwritten 2:11	43:4 133:10 136:2	135:18,22 143:24	idea 28:8,16,19
26:18,23	helped 5:22 30:22	144:20	37:10 57:18
hang 5:22	helper 5:18	honestly 33:21	123:17,23
hanging 5:24	helpful 7:16 95:8	44:2 52:5 63:22	ident 2:6
happen 74:16	helps 21:16	81:15,17	identifiable 33:3
125:11 130:12,19	hereinbefore	hopefully 52:24	57:3 84:8
135:4	150:11	hose 135:10	identification 20:6
happened 31:23	heretofore 51:12	hot 66:13	20:22 22:18 25:19
64:11 87:23 131:7	hereunto 150:19	hour 75:4 107:19	26:20 27:9 28:1
happening 63:22	herrin 117:25 121:20	hourly 43:18	53:6 95:2 97:23
happy 59:14,16		hours 4:8,14,16 43:22 44:1,3,7	101:5 108:2
109:3	herrington 3:6 hiccup 40:17	114:24	110:24 111:5
			·
hard 64:13	mccup 40.17	114,24	113:10 114:10,11 117:8

[identified - interviews]

			T
identified 5:10	49:1,2 53:1 54:10	industries 104:23	instances 147:9
35:6 44:11 47:2	59:24 61:18,25	industry 66:18	institute 32:16
48:16 50:9,12,21	62:2,9,18,22,24	67:5 102:14	institutional 32:20
52:15 56:10 62:14	64:20 67:1 71:6	104:22	instruct 79:8
69:23 72:12 74:3	73:21 88:15,19	inform 10:22	insulated 8:14
77:6 78:15 91:14	100:22 107:15,17	95:19 96:5 98:16	141:12 146:4
94:15 97:25	109:22 116:17	101:18 103:15	insulating 145:25
identify 25:21	includes 58:23	information 5:16	insulation 7:24
26:13 28:3 37:24	including 42:12	5:20 6:19,25 7:4	8:14 10:25 11:3,8
52:10 63:4 103:7	85:17 86:22	13:21 33:2,3	13:8 14:10 125:23
108:7 115:16	127:22	35:11 50:16 53:5	128:1,8,25 129:5,9
identifying 50:22	incorporated 23:7	56:14 58:4,5 59:1	129:14 130:9,19
identities 78:14	23:12	59:3 61:3 62:19	131:11 137:9,17
idiopathic 93:15	increase 105:16	62:21 64:21 65:22	137:19 138:2,6,11
ignore 69:24	106:1,4 137:4	68:24 75:1 76:5	138:21 139:1,5,13
ilo 121:21	increased 105:8	76:19 77:15,17	139:16,18 145:13
imagine 43:24	105:23	78:24 80:23 81:4	145:15 146:6
imbedded 136:7	independently	81:23 82:22 83:25	insulator 138:22
immaterial 31:11	89:22 122:12	87:1 100:8,10,12	insulators 138:12
immediate 135:4	indicate 25:1	100:16 103:5,18	intact 127:12
immediately 15:8	indicated 25:3	103:20 104:10,16	intend 108:25
impact 96:2	individual 46:6	105:1 107:6	intent 78:10
impacted 10:6	54:17 55:13 57:6	109:14 112:15	intention 116:7
95:23	61:23 62:5,9	122:10,18,20	interacting 15:16
impeached 60:12	63:20 65:8,17	125:25 126:10,16	interest 6:17 31:19
imperative 93:18	75:20 77:2 82:24	127:1 141:25	34:25 98:23 99:6
implications 51:15	82:25 84:24	initial 18:24 19:25	99:11
important 29:7	103:25 104:25	20:1 38:11,16	interested 31:21
30:8 33:5 68:7	120:15	40:3 47:12 61:3	32:7 39:19 40:5
83:21 112:19	individuals 39:14	71:11 100:20	150:17
inadequate 105:19	39:24 41:3 44:13	140:10	interesting 17:16
include 6:18 25:25	51:8 55:23 59:2	initially 17:23	internal 78:25
35:19 40:24 46:22	67:1 86:10 87:12	52:3 58:5 138:13	interpret 90:2
48:23 54:3 58:13	91:25 92:16	inside 131:20	interpretation
58:16,21 60:13	120:23 121:11	insider 100:8	43:8
77:16 85:14	136:9	installed 138:13	interpreted 89:25
106:13 112:21	industrial 7:12,12	138:18	interval 106:13,16
included 6:11	13:21 115:9 126:8	installing 138:10	106:20,22
10:18 18:8 19:18	126:14,24 140:18	138:21	interview 53:4
20:10 27:13 43:7	140:22	instance 65:9	interviews 23:6
45:22,25 48:24,25			

[investigation - latency]

investigation 7:6	131:6 132:16	keep 42:10 61:3	138:1,8,9,12,22
57:11 88:1	johnson 2:17,17	keeping 22:11	139:7,15,17,17,21
investigator 34:2	3:7,7 5:15,15	kenneth 119:4	139:24 140:14,19
67:18,25 68:6	23:18,19,21,21	127:21,24 128:7	142:15,20 143:9
69:5	24:1,1,8,8,12,12	128:23 131:6	145:18,18,24
invoice 4:25	96:7,11,11,13,13	133:1 135:7	148:3
involved 31:4,17	97:21,21 98:1,1,13	136:24	knowingly 69:18
32:5 33:1 46:13	98:13,17,18 99:17	kentucky 1:2 3:13	knowledge 31:3
118:9	99:17,25,25 100:5	5:19 123:16 142:5	45:14 69:20 82:25
involvement 50:1	100:6 101:19	kept 143:7	83:15,18,20 84:5
involves 104:12	104:13,13,20,20	key 50:5	99:15,23 100:4,5
involving 121:14	112:11,11 114:3,4	kidney 106:21	103:24 104:1
ionizing 102:17	114:8,8	kind 6:3 14:12	130:1 144:16
irb 30:22,24 32:11	johnson's 94:21	29:5 33:11 35:19	known 34:22 37:1
50:15	95:11 96:5,7 98:3	42:11 121:15	87:12,19 113:17
issue 8:6 59:6	99:16,24 101:19	146:4	113:23 114:3,4,14
90:25 91:6 123:10	joined 139:10	kinds 42:3	114:15,18 143:16
issued 73:10	joint 115:11,21	king 39:9	143:17 144:8,13
issues 27:14	133:24 134:2	knew 32:9 112:6	144:19,22 145:4
italian 121:1	jotting 119:22	knocks 127:18	145:12
iterative 21:7	journal 36:7,11,12	know 7:10,14	knows 113:23
j	36:13,14,19,21	10:20 11:11 14:18	konigsberg 3:2
j 4:1 149:1	38:7,20 39:12,15	17:22 18:14 21:25	109:7,12
j&j 111:15,15,20	39:19 40:7,14,21	33:19 36:18,20,21	kristen 30:9
111:20 112:3,7,7	41:6 44:24 144:14	36:25 37:6,8 42:2	l
112:24,24	journals 36:16	44:9 49:19 52:7	1 3:8 4:1,1 102:25
jacqueline 1:7 2:3	39:22	54:7,12 57:19	140:8
149:3,9 150:9	judge 1:2 146:12	58:2 59:21 65:10	lab 68:8 99:4,5
151:4,20	jump 121:19	67:12 68:13,16	labeling 19:2
janitorial 128:10	jumping 32:14	71:2 78:7 80:16	labs 68:9 98:14
128:11,17	jurisdiction 60:24	82:10 83:7,9,13	99:25
jaw 17:16 119:4	71:17	86:20,21 87:3 89:16,22 90:19	lacked 105:15
127:20	jurisdictions 59:6 59:11,13,13	95:14 103:1	ladened 14:2
jersey 1:22	jury 112:2,7	104:22 105:3	lamm 101:24
job 1:24 8:18 10:1	146:12	113:19 115:7,10	103:3,13,17
10:12 11:20 12:11		118:5,8,8,16,21	langer 115:23
12:15 19:2 110:11	k	122:5,6,15,16	large 8:1 124:1
144:9	kaylo 138:6,7,10	123:9,21 126:15	largely 105:6
john 3:8 119:7	kazan 18:21	126:20 127:1	late 40:15
127:25 128:3,20	kazan's 19:4	134:6,14 136:8	latency 96:1
128:23 129:23		12,1 . 120.0	

[latta - looked] Page 17

latta 1:3	letter 18:7,10,14	listing 50:10,12	62:16 63:8 64:10
laundered 14:25	19:4,4	111:14 118:3	66:24 70:1,21
laundering 5:23	level 11:2 87:4	lists 124:6	73:15 74:8 75:5
14:1,14,23 15:19	137:5 142:2	literally 108:19	76:18 78:20,23
laundry 5:22 15:1	147:20	131:20	81:14 87:9 88:4
15:3,4	levels 92:20 147:5	literature 13:7,12	89:5 91:20 92:14
law 19:17	147:18,18,25	14:16 29:8 51:9	92:22 93:20 95:13
lawn 67:2	levy 3:2 109:7,12	51:13 85:16	97:6 98:19 99:19
lawyer 31:10 56:2	license 118:6	114:17 120:24	100:2,21 107:9
109:25	life 23:21 52:25	litigation 31:1,4	108:9 109:12
lawyers 39:9	liked 14:4	32:1 41:5 43:14	113:2 114:6 115:2
40:23 43:2,3 56:5	likelihood 29:12	47:2,10 50:7 56:6	115:13,19 116:19
83:4,16 84:10,18	61:25 121:2	57:12 65:1 70:9	116:22 117:1
109:10,22	limit 47:23 49:14	little 7:18 17:24	119:17 120:20
lay 74:10	87:8	32:14 40:17 41:23	122:2 124:16,22
lead 145:14	limitation 78:1	67:6,11 83:10	129:3 130:14
leading 44:12,17	limitations 69:15	84:25 106:7	133:21 134:20
44:21,21 66:18	69:18 77:19,22	107:18 117:23	135:2 136:5 137:6
71:23	78:1,6 88:14	121:19 143:18	137:13,18,18
leads 142:25	105:13	live 65:15	138:15 139:2,4,9
leak 139:4	limited 64:22	lived 64:16 65:19	140:13 141:24
leaks 145:13	109:13	living 56:25 57:2	142:6 144:11,24
learned 115:6	line 63:24 69:11	65:14	145:8 146:7
leases 95:16	107:19 141:12,12	livingston 1:22	147:15 148:6
leave 90:9 112:19	151:5	llp 3:2,6	longer 9:14 74:21
132:21	lines 33:13 50:24	loaded 146:16	136:15
leaving 102:15	53:19 141:4,6,8	located 123:10	longhand 36:3
132:5	list 2:8,10,23	125:13	longo 17:1,5
led 6:23 12:25	13:19 16:4 20:17	location 54:21	longo's 16:8
15:13 23:23 62:1	20:21,25 21:2,6,12	55:4	look 11:25 13:7,13
67:5	21:21 22:2,11,13	long 3:4 4:21,22	13:18 19:7 60:9
lee 100:19,24	25:18,22 27:12,14	4:24 5:5 6:6 7:8	61:2 70:12,18
lee's 100:23	27:15 29:15 33:10	9:8 11:4,10 12:7	76:15 93:10 94:24
left 15:11 124:6	41:21 48:10,20,23	13:4 19:3 21:13	102:10 105:2,12
legal 31:11 146:9	53:23 98:24	24:21 28:9,13,19	106:20 111:11,18
146:10,16	108:19,21 116:24	29:1,1 38:9,22	113:14 116:2
legend 124:6,11	116:25 117:6	39:16 41:8 42:1,9	117:4 122:21,22
legitimate 64:6	120:12,13	42:25 44:9 46:8	124:11 135:5
65:2,4,5	listed 31:6 49:5	47:4,11 48:19	148:2
length 8:16 90:11	96:24 112:24	49:6,24 50:8	looked 46:10 54:7
90:15 91:8 137:23		52:21 60:8,19	70:25 76:19 139:8

$[looking\ \hbox{-}\ mesothelioma]$

looking 18:9 43:11	man 101:23	matches 50:6	measurements
48:7,10 67:15	103:19	matching 79:4	13:6 139:24 142:1
91:11 135:3	manage 21:16	material 10:21	measuring 115:24
looks 124:8	manner 11:25	125:13,19 126:17	139:8
losing 118:6	47:12	127:6,9,9 130:16	med 83:7,9,13
lost 52:13	manufacturing	131:12	medical 4:17,18
lot 99:18 106:24	8:13 64:18 120:23	materials 2:12	16:4 26:3,6,7,10
136:21 137:1	121:5,8,11 126:14	4:19 6:12,14 7:6	26:11,13 29:8
louisville 3:13	126:18,21,23	16:10,14 18:1,3,24	31:10,12,21 32:17
lovely 59:17	120:10,21,23	19:1 27:7 57:9	51:9,13 58:13
lunch 75:5,23	manuscript 2:13	58:9 61:15 62:7	62:15 83:11,16,20
lung 25:9 91:14	2:18 27:23 28:5	66:9 71:23 72:2	85:16 114:20
106:16	36:6,15 39:2	72:12 73:1,4 77:5	118:1,6 122:1
lyn 119:12 120:4	42:17 43:15,17	116:10 134:9	126:12 144:15,16
120:18 121:22	54:11 55:15 56:18	matter 1:16 8:21	medicine 23:9
120:18 121:22	62:2 73:8 101:4	11:1,18 54:16	31:13,19 36:8
130:1,7 141:4	101:11	150:18	40:22 80:7 84:5
144:8	manuscripts 42:12	matters 8:21	84:13
	map 119:2	maya 31:6	meeting 4:21,22
m	mark 20:2,18	maya 31.0 mayfield 123:15	37:2 42:7
m 4:1 140:8,8	22:14 25:15 26:16	mean 4:10 8:21	meetings 42:4
m.d. 1:7 2:3 149:3	27:5,21 97:19	32:17 44:18 45:18	member 58:25
149:9 150:9	101:1 107:23	49:7 54:21,24,25	61:23
ma'am 119:19	110:20,25 111:1	54:25 55:1 99:1,8	members 17:11,12
mackey 118:4	marked 20:5,8,21	106:6,8 109:17	36:18 82:24 83:17
119:12 120:4,18	20:24 22:17,20	119:11,18 123:18	84:11,24
121:21 128:19,24	25:18,21 26:19,22	126:20 129:13	men 53:18
129:24 130:1,7	27:8,10,25 28:3	139:10	mention 6:20 26:9
141:3 144:8	29:15 95:1,5	meaning 65:6 81:7	76:9 78:5 103:3
magnani 120:8	96:22 97:22,25	95:25 131:22	107:1 126:9
magnesium 94:14	101:4,7 108:1,4	means 32:18 93:3	132:10 137:21
mailed 118:18	110:23 111:4,6	99:14	mentioned 6:1
main 3:12 37:21	113:9,11 117:8	meant 46:4 112:13	26:12 34:4 102:6
maintain 38:13	marriage 150:17	141:9	102:21 118:10,21
74:14	married 5:14 8:22	measurable 66:3	119:4 120:2,6
major 51:1 84:3	8:24,25	measure 115:13	122:24 135:11
144:16	mas 111:24	measured 14:18	mentor 37:5
majority 4:20	mass 96:22	115:12 120:11	meso 102:4
making 37:11	master's 30:13	measurement	meso 102.4 mesothelioma
male 55:13	match 78:13	13:10 140:21	2:14 5:7 11:6,16
malignant 105:7	125:11	13.10 140.21	11:23 23:23 24:20

[mesothelioma - number]

24:25 26:8 27:24	missing 20:25 22:3	multiple 8:9 47:24	nice 44:4
28:6 29:6,20	mistaken 21:20	69:23	nicholson 115:23
*			120:10
44:12,17,21 51:7 54:16 55:8 79:18	118:11 modified 85:19	mysterious 101:23	
		n	night 136:4
79:22 80:1,12	moline 1:7 2:3,6	n 2:1 3:1 4:1,1	nine 48:21
93:14,19,24 94:4	4:6 19:8,22 20:5	75:11,11,11	non 44:13 105:7
101:20,22 102:1	20:21 22:17,19	102:25	114:8 127:10
102:12,22 103:3,4	25:18,20 26:2,19	name 17:18 21:19	147:1
103:21 104:12,18	26:21 27:8,25	50:7,21 117:14,25	north 9:11 125:2,3
105:17	46:24 74:12,17	118:8 145:17,18	134:1 142:21,24
mess 23:14	78:11,12,23 95:2,4	151:3,4	146:4
met 118:2	97:22,24,24 101:4	napier 3:11	northwell 1:17
method 91:6	101:6 108:1,3	natural 34:24	32:16 33:9,15
138:22	110:23 111:4	nature 7:20 33:8	notary 1:17 4:2
methodology	113:9 116:6,11	134:23 138:16	149:16 150:7
35:10 37:20,24	117:8,12 126:6	necessarily 6:7	151:21,24
68:10 81:7 96:17	143:15 146:23	90:2 136:20	note 12:1 79:11
100:25	149:3,9 150:9	137:22 139:11	90:10
methods 61:15	151:4,20	necessary 32:25	noted 17:1 20:10
66:9 91:3	moline's 2:8,9,10	109:2	72:9 75:9,13
mexico 123:12	2:11,12 20:20	neck 1:18	102:12 122:3
micrometer 90:11	22:16 25:17 26:18	need 27:18 44:3	125:16 148:8
90:15 91:8	27:7	94:24 97:7,8,16	notes 2:11 4:18
micrometers 91:2	monday 1:18	119:24	26:19,23 72:15,17
91:4	monferrato 120:8	needed 34:20	75:19 116:2 117:4
mid 128:21	monitoring 24:4	negative 39:6	119:16,25 122:3
middle 61:16	65:7	79:24 94:9	148:3
millers 105:6	month 23:10	negatives 39:9	notice 2:7 20:4,14
mind 13:17	months 17:22,25	neither 128:23	20:14
mine 104:3	21:24	131:6	november 1:18
mineral 2:19	morning 4:6,7	never 9:16,25 32:3	18:11 22:22 23:3
107:25 108:13	mortality 105:7	/	150:10
miners 102:1	106:11	47:25 60:9 92:23	number 13:19
105:6	mother 5:22 25:6	118:2,2 128:14	14:17,19 21:4
mines 104:13,20	25:11	136:8	47:23 49:13 50:25
minutes 4:24	move 9:17 17:23	new 1:18,22 3:3,3	51:10,15,20,20,22
mischaracterizat	78:9	3:8,8 4:2 23:6,7,8	52:2,6 54:2,3,11
109:8	moved 9:10	57:11 73:25 98:2	55:19 113:6
mishear 10:6	123:12 136:14	150:3,4,8	116:14 119:24
misinforming	mt 1:22	newhouse 143:21	140:15
98:25		143:24	

[numbered - paper]

numbered 21:21	obtaining 80:23	ones 5:25 6:1 7:4	original 18:13,25
102:6	93:18	48:17,24 76:16	original 18:13,25 orrick 3:6
	,	· ·	
numbers 13:5	obviously 35:12	123:1	osha 142:5,5
66:11 123:22	118:9 127:24	online 38:25	outcome 150:18
numerical 14:15	137:4 139:13	000 2:25 3:16	outside 39:14
142:7 147:19	occasionally 58:19	open 102:15	42:16 43:3 95:22
0	occasions 15:10	116:14 132:5	ovarian 22:9 25:8
o 4:1 75:11,11,11	occupation 50:23	operator 141:3	overall 49:1 57:8
object 9:9 14:9	56:20	144:10,22	overlapped 37:4
15:15 74:8 146:20	occupational 23:8	operators 135:9	overwhelming
objection 5:5 6:6	31:19 36:7 40:21	141:11	47:24
7:8 9:8 13:4 21:13	44:13 56:23 67:7	opinion 6:15 8:16	overwhelmingly
24:21 28:9 38:9	80:7 83:8,12,14	10:10,15 12:16	112:10
38:22 39:16 41:8	84:5,12 141:20	13:2 14:7,21	owned 117:21
42:1,9,25 46:8	occupations	15:12 24:10,18	р
47:4,11 48:19	102:17	41:10 80:12 92:19	p 3:1,1
49:6,24 50:8 60:8	occurred 8:15	97:2,12 114:3	_ * ·
/	23:10 40:10 63:18	115:4 126:6,11	p.m. 75:9,13 148:8
60:19 62:16 63:8	74:4 102:14,23	130:6 140:12,17	p1-3782925 151:2
64:10 66:24 70:1	104:18 130:20	140:18 143:19	page 2:2 66:8,11
70:21 73:15 76:18	131:5	146:11,14 147:3	66:14,15,15 67:12
81:14 87:9 88:4	occurrence 130:22	opinions 5:3 10:22	77:21 80:18 85:1
89:5 91:20 92:14	130:25 131:4	11:1,11,12,17	85:2 88:13 89:10
92:22 93:20 95:13	occurring 103:21	13:22,25 16:19	90:9,14 93:12
97:6 100:21 113:2	129:7 130:1	23:17 58:10 63:3	94:7 105:13
114:6 115:2,19	october 98:2	95:19 96:6 98:17	116:12 149:7
120:20 122:2	odd 117:24	99:2 100:17	151:5
124:16 129:3	odds 107:20	101:18 103:13,16	pages 102:7 149:5
130:14,17 134:20	offensive 24:10	108:16,25 112:25	paginated 66:12
135:2 136:5 137:6	offering 5:4 6:15	114:2,25	paid 43:1 99:5
137:13 138:15	10:22 23:17 113:1	opportunities	pallet 141:8
139:2 140:13	114:2,3	69:16,17	palletizers 141:13
141:24 142:6	okay 60:3 71:7	opportunity 16:24	pallets 131:3
144:11,24,25	76:13 102:9 104:8	17:9	141:10
145:8 146:7,19			pancreatic 25:8
147:15	109:9 117:1,12,21	opposed 10:16 11:19 56:1	paper 30:21 31:12
objective 44:10	130:4 133:22		31:14,17 32:13,15
obtain 7:15 82:20	143:6	oral 1:6,15	33:4 34:6 35:12
obtained 42:15	once 53:22 60:10	order 32:23 34:20	36:2 37:8 39:24
61:17 81:5 82:23	93:14 133:3	61:3 97:9	40:3,14 46:18,20
86:9	136:12 139:9,12	ordinarily 79:17	46:21 47:9,17
			51:2 54:2 59:24
		rvices Inc Δ Veriteyt (

[paper - play] Page 21

62:22,24 63:17	parties 150:16	96:25 97:3,13	picked 51:14
67:1,19 68:1	parts 101:14	140:9	piece 36:1 139:8,9
69:11,15,17,24	127:13	percentage 10:20	pieces 137:22
71:6,19 73:22	pass 116:1 117:4	11:22 140:7	139:10
76:12 77:17,21	passed 7:17 9:20	perfect 45:24	pipe 11:7 13:8
85:13,15,17 86:2	9:21 124:22	pericardial 54:20	14:10 127:25
89:19,20 91:7	passing 40:1 41:18	period 8:8 44:2	128:8,25 129:9,14
92:3,16 93:11,14	41:24 125:25	95:22,25 96:1	130:9,18 131:2
93:22 101:24	126:9	117:20 130:21	137:17,18 138:6
115:20,21,23	passive 113:17,20	peritoneal 5:7	138:11,25 139:1,5
127:19	pathological 55:10	54:20	146:6
paper's 77:25	pathologists 87:17	permits 78:10	pipes 7:24 8:14
papers 115:22	paths 37:4	79:14	10:19,25 125:20
paragraph 61:16	patient 77:9 79:18	person 17:17	126:5 137:9,17,19
66:6 85:2,3 86:8	79:21,25 80:11	19:11,16 65:19	138:2 139:3,19
88:1 102:10 105:2	82:7	71:6 89:10	place 34:13 78:25
105:3	patient's 89:3	personal 33:2,3	88:25 136:19
paragraphs 69:15	patients 34:22	60:13 61:12 82:25	placeholder
paralegal 110:1	62:13 67:9 77:8,8	86:11,12,15	116:16
parallel 28:18	78:3 81:10 82:14	103:24 122:9	places 138:19
parameters 46:5	83:17 84:10 87:16	personally 7:14	plaintiff 3:2 43:2
46:16	91:10 92:5,13	12:12 19:14 43:23	58:23 70:7 121:8
parking 137:1	93:19 94:16	80:10 81:10 82:6	147:6,24,24
part 21:1 43:5	patrick 3:13	82:14,19 83:3	plaintiff's 50:7
68:2 73:3 74:22	117:14	96:2 128:14	58:21 70:14
79:16 80:1 92:11	paul 36:24 119:7	perspective	plaintiffs 1:4
124:1 127:18	127:25 128:3,21	103:12	43:19 58:17 78:11
134:8 145:25	128:23 129:23	pft 121:21	84:12
participating 57:2	131:6 132:16	pfts 122:15,15	plant 5:19 6:10
particles 2:19	pay 55:3 123:7	ph.d. 30:15	7:14,15 16:8 65:9
108:1,13	peer 29:25 37:9,12	phenomenal 32:11	65:10 67:3 117:20
particular 24:5	38:1,8 55:18	phone 34:14 116:3	117:21 123:4,9,18
45:2,23 57:17	pel 141:23 147:13	phonetic 21:19	123:21 127:2
61:9 62:2 63:3	147:17,21,21,25	phrase 44:17	140:24 145:2,7,10
68:5 72:1 74:2	pels 147:9	physically 35:24	145:12 146:1
104:25 113:6	people 19:12 42:2	129:13	plants 64:18
122:19 134:14	42:11,11 79:5	physician 17:13	120:24 121:2,17
particularly 7:16	83:18 88:5,23	29:4 67:7 122:8,9	123:7 134:3
84:7	145:19	122:17,19	platy 92:24
particulars 86:7	percent 52:6,7	pick 74:21	play 30:16 35:2,14
	53:18,18 91:22		

[played - program] Page 22

played 24:19	potency 11:13	preferences	previously 31:25
plc 3:11	potent 12:4,5,6	109:11	43:13 78:12 80:5
pleasant 1:22	potential 5:25 6:3	prepare 58:10	84:3 85:21 98:3
please 4:15 20:3	6:16,18,21 8:12	109:15	103:12,16 111:12
22:14,15 25:21	15:21 24:7 49:16	prepared 4:25	112:15
26:16,22 27:5,6,11	52:10,15 53:12,21	19:8,9 21:6	prime 52:25
27:21 28:3 82:2	53:24 56:9,15	preparing 4:8	principal 34:2
101:2 107:23	57:10,14 60:15	72:11	35:16
108:8 110:21	61:9 63:2,4 64:5	presence 91:19	prior 43:16 60:12
111:2	64:15 65:2 66:16	93:3	70:2 104:2
pleural 54:20	67:5 68:3 71:16	present 11:3 62:3	priority 1:21
plus 112:13	72:20 75:17,24	79:22 92:24 103:8	151:1
point 7:9 9:5,17	76:8,14,15 77:3,7	112:2,6 115:14	privacy 81:21
22:6,10 23:2	82:8 84:6,17 88:2	125:17 128:20	privileges 79:6
27:19 28:14 29:9	89:2 104:2 120:4	129:14 145:10	privy 100:12
29:12 34:10 38:13	127:14 130:8	presentable 89:13	probably 4:23
39:1 40:11 48:14	134:2,19,24 145:3	presentation 55:5	21:9 34:10,11
52:25 75:22,23	145:11	presentations	86:3 129:16
102:5 114:14	potentially 53:2	110:2	problem 19:5
115:7 145:4	92:23 120:18	presented 31:20	procedure 1:16
pointed 105:14	142:11 144:9,20	45:19 49:22 63:1	proceed 78:17
points 43:25 68:25	powder 44:12,20	64:13,14 67:16,19	proceeding 34:5
70:9 114:5 145:14	45:10 56:11 80:13	68:1,9 70:19 76:3	34:17
polan 14:19 120:7	83:1 86:13,16,23	80:20 111:8,10,12	process 37:9,13
poorly 53:8	87:7,13 93:16,23	presenting 68:23	38:8 55:18 57:7
population 87:10	94:15,17,21 95:11	93:19	71:15 109:19
87:11,23 89:18	96:5,11 98:3	president 19:13	126:23
90:21 91:15,25	99:12,12,16,24	23:8	produced 134:7
94:16	147:7	press 2:17 95:16	product 96:9
pose 90:8	power 105:16,20	97:21 98:1,6,7,9	138:4
position 79:1,12	powerpoint 2:20	98:12 100:7,18,23	production 8:15
89:1	2:21,22 109:6,13	presses 66:13	125:7 126:3,23
possession 108:20	109:16 110:2,22	presumably 84:9	136:22 137:12
possibility 78:2	111:3 113:8	84:14	products 5:15
102:16	powerpoints	presupposing	23:19,20,22 24:1,8
possible 5:19 50:2	112:22	79:20	92:8,10 126:22
61:4 66:18 68:13	practice 55:24	pretty 34:14 39:11	127:3 138:11
68:20,21 88:11	79:16 80:1	47:14	147:7,8,10
102:17 104:11,16	predated 86:1,2,3	prevented 62:23	profession 57:1
possibly 70:10	predisposition	previous 54:13	program 109:23
101:22	25:2	96:12 98:11	

[project - recall] Page 23

project 33:11	public 1:17 4:2	73:3 74:18 76:7	rates 106:14
projects 31:22	30:13 149:16	76:13 78:16 82:2	ratio 106:11
projects 31.22	150:7 151:24	84:2 85:22 87:16	rauf 36:24 39:17
141:17	publically 99:18	89:24 90:7 95:18	40:2
proof 64:16 65:7	100:13,15	109:18 113:16,22	ray 117:25 122:11
proofs 38:24	publication 33:1	117:24 144:18	reach 70:17 79:14
proper 80:6 83:7	38:25 39:13 40:20	146:8	106:4 116:16
property 123:19	41:7 42:8 55:16	questionable	reached 17:6
propose 116:15	publications 23:7	48:22	read 19:19 21:3
proposing 116:20	144:16	questioned 83:17	42:18 44:14 45:12
116:22	publish 39:22	84:10 87:6	47:24 56:12 61:19
proposition	published 36:13	questioners 83:23	66:19 67:19 80:25
115:17	39:2 45:16 85:21	questioning 61:18	87:20 88:22 90:12
protected 50:15	86:24 144:14	76:20 83:2 84:16	90:16 94:11,11
50:16 78:24	publishes 36:14	84:22 88:16,20,25	98:11 99:18
protection 33:6	69:13	107:19	100:10,11 101:14
protection 33.0	publishing 34:25	questionnaire	101:15 102:18
protocol 32:19	39:20 40:6	76:22	103:9 105:9
89:16 90:1,3	pull 21:2 131:20	questions 7:11	107:12 108:24
protocols 89:23	pulmonary 118:4	17:4,7 33:10	129:8 130:5
provable 63:13	pulmonologists	62:12 70:19 78:17	134:14 140:14
prove 143:13	86:10	79:13 83:24 84:23	reader 47:24
provide 13:1,20	pursuant 1:16	86:25 88:23	113:21 122:22
18:22 19:17 72:10	put 44:25 69:15,19	108:11,22 116:4	readers 40:7
72:16 105:23	78:25 116:18	122:4 145:19	reading 4:17,19
110:8,15	138:14 139:9	146:14	7:12,13 108:18
provided 2:25 7:2	140:7	quick 107:21	118:3
7:7 19:16,17 33:9	puts 110:16	quite 17:2	reads 67:16
35:11,17 57:22	putting 29:18	quote 88:19	real 63:11 65:12
58:3,5 61:3,24	q	r	realized 22:2
62:4,19,21 65:13			28:23 34:19,24
65:19,22 66:2	qualitative 12:23	r 3:1 75:11 149:1	48:7
72:14 76:20 77:15	quantify 12:9	150:1	really 5:22 58:2
103:6 104:10,16	23:24 77:1 131:7	radiation 102:18	64:14 83:20 131:7
107:6 109:13	quantitative 12:17	radiologist 117:24	143:20
117:7 119:14	13:10,14 14:12	raise 19:15	realm 70:24
145:21	queen 39:9	raised 64:6 73:10	reason 51:3 151:5
providence 47:15	question 5:16 53:8	ranges 106:23,23	reasonable 126:11
provider 26:7,12	53:9 54:13,14,24	rare 94:4 105:16	recall 15:6 21:11
provides 93:14	57:19 58:1 60:1	rarely 58:19	21:14 26:11 27:15
94:1 105:5	60:11 63:11,15	rate 43:19	33:19,21 34:8,11
	65:23 68:19 71:9		, ,

[recall - research] Page 24

34:12 37:25 38:4	94:10 98:1 107:21	relatable 119:22	rephrase 146:18
40:12,13,19 52:2	108:7,24 110:5	relate 111:24	report 27:19 31:20
57:24 58:4 63:18	111:7 116:5,6,10	related 5:20 22:4,9	35:23 57:23 59:7
63:22 64:11,12,25	150:13	27:14 35:1 39:24	60:25 68:23 70:13
65:8,21,24 66:1	records 4:17,18	80:23 86:25	71:18,22,24,25
68:12 71:1 72:4	7:16 16:4 18:11	107:10 141:25	72:3,10,14,17,22
76:1 80:14,15,17	26:3,6,10,13 58:13	150:15	72:3,10,14,17,22
83:12 88:12 96:15	62:15 122:1,13,14	relating 7:19	73:24 77:2 94:24
96:19 98:10	reductive 109:18	relative 24:14,15	106:10 107:11,17
107:10,12,14,16	refer 19:10 117:19	release 2:17 97:22	118:1,3
117:24 119:3	reference 2:8	98:1,6,8,9,12	reported 92:16
			100:7 103:3
121:6,7,15 123:22 124:1 125:10	13:18 20:16,20,25	100:18,23 relevant 9:3,7	120:22
	21:6,21 22:2 51:2 51:14 69:12	/	
127:24 128:12		83:18	reporter 1:17
129:4,4 132:4,14	103:22 114:14	reliance 2:8 20:17	59:17 116:8 150:7
133:1,5,6 135:7,11	120:12 125:25	20:21 21:1 27:12	reporting 1:21
135:19,21 136:11	referenced 13:12	27:14 98:24	151:1
136:17,24 137:16	22:7 55:23 72:22	relied 2:12 27:8	reports 34:21
137:18 139:23	73:1,4 75:18	rely 83:19 108:25	35:20 53:15 58:6
140:15 142:17,25	122:5 123:3	115:4,16 120:3	58:16,20 70:7,7
143:1	references 14:16	140:17	75:19 78:12,13
recalling 132:22	21:3,17,23 105:3	relying 82:20	79:4 80:20 120:24
receive 58:9	123:20	84:17 108:16	121:13 125:17
118:21,24 134:8	referred 56:1	112:24 113:6	represent 74:11
134:11,12	101:24 113:22	122:19	111:7 113:12
received 20:5,21	referring 10:2	remain 45:15	117:14
22:17 25:18 26:19	19:23 41:25 43:10	114:24 115:5,17	representative
27:8,25 38:7 43:3	81:6,21 94:12	remains 103:19	112:12 113:4
95:1 97:22 101:4	reflected 112:8,21	remember 36:4	represented
108:1 110:23	reflects 116:12	37:22 40:9 41:20	112:16
111:4 113:9 134:6	regard 11:12	48:23 51:19 81:15	reputation 63:24
recess 27:4 75:8	120:4	82:10 118:16	69:10
107:22	regarding 7:1 47:6	128:5,7,18 131:19	request 18:23
recollection 81:17	61:18 85:11 87:2	132:9,23 133:4	33:14,23
81:25 82:3,5	103:6,20 144:6	144:1	requested 38:1,5
101:21,25 130:2	regardless 77:10	remove 133:10	requests 34:3
132:17 143:12	117:20 145:6	removed 77:9	required 32:23
record 18:5 19:22	regular 8:1	rendering 80:12	151:21
20:2,13 28:4	regularity 131:5	renovations 46:13	requirements 33:6
29:14 38:6 67:21	regulations 141:17	57:3 62:8	research 31:21
78:8 79:11 93:13			32:17 50:19

[researcher - see] Page 25

researcher 32:12	38:17,18 41:10	135:19,22 141:9	126:18 129:6
reserve 79:13	43:21 55:18 57:15	rights 79:13	145:17,18,19
residence 66:17	61:11,22 62:12	0	· · ·
residents 66:7	64:7 68:2,4 72:12	rigor 80:22 81:4,6 84:15,18,19,21	saying 48:25 59:22 60:5 72:6 79:23
	77:5 79:1 100:18	risk 11:23 65:16	81:19 82:4 93:7
respect 9:6 10:1,5			
11:12,15,17 13:2	108:14 118:11,13	105:8,23	99:3 106:8 114:14
13:23,25 23:18	118:21,24 119:7	rj 100:19,23,24	says 19:7 67:6
25:5 35:14 38:8	119:11 122:11,11	rohl 115:23	102:7 129:22
38:21 40:23 41:3	134:5,11,13	role 24:18 30:16	143:15 147:4,23
42:5 54:19 61:1	reviewed 2:12	35:2,14 145:24	scenarios 65:14
64:12,22 71:1	10:22 15:23 16:10	ron 28:14	scheduled 17:23
73:6 80:22 84:19	16:15 26:3,24	roof 7:25 127:14	schematic 123:3
84:22 87:23 88:5	27:8 28:23 32:20	127:18,19,23	schematics 123:5
90:21 95:11 96:6	37:8 48:6 49:10	132:8	school 30:14 31:13
98:11,17 99:1	51:21 52:4 53:16	roofing 127:5,9,9	83:11
103:13,16 104:1	54:8 57:16,21	room 59:15	schupbach 3:11
112:12 121:1	60:6,17,20 61:7	rotations 31:18	science 51:1
129:6 140:21	62:18,20 63:6	rubber 133:24	scientific 63:23
respiratory 105:7	67:7 69:7 71:18	134:15	70:17 77:18
105:9,23 106:14	71:22 72:2,22,25	rules 1:16 44:24	114:19,20
responsible 89:10	73:2,5 77:5 94:20	run 8:3 128:4	scientist 69:11,24
responsive 65:24	95:10,19 101:13	S	70:18
rest 137:21	101:16,17 118:15	s 3:1,6,11 75:11,11	screened 86:11
restrictions 78:25	118:16 121:10	75:11 102:25	se 83:21 123:5
result 5:7 37:12	reviewer 38:1	140:8 151:5	second 5:13 21:1
97:14 140:1	reviewers 29:25	safety 141:20	45:10 53:2 101:23
results 35:13,21	reviewing 17:25	sake 68:11	114:1 116:2
43:8 45:9 67:18	18:3 29:5,14,17	salas 21:19	secondary 7:22
68:1 85:3 96:1	48:10 57:9,14	sammel 140:8	section 30:21 56:8
98:25 139:18	60:15	sample 85:19 87:8	85:3 86:23 89:20
retained 17:20	revise 73:18	90:1 97:8	138:25 139:5
18:6	revised 23:4 74:25	samples 35:11	sections 137:18
retest 100:6	revisions 22:25	85:1,2,14,16 86:1	138:7
retested 98:13	33:20	87:2 100:20	see 15:25 23:7
100:9	rewrite 38:4	sampling 10:17,18	39:7,18 46:10
retired 5:14 8:20	right 39:5 41:13	10:20,21 62:5	83:24 96:21
10:3,8	41:16,17 49:13,17	64:16 65:7	111:16 117:4
returned 15:8	52:21 69:11 70:15	sanctioned 118:6	118:19 125:1
review 6:25 18:16	77:19 78:23 80:3	sarcomatoid 54:25	126:16 127:5
25:10 32:20 37:9	80:7 82:7 85:2	sar 21:21 41:17	129:21 134:22
37:12 38:8,11,16	110:7 128:17	118:1,2,3 123:25	
		110.1,2,3 123.23	

[seeing - south] Page 26

seeing 96:15 98:10	36:14 39:23 40:6	silica 94:14	slide 2:20,21,22
142:17	46:7 51:8,17,24	silicate 138:5,11	110:22 111:3,18
seek 7:15	52:15 54:16 77:10	silicates 94:13,14	113:8,13
seen 17:19 20:8	77:23 94:2,3	similar 47:25	slides 109:6,20
41:21 65:9 94:22	serve 41:4	72:17 80:21	110:3,14,17 111:8
94:23 95:6,7	services 1:21 2:15	similarly 8:13	111:10,11
96:10,19 98:6,7,8	94:25	simmons 119:5,7	slightly 130:5
98:8 100:23 101:8	set 19:1 85:11,12	127:21,25,25	small 102:2,3
107:13 108:4,6,15	113:7 150:11,19	128:3,7,21,23,24	smart 23:14
108:19 122:25	settles 114:25	129:23 131:6,7	sole 54:9
136:8 138:17	seven 80:18	132:16 133:1	solely 43:7
select 51:18	shake 5:23 12:8	135:7 136:24	solicit 50:20
selected 48:12	14:4	139:7	solutions 116:14
selecting 51:16	shaken 8:9	simon 109:5,15	somebody 34:21
53:10 54:15	shaking 14:5,14	single 64:25	41:20 45:24 57:1
	shape 26:10	102:22 103:21	
selevan 102:24,24 103:1,2	shape 20:10 sheet 151:1	102:22 103:21	110:1,16 son 113:19
semantic 44:19	shift 129:13 135:8	sister 16:7 25:7,7	son 113.19 sooner 17:24
semanue 44:19 send 19:3 40:8	shook 14:2	sister 10:7 25:7,7 sister's 7:3	
41:9			sorry 52:13 104:14 121:19
	shorter 44:1	sit 59:15 64:24	
sense 24:3 43:22	shorthand 1:17	68:16 80:15 82:9	132:13 133:19
46:9 51:23 57:7	150:6	97:11 115:15	134:10
138:25 140:19	show 71:4 78:11	site 119:2	sort 12:6 42:6
sent 4:19 18:12,20	95:4 142:23	sitting 110:18	107:20 116:24
18:20 19:7 29:25	showed 62:6	situation 74:1,17	sorts 127:22
38:23	showing 25:20	86:6	sounds 131:4
sentence 42:24	95:4 111:6 113:11	situations 74:11	134:4
45:10,18 93:11	shown 96:21	six 35:5 47:2,8,16	source 42:16 43:4
94:8,10 105:13	121:25 149:6	47:23 48:3,4,5,10	45:11 52:10 53:12
147:10	side 58:17,17	48:12,15,16,18,25	53:24 56:10 57:3
sentences 38:3	signature 150:21	49:12,14,22,23	62:23 63:4,16
93:6	signed 45:6	50:1,4 66:14,15,15	73:9 77:7 84:8
separate 24:16	significance 106:5	68:11 69:3,4	87:17 99:23 115:8
41:13,15 51:25	significant 8:7	74:21 80:19,20	sourced 96:11
104:2	12:25 13:3 21:22	81:8 90:2,25 91:6	sources 48:8 61:9
separately 43:16	34:3 106:1,2,9,12	91:10 92:4,12	61:18 66:6,16
sequential 53:14	106:18,19,25	size 123:17,24	68:3 71:16 88:16
139:3	146:24	124:14 138:9	88:20 89:2 122:8
sequentially 46:23	significantly 22:1	skimmed 125:16	137:11
series 28:13,19	140:3	skipping 67:11	south 9:11,16
29:1 33:4 34:17			125:2,4 131:10,13

[south - sure] Page 27

143:3	stacking 141:9	status 95:10	40:14 41:1,6,18
speak 12:7 16:25	staff 128:11	stav 67:12	42:10 55:15 70:13
88:8,9 122:14	stainless 138:13	steam 8:14 125:20	submitting 41:13
speaking 64:21	138:14,19,20	125:21 126:5	subscribed 149:12
70:22 71:2 74:9	standard 76:22	132:20,20 141:4,5	151:21
120:15	110:3	141:6,7,12,12	subsequent 38:24
speaks 95:14	standardized	steel 138:13,14,19	57:22 60:11 99:16
spearheaded 34:1	106:11	138:20	112:17,22
specialties 84:4	standpoint 9:18	stevens 3:11	substance 114:23
specific 5:3 12:16	12:24 140:23	stop 50:4 75:3	substantive 33:22
16:14 37:6 38:4	stark 1:2 46:3	114:16	substantively 39:3
41:11 45:2 59:23	starr 103:3	stopped 8:20	substituted 63:20
59:25 65:8,9,17	start 8:23 57:8	53:25	suffered 77:8
71:2 74:11 79:5	130:18	stored 33:12	suffering 5:6
118:20,25 120:3	started 8:24,25 9:1	straight 113:3	sufficient 67:4
124:2 126:16	18:2 29:17 46:22	straps 138:14	96:1 127:1
133:6 142:2	74:5 102:3 134:17	street 3:7,12	suggesting 81:22
specifically 4:13	136:12 142:19	strike 137:15	82:1 93:2
6:22 15:24 17:8	starting 48:14	struck 141:12	suggestion 77:13
21:14 57:24 65:25	starts 9:4	stuart 3:9	sullivan 102:3
66:1 77:21 78:5	state 4:2 92:7 94:9	student 31:11,12	sum 114:23
88:12 96:19	95:9 116:5 141:18	students 31:21	summer 31:24
107:10 123:2	150:3,7	83:7,10,13	40:15
126:2 129:18	stated 14:25	studies 13:19	summertime
specificity 144:5	103:16,23 112:16	14:17 50:6 111:24	132:20
specifics 57:6	statement 97:18	115:10 134:14	supervisor 128:10
specious 24:16	98:19 108:23	study 32:15 94:1	supplemental
speculative 24:24	statements 95:16	102:24 103:8	57:23 71:25
spelled 82:21	states 32:15 42:14	105:5,14,22 121:1	supposed 65:18
spent 4:8,12,15	45:10 86:8 91:23	133:23,24 134:2	94:11,11
37:2	93:13 96:17 105:4	134:17,22,23	sure 4:11 8:23
spoken 16:18,22	141:18 144:13	136:8 143:24	13:19 14:17 18:21
17:2,10,12,13,14	statistical 105:15	stuff 73:25	19:5 22:6 34:14
17:17 88:6	105:20 106:5	subject 74:14	36:20 37:11 39:5
spouse 46:12	107:13,17	149:6	41:12 54:22 55:2
65:10 76:25	statistically 106:1	subjects 33:7	68:21 70:16 74:9
square 124:3,7,8	106:2,9,12,18,19	submit 30:22	74:15 75:7 104:15
124:17	106:25	36:10,15 39:20	105:18 108:10,10
ss 150:3	statistician 107:3	41:5,19	116:19,21 120:9
stack 22:4	107:7	submitted 30:7,24	121:12 124:17,20
		32:18 33:15 38:23	

[surgeons - things] Page 28

surgeons 86:10	talc 2:14 23:19,20	130:15 132:19	testifying 15:6
surprising 134:16	24:1 26:8,9,12	133:4	70:8 79:2 109:5
survey 16:7	27:14,25 28:6	talks 61:15 66:16	109:19 121:7
118:22 125:12	29:7,17,21 36:13	67:24 76:7 88:14	127:25 128:8
139:18 140:25	41:4 46:1 47:2	102:11	133:1 135:7,21
surveys 12:21	48:9 52:1,11	tar 127:19	136:11,25 137:8
sutcliffe 3:6	53:17 54:10 56:21	taught 37:3	137:25
sweeper 133:14,15	56:24,24 58:9	technically 106:18	testimony 15:11
sweepers 133:2,5	60:16 65:1 86:4	telephonically	25:10,23 40:19
133:7,11	92:8,10,13,18,24	3:14	41:2 46:20 60:7
sweeping 105:20	93:3,5,7,8,8 96:4,7	tell 12:23 40:2	60:10,12,13,17,21
133:3	96:13 97:3,13	44:6 49:3 81:9	61:2,17,22 62:11
swept 133:8	98:18 101:19,23	109:1 124:21	62:14 64:24 66:21
switch 27:2	102:13 103:19	137:25	87:25 110:15
sworn 4:2 61:17	104:3,12,13,19,19	ten 4:14,16	112:11,17 113:14
61:22 149:12	104:22,22 107:14	term 84:19,21	114:22 123:14
150:11 151:21	114:12,12 126:8	146:16	127:5 128:18,19
symmetrical 51:5	126:14,24	terminology 76:11	131:19 132:4
synthesizing 43:11	talcum 44:12,20	terms 17:3 24:14	136:17 137:16
system 106:15	45:10 56:11 80:13	44:25 74:10	141:3,11 143:6,11
t	82:25 86:12,16,23	114:14 123:17,18	149:4 150:13
t 75:11 149:1	87:7,13 93:16,23	125:12 126:7	testing 12:19
	94:15,17 147:7	138:2,10 139:20	24:23 65:6 94:19
150:1,1 table 67:16 84:4	talk 7:18 13:22	140:16 142:3	94:20 95:10 96:5
	15:23 20:16 62:11	146:5	96:15,16 98:14
89:10,15 91:12,16 tables 30:19 90:23	66:6 69:10 71:15	test 96:2	99:16,17,20,23,25
tables 30:19 90:23 take 6:2 14:19	80:19 83:6 84:25	tested 98:4 99:3	100:5,24 112:21
15:7 19:7 22:5	87:11 92:3 111:1	100:9	tests 98:2 118:4
27:1,3 40:19 41:2	120:12	testified 4:3 41:22	text 87:2
46:1 55:7 56:25	talked 28:17 34:16	49:15 80:5 84:3	thank 22:13 60:4
58:7,8 70:14	35:18 41:23 52:14	109:12 121:12	79:15
79:12,17,20 80:2	56:18 77:18 110:6	127:8 128:3,24	thankfully 59:11
80:10 82:14,19	132:23 143:18	135:17	thanks 148:7
83:7,13 89:9	147:11	testify 6:22 60:22	thermal 138:1,11
94:24 107:21	talking 29:2 59:1	78:24 109:6	thing 44:5 74:20
119:25 120:9,12	60:23,24 74:1	121:24 122:21	110:25
120:22,25 122:21	75:24 76:1,2	129:25 130:24	things 32:11 33:13
144:20	84:15 88:13 99:19	141:16,21 142:1,3	37:21 41:13,15
taken 1:16 27:4	113:23,24,25	143:16 146:21,22	42:4,6 50:23
75:8 107:22	114:8,18 120:9	147:5,12,20,23	74:12 114:4 115:8
145:22 148:1	124:5 126:2		129:25 142:9
	One Court Penerting Ser		_

[things - two] Page 29

146:14	117:7 118:13	tires 8:13	transcribed 36:5
think 6:20 8:19	138:7	tissue 28:22 35:4,5	transcript 1:15
9:14,21 12:2,18	throw 18:8	35:8,13 37:20,24	64:8 119:17 120:1
15:9 16:5 17:23	time 4:12,20 5:14	46:25 47:8,13,16	149:6 150:12
18:19 20:9 25:12	8:17 9:5,15 10:19	47:19 48:1,14,17	transcripts 16:6
25:14 27:17 33:21	18:2 21:8,21	50:2 67:16,17,24	53:5 61:11 77:15
34:2 36:4 37:4,19	22:12 23:2 28:13	68:4,10,14,17,22	82:23 119:16
38:2,10 47:14	28:19 29:1,2,11	69:6,22 70:22	transpired 64:17
52:19 56:17,18	30:7 31:23 37:2	71:1,12,12 78:2	73:19
72:7,13 73:7	38:13 44:2 51:16	88:6 90:1,25 91:6	treating 17:13
74:12,17 76:2	52:19 53:10 57:16	91:14,14 92:13	86:9 87:18 88:7,8
82:21 87:10 92:15	63:16 64:6,25	93:1,3	88:10
93:25 95:8,21	65:2 69:13 71:13	title 29:20,22,24	trial 2:10 25:18,22
100:22 105:12,13	73:8 74:3 75:9,13	30:2,4,6 98:2	59:20 60:5,6,9,11
109:8,10,14 113:3	75:23 77:17 95:22	111:19	60:12,17,21 61:2
116:11 117:1	95:25 114:5	titles 30:8	73:12,20 109:5,20
118:15,21 120:8	115:12 117:20	tlv 141:22 147:16	114:23 121:24
123:2,3,5,11,12,15	118:19 129:20	147:25	triangle 1:8
125:25 127:20,21	130:21 137:20	tlvs 147:9,13	145:15,19,22,25
129:15,18 131:18	141:23 143:20	today 4:9 15:25	146:3,5
137:20,20 138:16	148:4,8	16:12 25:24 64:25	trick 58:1
138:18 142:22	times 12:4,4,5	68:16 80:15 82:9	tried 77:1
143:6,10,12,18,20	19:20 82:22	84:3,22 87:25	trivial 147:1
144:5 145:1	115:13 129:10	97:11 115:15	truck 132:1 137:1
146:15 148:1,6	timing 63:9	118:19 135:17	trucks 125:9
thinking 28:12,25	timothy 1:2	today's 25:25	true 123:21 149:5
29:4 96:20 115:22	tire 3:12 5:12,13	top 8:2 102:7	150:13
143:5	7:20 8:11,15 9:2,6	108:18 124:21	truly 106:3
third 3:3 19:10	10:8 17:15 24:9	141:8	truncated 44:25
118:17	117:16,17,20	topic 67:12	try 24:16 39:10
thorough 88:15	118:20,25 120:5	topics 27:2 35:19	124:12 146:18
thought 10:4 40:7	120:19 121:4,5,8	tornado 8:7	trying 11:4 42:23
49:12 51:4,9 94:9	121:11,17 122:25	127:17,23	57:7 67:12 70:17
129:8 133:18	123:9 126:8,13,15	total 124:15	79:24,25 81:24
143:1	126:18,21,23	touch 109:21	99:22
thousands 67:8	127:3 133:25,25	town 123:16	tumor 54:21 55:5
three 2:23 15:25	134:3,7,15,24	trachea 106:15	turns 87:5
16:11,16 18:25	139:23 140:2,4	train 131:20,22	twice 15:1,4 112:5
19:24 26:25 56:22	141:23 142:4,12	training 83:16	two 12:4 18:4
82:22 89:10 91:12	142:15 144:7,19	84:12	21:15 35:22 41:12
106:21 116:6,9,17	144:21 146:1		41:15 82:21 93:6
		L	

[two - warehouse] Page 30

99:20 102:4	126:4,13	98:22 99:7,9,14	vs 1:6
	understood 10:4	values 106:25	
118:15,16 119:13	77:23 84:2 90:9	142:7 147:19	W
125:8	136:23 145:2	varied 137:20	w 1:3 3:13
	unfortunately	various 26:24	wagner 51:2,5
54:16,18,24,24	59:13	43:25 46:10 52:3	waist 111:25
1 ' ' '	uniform 61:4	53:15 65:13 83:23	want 17:4 27:1
	union 133:25	92:10 114:5	41:12 70:12 74:9
	united 91:23	115:13 139:10	75:5 90:19 107:20
types 10:10 11:5	133:24 141:18	143:9 145:14	116:9,19 146:13
11:13 22:3,4 25:2	144:13	vein 69:21	147:9
	universe 85:20	ventilation 131:17	wanted 13:13
	university 134:1	132:5	34:19 37:19 38:3
	unknowable 89:7	venture 44:8	49:4 54:2 68:20
11 S	updated 21:8	verbatim 39:4	87:3 93:10 116:4
<u> </u>	27:16,18,19 102:7	verify 103:7	wanting 85:14
u 4:1 149:1	upper 124:6	veritext 151:1	ward 1:3 8:10,17
unimate 93:10	ups 148:3	verment 101:19	8:19 9:20,24
ultimately 30:0	usage 45:11 52:1	102:8 103:4 104:3	10:11 11:18 12:10
45:6 59:20	93:16,17	102.8 103.4 104.3	12:15 15:11 118:4
un 66:12	use 2:14 6:11	104.13,19 103.0	119:12 120:18
unable 103:6		version 23:1 45:15	121:22,25 126:7
unaware 93:7	23:25 26:8,9 27:24 28:6 29:21	version 23:143:13 versus 138:23	128:20,24 129:13
uncertainty	44:16 49:23 51:10	140:7	129:16,24 130:2
112:20	51:17 52:11 53:13	vested 98:23 99:6	131:13 135:12,18
unchanged 45:15			140:2 141:4,22
unclear 9:14	53:13 56:21 76:11	vianna 14:19 120:7	142:5,11 144:8,19
125:23	78:13 84:21 86:11	,	147:12
understand 44:23	86:12,15 87:7	view 6:5 12:13	ward's 17:14
57:5 58:2 73:23	91:18 94:17 109:5	87:7	120:4 130:8
74:18 86:5 94:10	115:14 138:13	vintage 95:25	136:12 140:3
139:20	147:6	violated 141:19	warehouse 7:25
understanding	usefulness 87:8	142:4	9:11,11,16 124:3
1 9.19 / 3 3/.//	usually 59:9	violation 141:17	125:21 126:3
46.74 47.7 20.17	utilized 126:22	virtually 23:21	128:1,9,16,20,25
50:20 63:25 85:18	uttered 60:10	vis 142:5,5	129:10 131:11,21
85:22,24,25 86:6	V	vitae 2:9 22:17	131:23 132:9,15
86:14 87:4,22	v 102:25 151:3	voice 113:18	133:2 136:13,18
90:4,19,20,24	vague 104:24	volume 118:14	137:1,5,8 142:14
	vaguely 134:4	volumes 118:13,14	142:21,24 144:4
	value 12:17 14:15	118:15,16	144:10,23
117:16 125:6,18	40:7 94:3 97:9,17		

[warehouses - à] Page 31

_			
warehouses	9:24 13:23 14:13	104:3 109:19,23	written 32:24 36:1
123:24 124:1,4,13	14:22 15:6,14	110:6,11 117:1	42:13 53:15 59:7
124:14,23 125:2,7	16:22,25 24:8	135:22,23,25	71:14,18,22 72:10
125:12,20 127:6	25:5 26:3 45:23	136:10 142:14	73:16,17,17 74:19
131:13,17 143:3,7	52:17,22 70:12	worked 5:12,13,18	86:23 94:23
143:9 146:4	72:18 95:22 96:2	6:19 8:19,20	121:13
wash 12:7	122:5 135:21	30:20 31:19 35:17	wrong 18:9
washed 14:3,3	136:11 140:1	43:25 44:1 56:20	wrote 18:22 36:2
way 11:5,10 13:9	147:13,16 151:3	57:1 89:12,14	46:14 73:8 77:17
26:10 44:19 51:5	wiman's 6:23 10:6	104:12,19,23	86:21 90:22
74:12 85:15 90:4	17:10 23:18,25	121:8,11	X
97:12 103:17	24:20 26:7 95:23	worker 102:13,13	x 1:3,11 2:1
104:24 115:6	wind 113:5	103:6 104:12,19	122:11
124:9,20 137:7	winded 11:4,10	119:10 123:2	
138:12 143:1	wire 138:14,18	128:19 136:17	y
150:17	wise 24:11	workers 7:24 8:5	years 6:21 8:17
ways 138:21	withholding 81:22	16:6 17:15,18	12:14 21:5 24:11
we've 56:18 75:3	witness 1:15 2:2	59:4 102:8 119:11	25:23 29:3 34:23
107:18 147:11	17:18 41:21 43:14	133:25 134:15	51:11 52:5 86:24
148:1	44:22 47:1,10	143:11,23	102:14,15 143:9
week 15:1,4 23:10	78:20 116:2 117:4	working 6:10 8:10	143:13 145:22
108:21 130:22	146:8,17 149:3	8:25 9:1,2,14,15	york 1:18 3:3,3,8
weeks 18:1,4	150:10,14,19	10:9 30:19 42:3	3:8 4:3 23:8 150:3
21:10,15	151:4	43:23 104:21	150:4,8
weight 96:24 97:4	witnesses 16:19	110:16 129:10,12	à
weirick 111:10,18	60:17	129:20 131:13	à 142:5
111:24 112:3,4,5,9	witnessing 130:1	136:13,14,15	u 112.3
113:13 114:23	woman 17:5 32:10	144:1 145:7	
went 30:19 46:9	women 53:18	workplace 9:5	
53:4,14 59:20	worded 53:8	147:18	
60:5 74:12 134:17	wording 94:6	write 28:10 29:5	
135:14,22 136:3	words 44:24 60:10	36:2,3 43:1,4,5,5	
west 1:22 3:7,12	100:14 130:12	46:17 48:2 54:2	
wet 133:2,3,4,7,14	wordsmithing	73:24 119:24	
133:15,17 139:6	85:6	writing 28:17,19	
wetting 133:15	work 4:12 5:1 6:3	31:12,14 33:4	
whereof 150:19	6:7,10 7:1,15	35:20,22 39:18	
wide 106:22	13:24 14:24 15:8	42:16 43:15,17	
widely 51:6,8	15:12 21:15 24:9	46:20 63:17 64:8	
wiman 1:3,3 5:6	31:1,22 34:25	69:24 70:3 74:5	
5:10 7:3,22 9:4,7	35:9 47:1 80:7	74:23	
	I .	1	I .

RULE 30.05: Submission to witness; changes; signing. Any party to an action may make written request before the officer taking a deposition therein that it be submitted to the witness. In such event, and when the testimony is fully transcribed the deposition shall be submitted to the witness for examination and shall be read to or by him. Any changes in form or substance which the witness desires to make shall be entered upon the deposition by the officer with a statement of the reasons given by the witness for making them. The deposition shall then be signed by the witness, unless the witness is ill or cannot be found or refuses to sign. If the deposition is not signed by the witness, the officer shall sign it and state on the record the fact of the illness or absence of the witness or the fact of the refusal to sign together with the reason, if any, given therefor; and the deposition may then be used as fully as though signed, unless on a motion to suppress under Rule 32.04 the court holds that the reasons given for the refusal to sign require rejection of the deposition in whole or in part.

DISCLAIMER: THE FOREGOING CIVIL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE STATE RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.